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Abstract  
 
 
Mark-Herbert, C. 2002. Functional food for added value. Developing and marketing a new 
product category. Doctoral dissertation.   ISSN 1401-6249,  ISBN 91-576-5837-4. 
 
 
In this study innovation involves the development of a new product category; i.e. new 
products, new processes and new business. The development process is conveyed in 
narratives where a radically new product group, functional foods, is developed. These high-
tech food products are associated with added value for the food business as well as for 
individuals and society at large.  
    In the past decades Swedish food companies have faced an increasing competition. With 
increased competitive pressures, low prices and large volumes may not suffice as strategic 
advantage in a long-term perspective. One way of gaining competitive advantages requires 
finding new ways of creating added value based on technological development.  It is a 
technological upgrading process that encompasses developing and making use of new 
knowledge. It may lead to the production of value added products, profits from licensing 
agreements and a boost for the company image. 
    Businesses that want to succeed in this market need to develop new managerial methods, 
in particular in identifying critical technologies. This refers to building internal skills, 
employing innovative external sourcing, developing new markets with strong brands, 
establishing alliances, developing packaging, and finding venture capital for new 
developments. The strategic options also include strategies of communication. 
    In the studied cases several factors have contributed to the successful innovation process. 
They are discussed in a creative management perspective, allowing for a creative 
perspective to be gradually complemented with a strategic planning perspective, as the 
innovation process proceeds. The early phases of the innovation process are characterized 
by an open-mindedness, flexibility and tolerance of ambiguity. The research procedures as 
well as the collaboration partners are changed several times during the innovation process. 
The later phases of the innovation process, however, are characterized by a more formal 
analysis seen through a strategic planning perspective. This part of the process appears more 
focused and communicable. In the cases this is conveyed as organizational arrangements, 
administrative routines for collaboration, and in different marketing strategies.  
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1.  Introduction 
 
 
 
 
"Fail to innovate and you can expect, at best, to see your rivals thrusting ahead 
while you languish in some backwater. Innovate, and do everything else well, and 
your business at least stands a chance of flourishing, though at times it may seem to 
companies that they are on the proverbial treadmill, on which they have to run 
faster and faster, just to stand still" (Traill & Grunert, 1997, xv).  
 
 
1.1 A practical problem 
 
Most businesses face challenges in remaining competitive1 and adhering to needs 
for change. This is especially the case for basic industries, such as the food 
industry, where a mature and stagnated market in itself is a challenge for growth 
and profit.  
 
In Sweden, a major change occurred in 1995, when Sweden became a member of 
the EU. It is clear that the membership has had effects on the food industry. One 
effect is perceived in an increased rate of development in which the competitive 
pressures are strengthened (Mark-Herbert & Nyström, 2000 B, 23-24). 
 
Developing new products, new processes and even new businesses thus seem to be 
ways of meeting these challenges. In reality, however, the food industry is rather 
low-tech, measured in terms of R&D2 expenditure. A recent study of food 
businesses in Sweden reveals that on average 1.6% of the annual turnover is spent 
on R&D (Ibid, 22). Compared to the pharmaceutical industry, with 19% in R&D 
expenditure, this is relatively low (SOU, 1997)3. The major reason for making such 
comparison is that the pharmaceutical industry shows interest in the area ‘between 
food and medicine’, which is the area of interest in this study.  R&D is an 
expensive undertaking associated with great risk. Even if costly R&D leads the way 
to a new product, studies of new product development indicate that up to 80% of 
consumer products fail in their first year (Doyle, 1998, 206).  
                                                       
1 Competitiveness is seen as when a company “… possesses the sustained ability to 
profitably gain and maintain market share in domestic and /or foreign markets” (Agriculture 
Canada, 1991).  
2 R&D, Research and Development 
3 A comparison of R&D expenditure of annual turnover in the agricultural area (1%), the 
food processing area (1%) and the pharmaceutical area (18%), in Sweden, further supports 
the perception that the food production and food processing areas are rather low-tech 
(Statistiska Centralbyrån, 2001, 18-19).  
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Assuming that the R&D-budget for most food businesses is limited, how can the 
scarce resources be used wisely? How can research and technology intensity be 
increased and markets be developed to achieve increased competitiveness? With 
these compelling questions in mind, it is time to ask who it is that gains from the 
innovation process, as it is demonstrated in the development of new food products. 
 
 
1.2 Perspectives on the development of new food products 
 
One might ask how great the need is for new food products. The food products in 
focus here are functional foods4, foods with a positive health effect. Depending on 
who gives the answer, it will reflect one or more of a number of perspectives. Four 
perspectives are presented below: of society at large, individuals, food businesses 
and of academic people interested in innovation. 
 
The first perspective is that of health and longevity for people on a societal scale. It 
is reflected in different cultures by the traditions, habits and guidelines by which 
entire groups of people live. In Western societies where resources are plentiful, 
starvation is in the twenty-first century no longer major causes of death. The 
problems in these cultures are rather that of overeating, eating an unbalanced diet 
and living a stressful life (Barnard, 1993). Treating the effects of these food and 
life-style related stress factors is seen in an escalating number of cases with cancer, 
coronary heart diseases and other signs of poor health management. As a result, the 
cost for medical care is escalating. From a societal point of view preventing a 
disease through certain food products, or even delaying the onset, appears 
financially sound. 
 
The second perspective is that of the individual. Most individuals are very 
conservative in their food habits (Feurst, 1991), but still want the assurance of a 
long and healthy life. Most of us want to eat meat, sweet deserts and salty peanuts 
now and then. We eat more than we need and we have an unbalanced intake with 
regard to our limited daily activities. Foods that promote health are needed. This 
need is reflected in a consumer interest for products that provide some kind of 
guarantee of a health benefit, without any call for major changes in habits. Some 
might argue that a long, healthy life has always been prioritized, but it is very clear 
that a new market is rapidly expanding, one where many consumers are well 
informed (Eklöf, 2001; Kollberg, 2000), aware of their choices and willing to pay 
for health.  
 
The third perspective is that of the Swedish food industry. It produces mainly bulk 
products for the local market. The value of imported food products is 
approximately twice that of exported food products in Sweden (1997: 22 077 M 
SEK vs. 13 266 M SEK, in Statistiska Centralbyrån & Livsmedelsekonomiska 
                                                       
4 A closer presentation of functional foods is provided in ‘1.3 Definitions of  terms’.   
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samarbetsnämnden, 1997, 64). Traditionally, the food industry at large has been 
regarded as a low-tech industry with production targeted for a local or national 
market (Nyström, 1990, 197). Food businesses are relatively positional in their 
activities, which means they are market searchers rather than market developers. 
(Ibid, 20). Most new food products are minor modifications of previous products.  
 
Functional foods, however, are different. They are the result of strong R&D efforts 
and of the development of new technologies as well as new markets. These 
products and processes provide the basis for patents, ‘know-how’, licenses and 
sales of high value added products, sold with health-related marketing arguments 
(Mark-Herbert, 1993,4-8). Studies of attitudes towards the development of 
functional foods among CEOs5 in the food industry indicate that there is a large 
interest in functional foods in the Swedish food industry (Mark-Herbert & 
Nyström, 1993; 2000 A & B).  
 
Lastly, the fourth perspective, is the researcher’s with an interest in the innovation 
process. Independent of their field and view, innovation for these people has a 
positive connotation. This is illustrated in a citation: “Innovation plays a role in 
nurturing the economy, in enhancing and sustaining the high performance of firms, 
in building industrial competitiveness, in improving the standards of living and in 
creating a better quality of life” (Goplakrishnan & Damanpour, 1997, 17).  
 
Innovation, seen as a high-risk endeavor, is often viewed as constructive, profitable 
and a way to solve a problem. New ideas that are not useful are usually called 
mistakes. The usefulness can, of course, be objectively determined once the 
innovation process has been completed and implemented. This positive bias, 
however, is found in studies of innovation, regardless of the research perspective. 
 
Hence, these four perspectives all seem to reflect a positive bias toward innovation 
and in this study, the development of new food products. 
 
 
 
1.3 Definitions of terms 
 
A few recurring terms are going to be used frequently throughout this thesis. Some 
of these terms are clarified below- functional foods, technology and innovation. 
Other terms are further explained in the text and in footnotes as they appear in the 
writing. 
 
                                                       
5 CEO Chief Executive Officer  
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Physiologically functional food  -  PFF6 
In most parts of the world, except in Japan, a legal recognition of a term for this 
food group is lacking. In Europe, as in the US, the lack of a legal definition leads to 
some confusion among people at large regarding PFF’s. This has not, however, 
prevented a growing interest in the development of such products among food 
businesses. 
 
PFF is a diverse group of foods, with little in common except what could be labeled 
as a medical effect. The medical effect is a physiological influence of certain 
chemical components in the PFF on different organ systems in the body. One might 
argue that all foods have such an effect, and to a certain degree that is true. All 
consumed foods affect the body in some way. Functional foods, however, are 
scientifically shown to have a preventive effect, which somehow delays or impedes 
the development of the onset of a disease or even in some cases, can be used for 
treatment of a disease.  
 
It is the scientific evidence of a health-related effect, which distinguishes PFF from 
any other food. The scientific evidence of a health effect is the key to the profit 
arising from the development of such products for the food industry. One way of 
dividing functional foods is based on how the product is developed; in nature or in 
a development process by man (Figure1.1) 
 
 
 
 
 
 
 
 
 
 
 
 
Developed by man 
Developed in nature 
Functional   
foods 
ProViva 
M agiform  
BRAmjölk 
IgY-eggs 
Products   Origin 
Citrus fruits 
Broccoli 
Garlic 
 
 
Figure 1.1 Functional foods can be divided in two groups based on the origin, 
developed in nature and developed by man.  
 
 
The naturally occurring functional foods, for example, garlic and citrus fruits are 
most interesting for health-conscientious consumers (Berhow et al., 2000; Edgson 
& Marber, 2000; Parliament et al., 2000; Sandberg, 2001; Shibamoto, et al 1997 A; 
Shibamoto et al., 1997 B). Developed functional food products, on the other hand, 
are of a particular interest for the food industry as well as for consumers. If 
protected by proprietary rights, these products can be sold with a health-related 
argument, providing grounds for a high margin pricing, licensing arrangements and 
                                                       
6 A review of the development of functional food is provided in chapter 4.  
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a strengthened business image due to proprietary knowledge in a strategic area 
(Mark-Herbert, 1993). This thesis focuses on functional foods that are developed by 
man. A closer presentation of these products is provided in Chapter 4.1, “Foods, 
medicines or what?” 
 
Technology and technological strategies 
The term technology is widely used in the literature with different meanings, but 
has mainly a narrow definition with associations to technical applications. The term 
for that kind of technology would be techniques, in this study.  
 
Technology, on the other hand, has a wider definition in this approach. 
“Technology means knowledge that is potentially useful for product and company 
development, even though the immediate implications may not be clear” (Nyström, 
1990, 43).  
 
Knowledge is perhaps the best way to describe the term technology. Technological 
strategies refer to how companies extend their knowledge base. R&D is an 
important part of technological strategies, but it is not the only source of new 
knowledge. With reference to time, strategies may be divided into intended 
technological strategies and realized technological strategies. Intended strategies 
are concerned with conditions for change, expressed as policies, visions or goals. 
Realized strategies, on the other hand, are concerned with the outcome, the actual 
evolution of patterns of decisions and activities. Realized strategies have been 
implemented. It is what has been done (Ibid, 43, 77). This is further discussed in 
Chapter 2.  
 
 
Innovation 
Innovation is the process of “bringing new ideas to use” (Nyström, 1990, 30). 
Sometimes the term refers to the process and at other times to the results of a 
change. The context will determine which meaning is implied. In the marketing 
literature, the innovation process is commonly referred to as the development of 
new products and processes. In the organizational management literature, on the 
other hand, the change process is in focus.  
 
In this dissertation, the innovation process refers to “the creation of the future” 
(Ibid. 75), which essentially means managing technological change and the 
outcome of it. This perspective includes marketing and organization management 
aspects of the process while focusing on technological and marketing strategies. In 
short, the innovation process encompasses all fundamental changes, which may 
affect product, process and company development. 
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1.4 A theoretical problem 
 
The innovation process can be seen as new technologies that bring changes. These 
changes require resources and acceptance among participants in the process. The 
innovation process is often seen in technological development as a way to solve 
problems. New or established – all businesses face innovative changes.  
 
”Strategy innovation is the only way for newcomers to succeed in the face of 
enormous resource disadvantages, and the only way for incumbents to renew their 
lease on success” (Hamel, 1998, 8). 
 
Although considerable attention has been paid to the outcome of innovation 
activities, little work has been concerned with describing the innovation process 
itself in the business. The need for understanding innovation, as it occurs over time, 
is discussed by Saren (1984, 11). But how can the innovation process be seen as a 
possible strategic advantage? How do innovative forces flow? Can a new market be 
developed?  Understanding the conditions for the creative process from the early 
idea phase to a later phase of product and market development is a theoretical 
objective in this dissertation. A theoretical understanding of the process is further 
discussed in chapter 2.  
 
 
1.5 Objectives and demarcations 
 
The main objective is to address the question: How do Swedish food businesses 
develop radically new products? Radically new refers to products requiring R&D 
efforts that give rise to new technologies (new knowledge). These technologies 
serve as a base for know-how in production, patents and as strategic resources.  
 
The empirical field of the development of functional foods is chosen for several 
reasons. Firstly, my choice is based on the fact that functional foods are radically 
new products, in terms of technologies (development of knowledge) as well as 
markets (the consumer’s perception of the newness of a product) 7. From a 
theoretical point of view this makes the innovation process readily identifiable with 
regard to the outcome as well as the progression of development. Secondly, the area 
of functional foods is seen as an expanding part of a new market and thus a 
strategic area for the food business. And lastly, my personal interest and 
understanding of health-related issues have certainly contributed to the choice as 
well. 
 
It is important to keep in mind that the development of functional foods by no 
means represents a development of typical food products. Consequently, the 
                                                       
7 The concept of a new product is further discussed in Chapter 2.  
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technological and marketing strategies differ from those used in developing most 
other food products. 
 
The products in this study are developed functional foods, based on natural raw 
material. Natural, in this case, refers to the fact that the raw material or product is 
not genetically modified  (GM). GM products that qualify as functional foods are 
labeled novel foods. These products are, just like functional foods, associated with 
major R&D efforts. At the time of writing this thesis I am not aware of any 
functional novel foods, but their existence is certainly only a matter of time8. They 
are not, however, studied here since problems in developing these products, in 
particular in marketing and ethics, differ from those of developing functional foods.  
 
Ethical problems in the production of functional foods, as a part of agricultural 
production and processing (Jordbruksverket, 1997), and ethics concerning the 
pricing and distribution of functional foods are not discussed in this thesis. It would 
require more of a consumer-oriented perspective. 
 
The discussion is limited in the area of financing the R&D process. In most cases I 
have had access to contracts and other unofficial empirical material but I have been 
asked not to refer to these documents or to use specific figures. Consequently, 
accessing resources will be discussed in terms of strategies and organizational 
arrangements. 
 
Although the organizational aspects of innovation management are of great 
importance (Adler, 1999; Lindell, 1988; Lundgren, 1991; Lundqvist, 1996) they are 
not the only or primary focus of this study. The organizational arrangements are 
described in the cases and discussed as a part of factors that affect strategies and the 
innovation process as such.  
 
The process of innovation can be stimulated or impeded by lack of certain factors 
in the setting and environment. A number of these factors have institutional 
character, such as the need for a legal framework and a structure within which 
growing business and ideas at universities can find financial support. 
Counterproductive factors are largely seen as deficiencies. They are not discussed 
in depth in spite of their influence on the process, since the object of this study is to 
study how technological an marketing strategies are realized – not why they are not 
realized. 
 
                                                       
8 “In a few years, we will not be able to distinguish what has been produced using GM 
technique and what has not!”(Sylwan, 2000, 3). The book “The Earth and the Genes” 
(Jorden och generna) provides a background for further discussion on possibilities and risks 
associated with genetic modification.   
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1.6 Approach 
 
Studying the innovation process in a new empirical field has offered many 
interesting insights. What started in the early 1990s as a pilot study (Mark-Herbert 
& Nyström, 1993) and a literature review (Mark-Herbert, 1993) grew to become a 
doctoral thesis. Many choices were made along the way and it would be impossible 
to explain the rationale behind every road taken. A few significant choices, 
however, deserve to be further explained.  
 
The research question, How do Swedish food businesses develop radically new 
products?, offers interpretation from several possible theoretical perspectives 
(Appendix 1). One part of the Ph.D. learning process is finding a perspective that 
offers a vocabulary and a focus that would provide grounds for analysis. My 
theoretical choice is further presented in Chapter 2. This is not to say that the 
research question alone has guided the process. Rather, the interplay between 
studied theory and empirical findings has guided the analytical process9. My 
theoretical background has influenced the research process as such, mainly in what 
questions are raised and how the answers are interpreted. This is reflected in the 
interview guide (Appendix 2), for example, where themes in the guide are rendered 
from studies of the innovation process in other industries. Some themes prove 
useful others less so. My ambition has been to conduct critical management 
research (Alvesson & Deetz, 2000), where an awareness of existing theories is 
balanced with an empirical sensitivity for discovering new trains of thought.   
 
Generating empirically grounded comparisons in a holistic analysis, applicable to 
the innovation process in the food industry, is therefore an objective. Another 
objective is to use the existing theories and concepts when possible, and modify 
them when needed. The approach used in this study is explorative and for the most 
part descriptive, which is fruitful when the problem is new and complex. A holistic 
analysis on several levels of aggregation puts information in a context, which 
increases the understanding of the problem (Yin, 1991). This approach is illustrated 
in the dotted ring in Figure 1.2. 
 
 
                                                       
9 The process of reflexive research is when theoretical and empirical understanding 
interplay throughout the research process, referred to as ' abduktion'  in Swedish (Alvesson & 
Sköldberg, 1994, 45).   
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A partial  
analysis 
A holistic  
analysis 
An analytical approach  An explorative approach,  
a creative research process 
Kind of 
approach 
Quantitative hypothesis testing 
Precise hypothesis formulation 
Qualitative hypothesis testing 
Tentative hypothesis formulation 
Theory generation 
Concept  
development 
Increasing novelty and 
complexity of a problem 
 
Figure 1.2 How increasing novelty and complexity of a problem affects the 
research approach and desired research contribution (personal 
communication, Nyström, 1998). 
         
 
 
The choice of case studies and interviews to illustrate the phenomenon in a context 
is thus connected to the complexity and novelty of the problem. In terms of an 
academic contribution, this dissertation provides a framework describing and 
interpreting the innovation process. Fruitful concepts and hypotheses are possible to 
theoretically generalize (Yin, 1991) in applicable areas. It is also possible to test 
hypothesis in, for instance, a survey analysis (Mark-Herbert & Nyström, 2000 b). 
 
 
1.7 Work phases and structure 
 
Within this project several studies have contributed with insights (Figure 1.2). A 
pilot study and a literature review (1993) provided grounds for communicating the 
project proposal to SJFR (Skogs- och Jordbrukets forskningsråd nowadays a part of 
FORMAS). Grants were given in 1997 and the research continued mainly as case 
studies (Figure 1.3). 
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  Magiform   
 
1993              1995          1997           1999          2001 
Time 
A state of the art study 
￿
 
ProViva 
	 
Case studies  
IgY -Egg 
A survey study  among 
Swedish CEOs in food 
businesses 
A pilot study 
	 
	 
BRA-mjölk 
 
Figure 1.3 Studies within the project. The basis for this dissertation is the circled 
case studies. (The 
￿  symbolizes a publication). 
 
 
In this thesis four case studies are presented and compared.  The previously carried 
out studies, the state of the art and pilot studies, have provided insights and further 
understanding which has been useful for a contextual understanding of the cases.  
 
In the next chapter, a perspective, a theoretical understanding of the innovation 
process is further explained. Chapter three offers some explanations as to how the 
longitudinal case studies have been carried out. A short historical background and a 
functional food market analysis are presented in Chapter four. This chapter 
provides further contextual insight that will enhance the understanding of further 
analysis of the cases in chapter five. Finally, Chapter six, offers a discussion of the 
empirical material, which is summarized in Chapter 7 along with suggestions for 
further research.   
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2 A theoretical perspective 
 
 
 
 
Researchers in many disciplines have been preoccupied with research that focuses 
on the innovation process. They represent a vast number of disciplines: economy, 
business management, political sciences, technical areas, sociology and 
psychology, and they all offer different sets of research questions (Gopalakrishnan 
& Damanpour, 1997). Between these disciplines and even within each discipline 
the views on the meaning, focus and the impact of innovation vary. The basic 
question pertains to the nature of the innovation activity, whether the focus is on the 
new outcome (a product, a method or a device) or on the process of developing 
something new.   
 
Assuming the innovation activity is regarded as a process, it is rarely disputed that 
innovation is a collective achievement (McCosh et al., 1998; Goldman 1985). Some 
even go as far as to say that corporate skills, correlated to business variables, rather 
than project-related skills or personal achievements, are accountable for innovative 
abilities (Schewe, 1994). While invention or the conception of innovative ideas 
may be an individual activity, “innovation is a collective achievement of pushing 
and riding those ideas into good currency" (Van den Ven, 1986, 591). In most 
research projects, the level of study is therefore aggregated, at a project, business or 
industry level, where the interplay between a number of individuals, functions and 
resources are studied.  
 
The innovation process is a series of steps that basically link an invention to a 
market in a multi-step process. It involves managing ideas into good currency so 
that innovative ideas are implemented and institutionalized.  
 
 
2.1 A creative management perspective 
 
The management literature is rich in interpretations of how to manage the 
innovation process10. The traditional perspective has been that of strategic planning 
(Cooper, 1979; Crawford, 1983; Urban & Hauser, 1980). The basic assumption on 
which this theory is built is that it is possible to allocate resources and reduce 
uncertainty by rigorous planning before execution. In this approach, planning 
precedes action. The plan guides the process in stepwise progression. It also serves 
as a tool for evaluation of the innovation process. The success of the innovation 
                                                       
10 A brief overview of management perspectives is presented in a time-table in Appendix 1 
(Perspectives of the innovation process in different management schools).   
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process is related to finding the optimal way to meet the strategic goal, outlined in 
the plan.  
 
An alternative interpretation is an entrepreneurial perspective, which involves 
innovation management and entrepreneurship (Albernathy & Utterback, 1988; 
Hamel & Heene, 1994; Loverridge & Pitt, 1992). The plan is replaced by a 
direction for development; a vision in which an intended strategy gradually finds its 
way towards a realized strategy. Realized strategies constitute visualization and 
realization of ideas. 
 
In this thesis the perspective is that of creative management (Henry, 1991; 
Nyström, 1990). Aspects of this perspective are described by authors, such as 
Crawford (1991), Mintzberg (1994) and Skat-Rørdam (1999). The term refers to a 
combination of the entrepreneurial perspective and a strategic planning perspective. 
In developing radically new products and processes, new opportunities are 
discovered. The early part of the innovation process is not possible to plan in great 
detail and thus is best viewed in an entrepreneurial, innovative perspective. 
Gradually, the innovation process becomes more focused and thereby possible to 
plan, allowing for a strategic intent to be expressed. In the later stages of 
development and in the marketing of a product, a strategic planning perspective is 
more useful.  
 
 
2.1.1 The creative process 
Creative management offers a perspective in which the innovation process itself, 
the creation of new technologies and new markets, is studied. The time perspective 
includes a context-bound history, a present and an unfolding future. 
 
The innovation process is seen as the visualization and realization of new ideas. It 
refers to the creative process in which information is transformed into useful 
products, processes and skills. This process is often carried out by insightful 
individuals, labeled as entrepreneurs, change agents (Schumpeter, 1934) or product 
champions (Weryzer, 1998, 318). Their capacity to make use of information and 
mobilize resources for the implementation of their visions is well recognized 
(Gaddefors, 1996; Johannissson, 1992; Nyström, 1990).  
 
The creative process is described by Nyström (1990, 55) as: “the balanced 
intellectual unfolding and converging of experience which is necessary to achieve 
technological and market innovation” in Figure 2.1. The terms divergent and 
convergent thinking are also used by Van de Ven et al. (1999, 16, 203-204) to 
describe cycles of a learning process. In their terminology the divergent process 
refers to a nonlinear chaotic process that facilitates learning by discovery. The 
converging part of the process signifies testing the trail and error outcome of the 
diverging part of the process in a context. 
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I n fo r m a tio n   T e c h n o lo g ic a l 
a n d market 
in n o vation 
U n fo ld in g   C o n v e r g in g  
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E n tr e p r e n e u r s h ip , the 
v isu a liz a tio n and realization of 
id e a s  
 
 
Figure 2.1 Entrepreneurship as the creative transformation of information into 
innovation (Nyström, 1990, 56).  
 
 
The creative process is regarded as an ongoing interaction with the environment. 
The early phase is characterized by open-mindedness, intuition, visions, and 
withhold of judgment. It requires flexibility, tolerance of ambiguity and a holistic 
perspective. The later stages of the creative process, however, are distinguished by 
convergent thinking and reasoning in more formalized analysis. This in turn greatly 
improves the possibility to communicate results, which is crucial in later stages of 
the innovation process.  
 
 
2.1.2 A choice of model for the innovation process 
The complexity of the innovation process not only makes it difficult to explain and 
study but also presents problems in developing a general model. Two major types 
of models are presented below, a linear phase model and a simultaneous phase 
model.  
 
When the innovation process is illustrated in a linear interactive model one phase is 
placed prior to another, for example in phases of generating an idea, development, 
production of a prototype, manufacturing, marketing & sales, and expanding to a 
broader market (Figure 2.2).  
 
 
D e v e lo p -
m e n t 
Id e a  
g e n e - 
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N eeds of society and the market place 
S ta te -o f-th e -a rt technology and production 
P ro to -
ty p e  
p rod. 
M a nu-
facturing 
M a rk e tin g  
a n d    
s a le s  
M a rk e t 
p la c e  
A new 
te c hno-
logy 
 
A new 
id e a 
 
Figure 2.2 A linear interactive model for innovation (Clark and Guy, 1998, 369). 
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A linear model11 for the innovation process may have parallel sub-processes, 
interconnected by feedback, but one phase precedes another (Cooper, 1990; Kotler, 
1976; Nyström, 1972; Robertson, 1974; Twiss, 1992; Zaltman et al., 1973). Each of 
these phases is influenced by needs in the society and the development of 
technologies. Clark and Guy (1998) label such a model an interactive model.  
 
The second type of model for the innovation process is one where a multitude of 
factors are affecting several interconnected phases that occur simultaneously 
(Gopalakrishnan & Damanpour, 1997). This is the multiple simultaneous phase 
model of innovation (Chiesa et al., 1996), Figure 2.3. 
 
 
Product 
development 
Process 
innovation 
THE PROCESS OF INNOVATION 
Concept 
development 
Technology 
acquisition  System and 
tools 
Resourcing 
Leadership 
Increased  
competitive-
ness 
 
Figure 2.3 A multiple simultaneous phase model of innovation where the phases, 
technology acquisition, concept development, product development and 
process innovation take place simultaneously. Leadership, resourcing and 
systems and tools are enabling factors for the innovation process (after 
Chiesa et al., 1996, 108). 
 
 
Before justifying my choice in model, it should be said that a number of arguments 
can be made for using either model. The theoretical, methodological and empirical 
arguments that follow are simply the arguments that I find fruitful.  
 
At first glance the second, multiple simultaneous model appears to provide a 
creative freedom and lack of rigidity that would be conducive to the innovation 
process. It is deceiving. It is my understanding that the creative process 
continuously requires flexibility. This flexibility refers to altered leadership, 
different resources and different systems in the different phases of the process, 
which is not included in the model (Fig. 2.3). With the multiple simultaneous 
model, the various phases (concept development, process innovation, product 
development and technology acquisition) are supported by a set of enabling factors 
that do not change throughout the process.  
 
                                                       
11 Another term for a linear model is a unitary phase model.  
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In the linear interactive model (Fig 2.2), however, the consecutive phases, each 
affected by needs in society and technological development, mark the different 
needs throughout the innovation process. My interpretation of the model is that it is 
a model where conditions for the different phases are created. This process is not 
possible to plan with a set of enabling factors but is rather a process of creating 
conditions for continual learning.  
 
Depending on the theoretical perspective of innovation, the choice of methods may 
vary considerably. In a linear process model, such as the one presented in Figure 
2.2, one can test if R&D expenditure, for example, correlates with the success rate 
of the innovation process. A statistical analysis could determine if any such uni-
dimensional correlation exists on a particular level of analysis. In a multiple 
simultaneous phase model of innovation, on the other hand, interaction between 
different factors makes such an analysis difficult. 
 
In this study, a linear model is better suited for understanding the innovation 
process. The main reason for choosing a linear model is, however, not associated 
with the difficulty of pursuing an analysis. It is attributable to the choice of studying 
the development of radically new products. In this development process, each step 
is dependent on the previous step, which makes the developmental path rather 
unpredictable and thus less suitable for planning and for the development of 
multiple parallel processes. It is an entrepreneurial process where continual learning 
leads the way for development of new technologies.  
 
A second reason for choosing this linear model is the fact that the interplay between 
technological and market strategies is readily discerned. These strategies are a 
major part of the analysis in chapter six. This model also shows the interplay 
between the innovation process, market needs and technology development. In 
discussions about organizational aspects of the innovation process, however, the 
use of more complex models is fruitful (see 2.3.6 Fourth and Fifth generation 
industrial innovation models).  
 
The third reason, and perhaps the most important reason for choosing a linear 
model, is associated with the conception of the process from the narrated empirical 
material. The innovation process is described in the interviews as a story. That in 
turn may be compared with narrative arts, where a process is often depicted in a 
sequential and chronological order.  
 
Assuming the innovation process is perceived in a linear model, the process can be 
divided in two main stages: the generation and the adoption of innovation. These 
can in turn be further divided into phases as shown below in Table 6.1. Some 
researchers focus on one stage or phase (Table 6.1). Others take interest in the 
innovation process as a whole (Cooper, 1990; Henry, 1991; Nyström, 1990). 
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Table 6.1 Innovation seen as a linear process divided into stages and phases. 
Generation of innovation 
(Utterback, 1971; Saren, 1984; 
Ford, 1988) 
Adoption of innovation 
(Ettlie, 1980; Zaltman et al, 
1973) 
-Idea generation  -Initiation  
-Project definition  -Implementation 
-Problem solving   
-Design and development   
     Stages of the 
         innovation 
             process 
-Marketing or 
commercialization 
 
 
 
In attaining my research objective, the entire innovation process is of interest. In 
the cases (chapter 5), however, it is clear that all the phases of the process do not 
get equal attention. One explanation is, as we will see, that the innovation process 
was in different phases at the time of the completion of each case study.  
 
 
 2.1.3 What‘s “new”? 
Innovation is seen as the development of something new or, rather, we should say 
the development of something that someone perceives as new. In this study the 
products are not only new but radically new. Ideally, we would like to have a 
universal map of what is “radically new”, “fairly new” and “established”. This is 
epistemologically infeasible and any kind of classification would soon be outdated, 
if it ever gained general recognition. We will have to accept that the perception of 
“newness” lies in the eyes of the beholder (Rasmussen, 1968, 47 -49).  
 
Crawford (1983, 35) elaborates further on the concept of consumers’ perception of 
new products. He identifies nine types of new products: 
1 A product performing an entirely new function such as television, which for the 
first time permitted the transmission of audiovisual signals. 
2 A product that offers improved performance of an existing function, such as a 
wristwatch whose balance wheel has been replaced by a ‘tuning fork’.  
3 A product that is a new application of an existing one. For example, the aerosol 
bomb, which was first developed for insecticides, was later applied in paints, 
etc.  
4 A product that offers additional functions. The hands-free telephone, for example 
does what the earlier telephone did, plus more.  
5 An existing product offered to a new market. This may be done, for example, by 
repositioning or by taking a regional brand into other regions.  
6 A product that through lower cost is able to reach more buyers. The hand 
calculator is an example. 
7 An upgraded product defined as an existing product integrated into another 
existing product that had previously been purchased. 
Phases  
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8 A downgraded product. For example, a manufacturer markets a component that 
had previously been purchased. 
9 A restyled product. Annual auto and clothing changes are examples.  
 
 
An alternative term to “new” would be using degree of  perceived uniqueness. In the 
model below (Figure 2.4) the “newness” is  expressed as technological uniqueness 
and market uniqueness (Nyström & Liljedahl, 1994). The technological uniqueness 
refers to the technological challenges the business confronts in the development of 
a new product or process. These challenges are seen in needs to develop new 
technologies in, for example, processing techniques. The market uniqueness, on the 
other hand, is what the customer perceives. This does not imply that the customer’s 
need in itself is new; it is rather the product that fills these needs that is perceived 
as new.  
 
It is possible that a business develops products that have a high degree of 
technological uniqueness (based on a technologically advanced process) and, yet, to 
the consumer they may appear as products of low uniqueness (“just cultured milk” 
so-called “filmjölk”). The contrary situation is also a possible outcome, when a 
product is seen as radically new on the market even though this product is based on 
established technologies. This may even be a desirable outcome in a business 
perspective as it promotes the discovery of new areas of application for a new 
technology (Strategy B in Figure 2.4). The relative impact of technological and 
market strategies on the innovation process is illustrated (Figure 2.4.1) and further 
described below.  
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Figure 2.4 Technological and market strategies as parameters illustrating the 
innovation process (Nyström & Liljedahl, 1994, 7). 
  
Strategy A- means finding a new market niche and creating new 
relationships with customers. The costs are related to market activities to 
promote a product on a market. There is no cost or risk for the development 
of new technologies.  
 
Strategy B - involves finding a new market for a new technology. A condition 
for this strategy is that technological and marketing activities are well 
coordinated. Although the financial gain may be large, the risks associated 
with finding a new market and developing a new technology are 
considerable. 
 
Strategy C- is less interesting in an immediate commercial perspective, as 
the market has not yet been defined. This strategy implies primarily basic 
research with no apparent market applications. In the long run, however, this 
strategy can lead to core competencies and thus competitive advantage.  
 
The degree of technological uniqueness is defined as the degree of creativity that 
companies have to employ to solve critical technical problems in developing new 
products and processes. Therefore, achieving a high level of technological 
innovation is associated with the radical development of new knowledge, which 
may lead to patents or know-how protection. 
 
Market uniqueness, on the other hand, refers to how interchangeable a product is 
perceived by a consumer. It is assumed that greater product uniqueness, the more a 
product differs in features and performance from competing products, signifies 
more of a market potential. 
The innovation process is illustrated in this model (Figure 2.4) in terms of 
technological and market strategies. These strategies are not inherently good or bad. 
They are more or less conducive to the innovation process as such, and more or less  
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financially rewarding in different industries, in different markets and with different 
time perspectives. 
 
 
2.2 Dichotomies to describe innovation 
 
Competition at an industrial level is a reflection of changes in products and 
processes at the business level. It is assumed that businesses need to renew 
themselves, to innovate and change, in order to maintain their competitiveness. 
These changes at a business level can be described in terms of dichotomies. 
 
Prevalent dichotomies for describing the innovation process and outcome are, for 
example, process vs. product, technical vs. administrative, incremental vs. radical, 
sustaining vs. disruptive, continuous vs. discontinuous, low-tech vs. high-tech, and 
technology-push vs. demand-pull. It could be argued that these dichotomies are not 
mutually exclusive and that is true. Furthermore, whether the innovation is 
considered as one type or another much depends on the time and level of analysis. 
These dichotomies are presented to provide a basis for a common understanding of 
the concepts in further discussions of the empirical material.  
 
 
2.2.1 Product vs. process 
Process innovations are defined as new tools, devices and technologies for an 
industry, business or subunit (Ettlie & Reza, 1992). Product innovations, by 
contrast, are new outputs or services that benefit a customer (Utterback & 
Abernathy, 1975). The difference between the two relates to the competitive 
advantage and activities that are born from these innovations. 
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Figure 2.5 Product and process innovation in phases of development (adopted from 
Albernathy & Utterback, 1988, 27) 
 
 
This model is further developed with descriptions of the changes that occur with 
regard to the product, the process, the organization and the market (Figure 2.5,  
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Table 2.2). It shows that the innovation rate is highest in the fluid phase. This is the 
time for radical technology development. Experimentation leads to product 
innovation and less attention is given to process development. During the 
transitional phase, product innovation slows down and the rate of major process 
innovation accelerates. Dominant designs of products and processes gradually 
appear as best satisfying users’ needs.  
 
The last phase, the specific phase, refers to a stable and mature market. On these 
markets businesses become extremely focused on cost, capacity and volume and 
the innovation process progresses in incremental steps. The first phase would 
include the introduction of a new technology that gives rise to productivity gains. 
This technology is refined, allowing for optimization and economies of scale. In the 
last phase the technology is mature and the only way to increase profitability is to 
once again introduce a new technology.  
 
It is fairly clear that the food market is best described by the last step of this model. 
Most products are minor departures from existing products and the focus is on 
production efficiency.  
 
Table 2.2 Competition on an industrial level as innovation and change processes 
(Utterback, 1995) 
 
Level of 
analysis  Change process 
Product  From high variety, to dominant design, to incremental innovation 
of standardized products. 
Process  Manufacturing processes from heavy reliance on skilled labor and 
general purpose equipment to specialized equipment tended by 
low skilled labor. 
Organization  From entrepreneurial, organic firms to hierarchical, mechanistic 
firms with defined tasks and procedures with few rewards for 
radical innovation. 
Market  From fragmented and unstable markets with diverse products and 
rapid feedback, to a market for commodities with largely 
undifferentiated products.  
Competition  From many small firms with unique products to an oligopoly of 
firms with similar products. 
 
 
Utterback’s model (Table 2.2) suggests that small companies have a tendency to 
focus initially on product innovation, grow larger, shift to emphasize on process 
innovation, and eventually reach a large-scale low-cost production as a mature 
business. This model has been criticized (Clark & Stauton, 1989; Pavitt, 1986) and 
studies of food businesses suggest that food businesses seldom evolve from small- 
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scale production to mass-market production (Christensen et al., 1996). The maturity 
of innovations, seen as temporal development patterns, is also described by Clark et 
al. (1989) as a phase of revolutionary technological developments followed by 
phases of evolutionary and incremental developments.  
 
Traill and Grunnert (1997) have presented a model for the innovation process in 
which the studied food businesses were oriented towards either process innovation 
or product innovation. Other researchers would argue the contrary, that the 
development of products and processes cannot be separated (Albernathy & 
Utterback, 1978), let alone separated from the development of the business firm as 
such (Nyström 1990). 
 
 
2.2.2 Technical vs. administrative 
The distinction between technical and administrative is reflected in the difference 
in focus between a more structural vs. a human relations perspective on the 
organization (Bolman & Dale, 1995). Technical innovations pertain to the outcome: 
products, processes and services related to the innovations. Administrative 
innovations include organizational aspects of administrative processes and handling 
human resources. 
 
Economists typically focus on technical innovations at a high level of abstraction 
and aggregation. A sociological perspective, on the other hand, tends to focus on 
administrative innovations and a business management perspective may include 
both technical and administrative aspects of innovation.  
 
 
2.2.3 Radical vs. incremental 
An innovation is regarded as radical or incremental depending on the degree of 
change it involves (Weryzer, 1998). A model for the change arena for 
discontinuous, continuous, sporadic change and status quo is presented by Stebel 
(1994, 32). Radical innovation refers to fundamental changes and a high level of 
technological novelty. The innovation represents a departure from existing 
practices often associated with a high degree of uncertainty. The product or process 
is referred to as a breakthrough, revolutionary, really new, game-changing or 
boundary-expanding. In developing a radically new product the innovation process 
is often found to be discontinuous. It involves the development and use of new 
technologies as well as challenges in commercialization. Weryzer (1998) declares 
that it is apparent from his empirical studies that discontinuous product 
development differs significantly from incremental product development in its 
orientation, progression and need of support. Examples of such products are 
airplanes, automobiles, televisions and personal computers when they were first 
introduced (Stebel, 1994). 
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An incremental or new generation innovation, by contrast, requires marginal 
departures from existing practices (Wheelwright & Clark, 1992). It refers to the 
development of an area, a product or a process that is already known. The degree of 
newness is minor and consequently it causes little uncertainty. Developing a second 
or third generation of products would be regarded as a continuous process, which 
can be made in incremental steps towards an improved version of a known product. 
 
 
2.2.4 Sustaining vs. disruptive 
Christensen (1997) offers two concepts to describe thedegree to which an 
innovation supports existing technologies or not, in the eyes of a consumer. He 
labels technologies as sustaining or disruptive. Sustaining technologies refer to 
logical progressions from previous product lines, using the demands of the existing 
customers to determine the need for an innovation. Disruptive technologies, on the 
other hand, are generally dismissed as "shoddy work" in the innovation evaluation. 
The outcome is regarded as functionally inferior and less desired by customers.  As 
it turns out, sometimes these "shoddy" products may very well meet some 
customer' s needs. An example of such products could be an airplane trip. It can be 
viewed as an adventure, including a meal, a movie, a high degree of comfort etc., or 
it can be viewed simply as a transport from one place to another, such as the 
transport provided by Ryan Air (Capell et al, 2001). Customer preferences will 
ultimately determine the expansion potential for innovations that rely on the use of 
disruptive technologies. 
 
Schon (1971) also uses the term disruptive in describing an innovation process, but 
he refers to an early phase of an institutionalization process in which a change is 
perceived as a disruptive event. The change has low currency in the early 
appreciative phase. As the institutionalization process progresses the change 
gradually becomes articulated and accepted and turns into good currency. 
 
 
2.2.5 Low-tech vs. high-tech 
The use of the terms high- and low-tech may refer to a product or a process or, in 
other cases, to a business or an industry. The terms are deceiving. Technologies, 
which are regarded as advanced by an outsider, may be seen as basic to that 
particular industry or business (Ford, 1988). The difficulty in declaring a 
perspective calls for caution when using these terms.   
 
Nyström (1990, 20) uses the terms to differentiate business strategies from one 
another. The low-tech strategies are commonly found in businesses on mature and 
consolidated markets, whereas the high-tech strategies prevail in successful 
businesses on rapidly changing markets. Low-tech business are relative positional 
in their strategies, using product differentiation and market segmentation. The 
innovation process would be one of defending and exploiting achieved advantages, 
rather than developing new opportunities.  A high-tech business, on the other hand,  
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is signified by open technological strategies aimed at creating and exploiting 
change. The innovation process concerns developing new technologies and new 
markets.  
 
 
2.2.6 Technology-push vs. demand-pull 
The terms market push and pull are widely used in the marketing literature. They 
usually refer to factors that enhance the process of marketing a product. In 
reference to new product development they are viewed as factors that support the 
progression of the innovation process (Clark & Guy, 1998).   
 
Using Rothwell' s terminology (1992; 1994) there have been five dominant models 
of industrial innovation in the time period 1950-1994. The first generation model 
was developed in the 1950s, which was a time of rapid economic growth through 
industrial expansion. The belief in science and technology was great, and it was 
assumed that more money put into R&D would automatically result in more new 
products. This first generation model is a simple linear Technology-push model.  
During the 1960s many new products were still introduced but they were based 
mainly on existing technologies.  
 
A shift in emphasis towards market needs occured in the 1960-1970s. This is 
reflected in the second generation model, the Need-pull model. Customers needs 
and preferences are seen as driving forces for the innovation.  
 
The third generation model was developed in the late 1970s and early 1980s. This 
was a time of two major oil crises, high rates of inflation and demand saturation. It 
became increasingly clear that the third generation model for successful innovation 
needed to take into account both technological development and market needs. It 
was labeled the Coupling model (see Figure 2.2) and it was assumed that “the 
innovation process was rarely associated with performing one or two tasks 
brilliantly, but with doing most tasks competently and in a balanced and well co-
ordinated way” (Rothwell, 1992, 11).  
 
The fourth model for industrial innovation was developed in the second half of the 
1980s. In this model the emphasis lies on technology accumulation (technological 
strategy) where rapid growth is promoted in organizational arrangements such as 
joint ventures and increasing collaboration activities. These strategies led to 
shortened product life cycles with parallel development in an Integrated innovation 
model. When Rothwell wrote the article about the generations of innovation models 
in 1994, a fifth model was just budding. This model “involves inter-company 
networking and it employs a new electronic toolkit” (Rothwell, 1994, 221).  
 
The fifth generation model is later described with an example, in a case study of a 
biotech company, as a network organization (Weisenfeld-Scenk et al., 1998). This  
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network is a virtual organization that provides flexibility, shared costs and effective 
use of relative competencies.  
 
 
   
2.3 Innovation management  
  
Strategic innovation management is concerned with innovation strategies and 
innovative performance, or in other words, the ability to perceive the need for and 
implement a change (Loveridge & Pitt, 1990). It is defined by Markides (1998, 32) 
as “a fundamental re-conceptualization of what the business is all about that, in 
turn, leads to a dramatically different way of playing the game in an existing 
business”.  
 
Hamel and Prahalad (1989, 63) describe the strategic intent as "a marathon run in 
400-meter sprints". This implies clarity about the ends but flexibility as to the 
means, leaving room for improvisation along the way. As conceived by Mintzberg 
(1993, 37), it could also be described as a visionary approach to deal with 
uncertainty and changes: "Visions set a broad outline of a strategy, while leaving 
the specific details to be worked out ".  
 
 
2.3.1 Innovation strategies 
Strategies are “patterns of decisions which evolve over time in largely 
unpredictable ways” (Nyström, 1970, 50). The goal for these strategies is “the 
creation of order without careful crafting” (Hamel, 1998, 11), or, in other words, it 
is a direction but not a strict road description. Innovation strategies are closely 
related to an image of the desired path for a business. They provide guiding forces 
and enabling conditions for innovation to take place.  
 
Nyström (1990) divides innovation strategies into realized and intended strategies. 
“Intended strategy is the overall, often indirect, guidance of company activities, 
with long run implications for product and company development” (Ibid., 23). In 
the management literature this is often called policy, and it is more concerned with 
conditions for change than with the actual outcome. These conditions include the 
development of new technologies, new markets and organizational conditions that 
will facilitate these changes.  Realized strategy, on the other hand, “is the actual 
evolving of patterns of decisions and activities” (Ibid., 24). Here the outcome, what 
the business has done, rather than what it intends to do, is of main interest. In the 
management literature, realized strategies refer to different kinds of strategies, for 
instance marketing, technological and financial strategies, tactics and their 
outcome. Planned, intended and realized strategies are illustrated in Figure 2.6. 
 
The strategic management of innovation is reflected not only in realized and 
intended strategies on a company level but also on an outcome level referring to  
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products, processes and marketable know-how. The interaction between the two 
levels of analysis is of main interest. Furthermore, Nyström (1990) and Crawford 
(1991) argue that the innovation process is a “dual-drive”, where both technological 
and market strategies play important roles throughout the innovation process.  
 
New intended strategies emerge, according to Hamel (1998), in contact with 
‘news’. New voices as in newcomers in a business, new conversations in dialogs 
which cut across the usual organizational boundaries, new passions felt in a creative 
process, new perspectives through new conceptual lenses, and new experiments in 
testing new ideas on the market. These new influences are regarded as 
preconditions for innovation. Strategic health (Markides, 1998) predicts a 
company' s future financial health. Studies show that a company with sound 
finances may not be tendering its strategic health and consequently it shows poor 
finances a few years later.  
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Figure 2.6 Strategies in different environments (with minor alterations from 
Mintzberg & McHugh, 1985). 
 
 
Strategies are not to be confused with plans. Strategic planning is concerned with 
creating a plan (Mintzberg, 1993, 33), which would be conducive in a stable 
environment. Assuming the environment is changing, if not “turbulent”, a plan 
could be seen as a need for control, paralyzing other ways of development that were 
not part of the plan. This could be seen as “crafting”, leaving little room for 
creativity and innovation.  
 
 
2.3.2 Time for change  
Assuming the innovation process involves some kind of change, this change may 
be stimulated or hindered by factors within the organization as well as by factors in 
the environment. These, time related factors, can for example be structural, 
functional or related to customers’ values and preferences. This supports the need 
for a contextual understanding of the innovation process as such.   
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The time dimension becomes essential when regarding the innovation process as 
including both the future, present and the past. Intended strategies set outer 
boundaries for realized strategies (Nyström, 1990, 24) and thus become important 
factors in explaining the outcome, in terms of realized strategies.  
 
Much attention is given to the structural and functional differences between 
businesses with regards to strategic innovation. Businesses are studied in the 
organizational literature and divided into successful vs. less successful, hierarchies 
vs. ‘adhocracies’, small vs. large and established vs. new with special interest in 
organizational mode.  The underlying question in most contributions in this area is 
whether or not it is possible to organize to facilitate the innovation process, for 
instance based on contextual differences. 
 
Few, if any, authors provide a complete understanding of the complex 
organizational impacts on the innovation process. Conclusions from studies are not 
only non-uniform, but also in some cases contradictory. It is, however, widely 
accepted that the ability of an organization to continuously change in a “self-
renewal” process is the ultimate goal of strategic innovation (Markides, 1998). It is 
also assumed that it is desirable to perpetuate continuous innovation, as opposed to 
occasional innovation (Dogherty & Corse, 1997). Several suggestions regarding the 
stimulation of this self-renewal process are given in, for example, a location of 
business (Ferugeson, 1998; McCosh et al 1998) and through allowing for co-
existence of old and new (Markides, 1998). Others have suggested iterative 
organizing and non-hierarchical innovation teams to facilitate the innovation 
process (Dogherty & Corse, 1997). Studies of industrial innovation also suggest 
that comprehensive project evaluation systems play an important role (Granstrand 
& Sjölander, 1990). 
 
Evidence suggests that small and new businesses, as opposed to those that are large 
and established, are more successful relative to their size (Dogherty & Corse, 
1997). This is explained by a number of interdependent factors such as inertia of 
success, hierarchies and lack of support for change from different stakeholders 
(Markides, 1998). Goldman (1985) offers two additional obstacles accountable for 
this disparity, namely: bureaucracy drowning the innovation projects in 
organizations with large overheads, and the development time for a product to 
reach the market with regards to communication and coordination in large 
organizations.  
 
It is also of organizational interest to discuss how technology is acquired (Ford, 
1988) and where R&D may be carried out, if it is not located at the business site 
(Knox & Denison, 1990). Forming strategic alliances, working in joint ventures and 
using suppliers or ‘leading customers’ (von Hippel 1986,1988) as partners in 
development are all examples of strategies to access technologies.  
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A comparison of forms for R&D collaboration provides theoretical arguments for 
different organizational arrangements. Assuming that the innovation process 
requires access to resources and flexibility with regard to the organizational mode, 
these needs are often contrary to what is desired from an operative manager’s 
perspective. This is in part an explanation for why it is hard to organize for 
innovation. Organizational and managerial aspects of different collaboration 
arrangements are illustrated in Figure 2.7.   
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Figure 2.7 Organizational and managerial implications of different forms for R&D 
collaboration (minor alterations from Chiesa & Manzini, 1998, 80). 
 
 
This simplified version of the model presented by Chiesa & Manzini (1998, 80) 
gives an overall impression that acquisition is associated with high commitments 
(impact on resources, control over activities, risk, and start up time and costs) but 
low reversibility. Simply put, it is hard to pull out of a commitment. Negotiated 
outsourcing, on the other hand, is associated with less commitment and high 
reversibility. It is theoretically easy to terminate such arrangements.  
 
 
2.3.3 Managing the innovation process 
It may be argued whether or not the innovation process can be managed at all. 
Schon (1971) rejects what he calls a ‘rational view’ of innovation. He argues that it 
is a non-plannable process. Most management researchers, however, seem to agree 
that the process can be managed. Van de Ven (1986) suggests that a leader can 
create an infrastructure that is conducive for the innovation process. This leadership 
"offers a vision of what could be and gives a sense of purpose and meaning to those 
who would share that vision. It builds commitment, enthusiasm and excitements"  
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(Ibid., 601). He views the leader' s main responsibility as that of institutionalizatio n 
(with references to Selznick, 1957), or in other words, providing organizational 
identity and a social integration. 
 
At the product level, a leader may be called product champion (Weryzer, 1998, 
318), or simply a person with a vision for the innovation project. This is especially 
important in a discontinuous innovation process, which tends to be less market-
oriented. A product champion ensures that the innovation process advances. 
 
 
2.4 The use of a theoretical perspective 
 
The literature review provides a picture of a theoretical perspective for studying the 
innovation process. The purpose of this theoretical framework is to provide a guide 
for interpreting and structuring the empirical findings. An underlying assumption in 
this study is that of positive effects from innovation activities. It is assumed that 
innovations will result in a competitive advantage gain for the innovators. The gain 
can in turn be attributed in part to a number of short and long-term effects. 
 
Following what could be described as a Scandinavian approach to management, 
this study is a cross-disciplinary analysis of empirically based management 
phenomena  (Nyström, 1990, 7 note 12). The focus in this study is on innovation as 
a whole, including idea-generation, the R&D process, a new product, a new 
process, new skills and technologies, new markets, and the organizational 
development to facilitate the process. This indicates that no one factor or phase is 
emphasized as a major determinant of the innovation process. Rather, a multitude 
of context-bound factors are studied to gain a better understanding of the process. 
The time perspective includes a context-bound history, a present, and an unfolding 
future. 
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3 Method  
 
 
 
 
Method is a mode and a framework for engaging in a research process. It is about 
empirical material, tools and techniques, vocabularies, ethical implications and who 
we are as researchers. It is a matter of making choices and being aware of research 
conduct.  
 
 
3.1 Research is about making choices 
 
Many factors have affected my choice of method. First and foremost, the research 
objective calls for a contextual understanding of a problem. In order to develop this 
understanding closeness to the empirical material has been essential. Previous 
studies of the theoretical problem (Nyström, 1990) as well as the empirical area, 
through literature (Mark-Herbert, 1993) and a survey study (Mark-Herbert & 
Nyström, 1993), provided a broad picture of the research area. The choice of 
theoretical problem, as well as study objects, are derived from these experiences. 
The choice may be regarded as one of interest with the expectancy of intriguing 
results.  
 
In the Scandinavian management school, a methodological tradition offers 
acceptance of qualitative approaches. From my previous training in what could be 
labeled as a quantitative approach, but the Ph.D. program has offered many 
opportunities to enhance the skills of qualitative methods.  
 
Depending on epistemological beliefs, the use of qualitative studies may vary.  I 
believe that an example or a case may very well provide a theoretical understanding 
that can be applied in a wider area, assuming it is written with “an instrumental 
interest” (Stake, 1994, 237). The ‘generalizability’ is determined by reflexive 
reasoning and rhetoric skills to recognize the ‘domain’, i.e. adequate areas, for 
further applications  (Alvesson & Sköldberg, 1994, 32).  
 
A significant choice is that of making a proper selection of cases (Yin 1989; Miles 
& Huberman, 1984). Understanding a phenomenon may very well depend on an 
illustrative choice and portrayal of a small number of cases (Stake, 1994, 243). 
Working with cases is thus quite time consuming, which explains the limitations on 
the number of cases that can be studied.   
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3.1.1 Choosing case as a method  
This thesis is built upon the empirical material from three solid case studies 
ProViva, Magiform and IgY Egg. In each case, the innovation process has resulted 
in the development of a radically new functional food product. Initially, a fourth 
case was planned and started but it did not get permission for further investigations. 
This fourth study is therefore presented as a short case (5.3), and it will be used in 
the analysis since it provides interesting contrasts to the remaining empirical 
material. In my analysis I draw conclusions from comparisons of all four cases. My 
understanding of the process, however, is greater in the case studies where my 
investigations were not limited. Problems with trust are further discussed in ethical 
considerations (2.3.2). The total process is studied over time in the chosen context 
(Miles & Huberman, 1994).  
 
A case study method is chosen for a number of reasons, but most importantly it is 
chosen to match the research question (Wigblad, 1997, 56). The object of this study 
is to make a detailed analysis, a comparison between the innovation process in the 
three cases.  According to Saunders (1997), a case can generate new concepts and 
provide an understanding of how these concepts relate to one another. These 
concepts are put in relation to one another as hypotheses and empirically grounded 
theories.  According to Strauss & Corbin (1990, 23): "A grounded theory is one that 
is inductively derived from the study of the phenomenon it represents. That is, it is 
discovered, developed and provisionally verified through systematic data collection 
and analysis of data pertaining to that phenomenon. Therefore, data collection, 
analysis, and theory stand in reciprocal relationship with each other. One does not 
begin with a theory, and then prove it. Rather, one begins with an area of study and 
what is relevant to that is allowed to emerge".  
 
Looking closely at the empirical material in the attempt to define concepts and 
uncover structures does not mean, however, to disregard the prior works carried out 
by other researchers. It merely means making those experiences and theories a part 
of the perspective from which the empirical material is analyzed (Merriam, 1994, 
31, Strauss & Corbin, 1990, 49). 
 
A case can be regarded as a unit of analysis. Yin (1998) calls such a case a holistic 
case study. He also states the possibility of more than one level of analysis within a 
single case study, so called embedded case studies. In embedded case studies, one 
level of analysis will reflect other levels, such as product, product group and 
company, in terms of marketing (Nyström, 1990, 140). The cases in this 
dissertation have two levels of analysis: the product/process level and the company 
level. They would thus qualify as embedded case studies.  
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3.1.2 Selection of case studies 
A selection of case studies has been made to provide credible description of 
differences in factors that have an effect on the innovation process. The aim was to 
find case studies that illustrated different strategies in development, marketing and 
organization. The end result in each case, however, was required to be a radically 
new functional food product.   
 
The search for products in different food groups, for example meats and vegetables, 
did not succeed in identifying the development of radically new product. This is not 
to say that meat-based functional foods do not exist. They do, in Finland, as hot 
dogs containing crushed flaxseeds12 (Anonymous, Kemivärlden, 2001). The 
development of chewing gum that lowers the cholesterol is also an example of a 
new Finnish functional food product (Jacobsson, 2001). Benecol is yet another well 
know product, but the development of these products took place in Finland; and 
thus in a different context. In delimiting the empirical scope and thus simplifying a 
contextual understanding, I decided early in the process to study the development 
of Swedish functional food products.   
 
The case study selection was based on empirical findings in the pilot study (Mark-
Herbert, 199313), contacts in the food industry14 and a careful screening of articles 
about research novelties15 in the area of functional foods. Other than looking for 
differences in strategies, a major factor in case selection was the expectation of 
access to interesting material. It may sound trivial but the willingness to share “the 
story” in an interview makes all the difference for a case writer.    
 
 
3.2 Using interviews to build cases 
 
The process of constructing a case can be compared to the process of creating a 
piece of art (Birgerstam, 2000). The artist, or in this case the researcher, chooses to 
take interest in a certain phenomenon, from a particular angle. A rough sketch 
receives more nuances with more colors and artistic efforts. That is much the way a 
case takes shape as well.  
                                                       
12 Crushed flaxseeds have multiple health effects. The main effects are a decreased risk of 
coronary heart disease and hormone related forms of cancer (Anonymous, Kemivärlden, 
2001).  
13 The ProViva study was presented in Appendix IV of the-state-of-the-art study (Mark-
Herbert, 1993).  
14 The cases about the development of Magiform and L. reuteri were chosen based on 
personal contacts and previous knowledge of the development of functional foods (personal 
communication Lindgren  (1986) and Börjesson (1999)).  
15 Two articles and a personal meeting at a health conference opened the door for the last 
case about the development of IgY-egg products  (personal communication, Andersson, 
2000).   
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In practical terms the process of letting a case take shape can be translated into a 
number of work phases in an iterative model (Wigblad, 1997, 22) of abduction. 
This refers to making use of theoretical knowledge and empirical insight while 
remaining open for new explanatory factors. One interview creates the basis for 
understanding the next and so forth. Interviews are carried out until saturation 
appears, during which the interviewees no longer add information to what appears 
to be the case. Prior to each personal interview the respondent receives a letter and 
an interview guide, (Appendix 2) if requested, to prepare the interview.  
 
Themes in the interview guide are based on what has been reported in scholarly 
journals as factors that affect the innovation process. The guide serves as a support 
during the interview but the interviewees are free to talk about anything that they 
feel might affect the innovation process as such (i.e. the development of their 
products and processes). This would thus qualify as semi-structured interviews.  
 
As the main method for gathering empirical material, the research interview 
exhibits a number of characteristics. It is an interaction between two people with 
reciprocal influence on the outcome (Kvale, 1997). What may appear as a relaxed 
conversation aims to describe a specific situation in the world of the respondent. 
The respondent’s story is built on his or her logic and structure, thereby 
determining what is of importance and what is not.  
 
During the interview a continuous validation process ensures the researcher of an 
approximate understanding of the interviewee (Kvale, 1997). Typically such 
validation would be a question such as ”Do I understand you right if I say that …?” 
or, in some instances, it is a questioning statement that summarizes what the 
interviewee just said.  
 
Multiple interviews in each case are used to create narratives of a development 
process. Usually the respondent starts with some personal and general background, 
providing a retrospective understanding of the story that follows. In most 
interviews the story follows a chronological development. Towards the end of an 
interview most respondents are willing to share strategies for future developments, 
assuming that this information is handled with discretion.  
 
After the interview, tapes are transcribed and translated. The transcriptions are sent 
to the respondent for corrections, additions and in some cases to delete a paragraph 
or two. Once the transcriptions are returned they are corrected in accordance with 
the interviewees’ comments. Each interview renders a part of the base that is used 
for writing the case. 
 
A second step in validation occurs when the interviewees, experts and other 
representatives for the food industry read the cases. Cases are sent to each 
respondent once a case is finalized. In the ProViva case a ‘post-case interview’ 
created grounds for an epilogue. The present CEO felt that the changes that had  
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occurred in the last two years were of major importance for understanding the 
present situation. So far the cases have fortunately been met with supportive 
comments and acknowledgements during presentations (Örnewall, 2000). Even the 
survey studies (Mark-Herbert & Nyström, a pilot study, 1993, and a follow up 
study in 2000) have been greeted with recognition among representatives from the 
food industry (personal communication, Nobelie 1999; Rosenström 1999; 
Wennström, 2000). 
  
 
3.2.1 Ethical considerations 
Most qualitative research working with interviews to build cases requires taking 
interest in another person' s views and experiences. Those who have been 
interviewed risk exposure and embarrassment. To counteract possible undesired 
effects, the ethical implications of the interview procedures are discussed prior to 
each and every interview. This trust allows for the interviewee to talk at liberty 
about what he or she feels is of value with regard to the main questions in the 
interview guide. Sometimes the conversations went far beyond the scope of the 
guide, but at the time it was impossible to judge what would be of explanatory 
value to the study and what would not.  
  
The research procedures were, at all times, carried out in accordance with the 
agreement that was made prior to the interview. A few interviewees felt 
uncomfortable with the tape recorder during our first encounter. It was turned off 
and in most cases the tape recorder was not a problem during a second meeting. A 
draft of the interview was sent to the interviewee - and for the most part it was 
returned with minor corrections, clarifications and suggestions.  
 
Examples of correction and clarification are seen in many of drafts for each case. 
Respondents were asked for comments and in some cases these comments were 
contradictory to each other, which lead to numerous mails and phone calls. In the 
ProViva case, the new CEO did not feel that the case left the reader up to date with 
the development. This was resolved by a brief interview that gave rise to an 
epilogue. 
 
In one case, however, ethics posed a major problem. After two completed 
interviews with persons in key positions in the business and major investigations, 
the CEO withdrew his promise to engage in the research process. The reason being 
that a business on the stock market cannot reveal such sensitive information 
regarding technological and market strategies. My personal disappointment did not 
undermine my ethical guidelines established for the interview and I respected their 
choice. This case is, therefore not presented as a full case, since much of the story 
remains to be told, but it is presented as a short case and, as such, provides 
interesting information.   
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3.2.2 Level of analysis   
The level of analysis refers to what is regarded as an analytical unit. Assuming the 
innovation activity is a process in which several actors and resources are involved, 
the analytical unit has to be aggregated. Four possible levels of analysis are 
identified: the innovation itself where a number of individuals are engaged 
(referred to as product/process level), an organizational sub-unit (departments), the 
organization (company) and the industry.  
 
One level of analysis may be sufficient to provide an answer to a proposed 
question. It is also possible to use different levels of analysis, thereby enhancing the 
understanding of a problem. Here, an institutional analysis of the industry (Chapter 
4) provides a contextual understanding for case studies on a company and 
product/process level (Chapter 5). The interest is in this study is on factors that that 
enables businesses to generate and develop viable new products on a regular, not 
occasional, basis. 
 
 
An innovation project 
Studying the process at the level of innovation tends to focus on the outcome. It 
makes it possible to study certain characteristics of a project in detail such as: 
complexity, “radicalness”, relative advantage, the need of resources and use within 
the organization.  
 
 
A subunit activity  
On a subunit level the process is commonly in focus. Studying the R&D process in 
organizational subunits include communication, decision making within a 
department (Farris, 1988), tenure of R&D groups and the diversity of R&D teams 
(Gordon et al, 1991). This level of analysis may also include studies of interaction 
between different subunits (departments and functions within a business). Typically 
these studies tend to identify critical factors within the company that either hinder 
or facilitate the innovation process.   
 
 
An organizational  process 
The organizational level of analysis offers two approaches, firstly with focus on the 
outcome and secondly with focus on the process. Studies of the outcome largely 
describe structural, behavioral and contextual characteristics, which differentiate 
innovative companies from non-innovative (Markides, 1998). Studies where the 
process is of interest mainly describe events, sequences and factors that are critical 
for the innovation process (King, 1992). The organization as a unit of analysis 
offers a management perspective for studying how the company adapts to changes, 
allocates resources and strives for overall effectiveness.  
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An industrial development 
Studying innovation at an aggregated industry level provides an understanding for 
the institutional setting. This includes, for example, legal aspects and general 
financial aspects of innovation, production and trade. The focus may be on the 
industry in a context or within the industry itself. Studies of the industry in a 
context identify differences in innovation patterns between different industries 
(Clark & Guy, 1998; Von Hippel, 1983).  
 
Studies of an industry usually seek explanations for relative differences in 
innovation performance between companies. Other studies of the industrial context 
include an understanding of broad cultural and resource endowments provided by 
society,  
distribution of resources, and structure of the industry. Research by Ruttan and 
Hayami (1984) suggests that innovation can be seen as a reflection of the amount of 
support an organization can draw from the larger community.  
 
 
 
3.3 A continuous analysis 
 
Facts are theoretically laden (Alvesson & Sköldberg, 1994). What is seen and 
communicated has to be understood and that calls for a perspective. This is 
revealed in a theoretical understanding and the use of a subject-related vocabulary 
(McCloskey, 1986). As a researcher I have an understanding of the phenomena I 
take interest in, prior to carrying out interviews (Van Maanen, 1988, 41). During 
the interviews my themes are chosen with a theoretical bias, allowing for some 
empirical material to be interpreted - and other to remain further untold. It is thus 
more than my prior experiences and understanding that delimits the first analysis of 
the socially constructed empirical material (Kohler-Riessman, 1993).  
 
Combining different methods of analysis is sometimes referred to as 
methodological triangulation (Janesick, 1994). In the project, a combination of 
methods are used in a number of analytical steps (Figure 1.2). In this thesis the case 
studies are presented as a base in a continuous analysis process. It is revealed as 
three analytical steps, but there are no fixed boundaries separating the early 
analysis, later analysis, or the final analysis. The first, within-case analysis, 
addresses the product that has been developed and how this development occurs. 
These developments are presented as narrative stories, “cases” in Chapter 5. A 
second step is a comparative content analysis of the cases, which is revealed in 
Chapter 6. And lastly, in Chapter 7, a conclusion of the analysis, of the cases and a 
context, that may provide an understanding of the institutional factors for the 
development of radically new food products.   
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3.3.1 Narrative cases 
A case is a piece of a created reality. When communicated in interviews, this reality 
is commonly shared as a story, a narrative. It provides a time, a social and a 
contextual dimension for a phenomenon (Mishler, 1986). Keeping these structures 
in a case provides a contextual understanding of the phenomenon for a reader 
(Kohler-Reissman, 1993). 
 
Precisely because cases are “meaning making structures”, narratives must be 
preserved, not fractured. The primary narratives appear in interviews when the 
interviewee shares an experience with the interviewer. A second level of narrative 
is created when these narratives are analyzed and combined to create a narrative 
case. Narrators thus create structure in a disordered experience.  For the present 
study, it does not mean that the interviewee describes the innovation process in a 
logical sequence – the sentences in the narrative cases provide this logic for the 
reader (Czarniawska, 1999,8).  
 
In sharing an experience, the interviewee chooses to reveal some things and others 
remain untold. Depending on the listener, the rhetoric and the content of the story 
may even vary. My interview guide has, no doubt, guided the interviewee in a 
specific direction and stimulated the use of a certain vocabulary (Barry& Elmes, 
1997). In the figure below (3.1) Kohler Riessman (1993) shows how an experience 
is “reduced” in the narrative process (the lower trapezoid).   
 
 
 
Primary experience 
Attending 
Telling 
Transcribing 
Analyzing 
Reading 
 
Figure 3.1 Levels of representation in the research process (Kohler-Riessman, 
1993, 10). 
 
 
In this model the primary experience, attending in the figure (3.1), refers to 
individually perceived sensations, such as olfactory sensations, visual input and  
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auditory impressions. Examples would be the scent of newly baked bread, and the 
sound of the oven door closing. The next level in the model, telling, requires a 
picture of how these impressions fit together. In the narrated story some 
impressions, the smell, for example, is difficult to convey. In the process of 
transcribing, more nuances are lost, such as facial expressions and articulation. In 
the analytical step the information is even further delimited with regard to what 
seems to provide insights to a research question, and what does not. In the last level 
of this model, a reader meets with what remains of the primary experience. Kohler- 
Riessman (1993) does not provide a distinct interpretation of what the trapezoid 
with the base upwards resembles.  
 
My interpretation of the figure is that the lower trapezoid signifies only some 
aspects of a story can be told – and furthermore told again, in a second narrative, so 
as to be understood by a reader. In terms of this thesis, many hundred pages of 
interview -transcripts, brochures and articles are narrated to a fairly short part of my 
dissertation. I interpret the upper trapezoid as representing the perception of the 
narrative perceived by the reader. The broad base represents the total understanding 
for the reader (preconceived ideas16 and the perception of the actual narrative).  
 
Kohler-Riessman (1993) does not address the problem of translation that a person 
with English as his or her second language will face. Every translation implies risks 
of loosing contextual understanding and linguistic nuances. This problem could be 
illustrated as yet another level in the trapezoids in Figure 3.1 (perhaps a top of the 
trapezoids from both sides, creating two triangles in Kohler-Riessman’s figure).  
 
The interplay in the narrative between the interviewee, the author and the reader 
suggest that the interpretation of the text is both pluralistic and dynamic. It is 
reflecting the interviewee’s intent, the narrator’s perception and intent, and the 
reader’s constructed meaning.  
 
 
3.2.2 Comparative content analysis 
Comparative content analysis refers to cross case analysis. This is where 
similarities and differences between cases are shown and discussed. These 
comparisons are often illustrated in matrices with explanatory reflexive thoughts to 
explain the comparison. Quotations from the interviews are also used to illustrate 
the comparative analysis.  
 
Depending on the strategy for cross case analysis, different comparisons are 
performed. As pointed out by Ragin (1992) a distinction can be made between case-
oriented and variable-oriented comparative studies. The latter focus on 
predetermined variables of particular interest.  In this thesis, however, a cross 
comparison is carried out as a case-oriented replication comparison (Yin, 1984). 
                                                       
16 Förförståelse  
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This refers to building a conceptual framework around one case, the ProViva case, 
and successive cases are examined to see whether the new patterns match the one 
found at first or not.  
 
In principle, this approach can be compared to generating a ' grounded theory' 
(Strauss & Corbin, 1990) where a framework is built up inductively and refined by 
multiple comparisons (Huberman & Miles, 1994). The inductive process does not 
mean looking at empirical data alone. It refers to the interplay between the 
understanding of one case, with a theoretical preconception of the phenomena, and 
refining the understanding in repeated comparisons with other cases. 
 
 
 
3.4 Ensuring rigor 
 
There are numerous ways to ensure rigor in qualitative research, where some of 
these methods are more appropriate and usable than others (Denzin & Lincon, 
1994). Traditionally, the terms validity and reliability are used in discussions about 
ensuring rigor. In qualitative research these terms are refined using, for example, 
the terms criteria of adequacy and appropriateness of data, careful documentation, 
and different forms of validation.  
 
 
3.4.1 Criteria of adequacy and appropriateness of data  
To attain adequacy, a number of persons are interviewed for each case. Each person 
tells their story, where parts of one interview confirm parts of another interview. 
Printed material and internal documents also provide information. This provides 
concurring and confirming data, and with sufficient number of interviews it ensures 
saturation. Seeking cases that are as different from each other as possible gives a 
rich empirical picture. Additional interviews with people representing, for example, 
legal authorities may also be a part of confirming data. 
 
 
3.4.2 Careful documentation and validation 
Careful documentation in ' thick descriptions'  (Stake, 1994, 242) and explanations of 
the many research steps taken are two ways of aiming for research transparency. 
Organizing the data material and dating the documents are important factors in a 
careful documentation. These notebooks of transcripts and articles of empirical 
material are preserved for researchers to use in future studies. 
 
A research log-book helped me keep track of versions of cases, of who to ask about 
what and the questions that each analytical step gave rise to. I have not been able to 
follow up on all the questions that emerged as the research process progressed.  
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Some of the questions are addressed in this dissertation. Others remain as 
allurements for future research.  
 
Validation in different audiences is a prerequisite for research rigor. The first 
validating step is taken during the actual interview, in a conscious approach to the 
interview technique (Kvale, 1997). This means continuously validating the 
interpretations of what has been said.  During the interview it is also possible to ask 
about interpretations of what has been told in previous interviews, thus allowing for 
help in rating as well as verifying data.  
 
Validation is also given in reader responses to drafts, presentations and conclusions. 
Presenting the studies for different audiences has proven helpful in creating 
credible interpretations based on empirical data and theory. 
 
 
3.4.3 Method in retrospect 
Working with narrative cases has been rewarding and challenging. I realize that my 
linguistic sensitivity puts limits to the art of working with narratives. My role has, 
for the most part, been that of an author that excludes her self in the presentation of 
a singular external perspective. That may imply a false sense of objectivity and an 
unbiased view of my role. On the contrary, I see subjectivity in choices of what 
should be included and how it should be worded. In these subjective choices I rely 
on validation and the use of good judgment from my interviewees and critical 
readers.  
  
Using interviews to build cases provides an understanding for the innovation 
process in these four case studies. These cases are stories that provides some 
answers to a few “what?” and “how?” questions. A continuous validation pr ocess 
provides high internal validity and reliability (Yin, 1984, 40-45).  But, how about 
the external validity; are these findings possible to generalize? Reflexive reasoning 
and empirical insight might allow the reader to find other appropriate areas for 
generalization.  
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4 A review of functional foods   
 
 
 
 
Phyto-foods (Hanman, 1993), therapeutic foods (Ruderus, 1992), kinoseishokuhin  
(Japanese for ”foods for specified health use”; PA Consulting, 1990),  designer 
foods (Caragay, 1992), neutraceuticals (Foundation for Innovation in Medicine, 
1989), "funkismat", good-for-you-foods and ”added value foods”17 – the 
designations for functional foods are numerous.  
 
This chapter offers some clarification of the concept functional foods, a short 
historical background and a brief market analysis.   
 
 
4.1 Food, medicine or what? 
 
The term functional foods leads the thought to a food with a specific function or 
effect. The product may vary in shape as well as in specific function but the desired 
outcome is a scientifically proven medical effect. It may be a preventive effect, 
which delays or altogether impedes the onset or further development of a disease, 
or even a curing effect. It is especially with this last effect that the distinctions 
between food and medicine get blurred, in the communicated functions of this 
product (Figure 4.1). 
 
F oods- 
part of a 
healthy  
life style 
 
F unctional  
food - 
prevent 
illnesses 
M edicine- 
cure 
illness 
 
Figure. 4.1 Differences between foods, functional foods and medicines (Mark-                           
iiiiiiiiiiiiiiii Herbert, 1993, 4). 
 
Foods provide energy, nutrition, organoleptic18 enjoyment and in many cases a 
mode of social interaction (Briggs & Calloway, 1984). Functional foods do all of 
the above and also have a preventive effect. If functional foods are seen as food 
products, they are also expected to appear food-like (Ruderus, 1992) and have a 
pleasant taste. If functional foods, on the other hand, are seen as proactive 
medicines, they may assume medicine-like shape and taste.  
                                                       
17 ’Added value foods’ is a direct translation of ” mervärdesmat” which in turn is a 
translation of functional foods in a text on novel Swedish words (Moberg, 2000).  
18 Organoleptic refers to taste and smell.   
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Consumer perceptions of functional foods thus seem to be one way to establish the 
categories of foods, functional foods and medicines. Other distinguishing grounds 
for division are, for example, the effects of these foods (Mark-Herbert, 1993, in 
Appendix 3 & 6), whether these products are developed by nature vs. developed in 
an industrial development process (Chapter 1), or how these products are marketed.  
  
4.1.1 Strategies for marketing functional foods  
Depending on the marketing strategy for functional foods, the conditions for sales 
and distribution will vary. If a functional food product is sold as an OTC (Over The 
Counter), for example, the distribution channel (in Sweden) would be a pharmacy. 
The marketing strategy would include information to medical professionals. If, on 
the other hand, a product is sold as a normal food or a health food the expected 
distribution channel would be the retail market where consumers would find the 
product in a food store, or possibly a health food store.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
D istribu tion channels 
 
C on su m er/ Retail (foodstores) 
M edical professional  (pharm acies) 
P rescription 
dru gs 
 
 
  H ealth  
n u trition  
 
O T C   M edical  
n u trition  
T radition al 
 food 
S trategic functional foods categories 
O T C , Over The Counter, refers to a group of products which are sold as a drug 
b ut without a prescription in a pharmaceutical area of a food store, a health 
sto re or in a pharmacy. Exam ples are Q10 and head ache medicines.  
M ed ica l Nutrition includ es products such as tube feeding nutrition and dietary 
sup p lem ents.  
H ea lth Nutrition is seen in products like sports drinks, cholesterol lowering 
m argarines and high-fib er cereals.  
 
Figure 4.2 Marketing strategies for functional foods. Depending on the strategic 
position the business chooses to take, the marketing, sales and 
distribution channels will vary (Mark-Herbert & Nyström, 2000A, 42).  
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The marketing strategy will thus greatly affect the price of the product19 and the 
sales volume. Figure 4.2 also illustrates that functional food is an arena where the 
food and the pharmaceutical industry may have mutual interests. This is further 
discussed in Chapter six. 
 
It is mainly in the sales argument for the product that companies reveal their 
marketing strategy. History shows that the very same product can be sold as both a 
pharmaceutical and a food product. An example is Wasa Fiber (a hard bread) which 
was sold as a food product in the 1970s, with health arguments. The Medical 
Products Agency20 did not accept these arguments - not because they did not hold 
scientifically, but because health arguments could not be made for food products. In 
Sweden the medical product legislation has precedence21 over the legislation that 
concerns food products. Registering the product as a medical product, however, 
allowed for appropriate health-related arguments to be proclaimed in marketing the 
product.  
 
 
4.1.2 Legal definitions 
Marketing functional foods in Sweden in the 21st century is still an area of debate. 
It is guided by the National Code of Practice22, which allows for eight well 
established relationships between diet and health to be made (Table 4.1) in 
marketing food products. 
 
Table 4.1 Eight established relationships between diet and health (Asp, 1999) 
Health problem  Well-established relationship with... 
Obesity  Energy content 
Cholesterol level  Fat 
Blood pressure  Salt 
Arteriosclerosis  Omega-3-fatty acids 
Constipation  Dietary fiber 
Osteoporosis  Calcium 
Caries  Easily fermentable carbohydrates 
Iron deficiency  Iron 
 
 
The generic claims have to be presented in two steps, where step one is information 
regarding the diet-health connection, which is related to step two, information on 
                                                       
19 The sales tax will also vary depending on if the product is marketed as a medical product, 
health or hygiene product (25% tax) or a food product (12% tax) in Sweden.  
20 Läkemedelsverket 
21 When one law takes precedence over a second law, this is referred to as a superceding 
law. (Läkemedelslagen har tolkningsföreträde). 
22 The National Code of Practice is an agreement between the food industry and legal 
authorities. It provides guidance to marketing health related foods.   
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the composition of the product. An example would be  "Dietary fibre can help 
prevent constipation. Product X contains high amounts of dietary fibre." (internet, 
functionalfoods.nu, 2001). 
 
A legal framework is being developed within the EU, where a European Food 
Authority is proposed to have a number of functions. One function is to harmonize 
the future food legislation "from farm to table" within the community  
(internet, functionalfoods.nu/file/dyn/0000m/619i/dyn, 2001).  
 
 
 
4.2 Functional foods  
_ 
 where did it all start? 
 
The question regarding the need for functional foods is often raised in debates. To 
understand this development, a brief historic review of influencing factors in the 
development of functional foods is presented below.  
 
4.2.1 Cultural food habits 
One might argue that people have always been interested in health and to a certain 
extent that is true. This is expressed as habits on an individual level as well as in 
cultural rituals.  
 
Ancient cultures developed skills in, for example, the use of herbs to promote 
health. Living conditions and climate also promoted the development of processing 
skills to maintain food freshness and enhance nutrient availability. This is, for 
example, seen in cultured milk products and hard bread in Scandinavia (Swahn, 
2000). In other parts of the world the use of garlic, olive oil, spices and numerous 
vegetables and fruits are other examples of cultural habits that promote health.  
 
The discovery of vitamins can be seen as a precursor for the concept of functional 
foods. A well-known example is the proactive treatment of scurvy23 by simply 
having, for example, citrus fruits on a regular basis as a part of a meal.   
 
Nowadays, food related poor health is, in the rich parts of the world, mostly not 
associated with lack of nutrients. Rather the contrary, the problem is that of 
overeating (Peyron, 2001)24 and having an unbalanced food intake. These problems 
cause individual suffering and costs for society. It should be pointed out that much 
attention is given to infectious diseases, such as BSE and Salmonella infections. 
                                                       
23 The term  scurvy  refers to a condition which is caused by lack of C-vitamin.  
24 In the article "An industrial perspective on obesity and poor health. Obesity is one of the 
biggest threats to health in society" (2001) Bitti Peyron discusses the effects of obesity. The 
increased risk of developing diseases like diabetes, high blood pressure, metabolic diseases 
and cardiovascular diseases is pointed out.  
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The major cause of disease and early death, however, is associated with poor food 
habits, which may result in hypertension, diabetes, cancer and coronary heart 
disease. Despite a great deal of knowledge gained on the impacts of diet on health 
and specific diseases, relatively little is known about how to influence dietary 
choices (Shepherd, 1989). It is assumed that possible explanations of dietary 
behavior are related to an optimistic health bias (sickness does not strike me) and a 
problem with comprehending complex health issues as well as factors that affect 
human behavior in general (for example, physiological needs, social and cultural 
factors).  
 
 
4.2.2 A societal investment25 
It was the threat of escalating medical care costs that stimulated a societal 
investment in functional foods in Japan. Demographical studies in the early 1980s 
revealed an increasing number of aging people. This group of ‘old people’ was 
getting larger and their expectations on their standard of living were increasing. In a 
societal perspective that implied increased costs for care in general, and medical 
care in particular.  
 
One way to lessen the costs for medical care was to offer old people health-related 
products that allow for ‘self-care’ as long as possible. A major research fund was 
set up by the Japanese government in 1984, parallel to the development of a legal 
structure that would allow for these products to be sold with health arguments.  
 
Japanese industrial interests were stimulated in part by the fund and in part by the 
shareholders interest in long-term pay back. The long-term pay back interests 
facilitate long-term R&D investments that are seen as a prerequisite for the 
development of functional foods.  
 
 
4.2.3 A growing interest for functional foods among food companies 
One way to show the growing interest for functional foods in the food industry is to 
look at available functional food products on the market. In 1993 some 16 products 
were mentioned in a survey study about functional foods (Mark-Herbert & 
Nyström, 1993 B, in Appendix 5). A quick review of available products today 
shows well over forty products with web sites (Appendix 3). A closer investigation 
in a food store will show vastly more products than those listed in the appendix 
(with a web site).  
 
A growing interest in functional foods in the 1990s is also reflected in an increasing 
number of articles about these products. When I started my article collection in the 
early 1990s I was thrilled to find an article that remotely touched on functional 
                                                       
25 Mark-Herbert, 1993 (a literature review).  
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foods. Ten years later I find myself with many notebooks full of articles, unable to 
keep up with the progress.  
 
A database search26 on functional food* showed that the number of publications 
about functional foods has increased significantly in the last decade (Table 4.2, and 
4.3). 
 
Table 4.2 Data base search for publications about functional food*  
Data base  Þ Þ 1990  1991-2000 
Libris  4  41 
Affärsdata (Tidningsdatabas)  0  18 
BTJ Artikelsök  0  128 
WebSPIRS**  1990: 7  2000: 240 
*     The search was carried out on functional food* (singular and plural).  
**   During this year alone. 
 
 
The data-base WebSPIRS is large and a (non truncated) search for the years 
between 1990 and 2000 shows an increase in articles with time (Table 4.3). At a 
first glance, the number of displays for 2000 may seem low. Why the sudden 
decrease?  The lower number, compared to the previous year, may be attributed to 
the fact that there may be a significant delay in coding articles in the data-base.  
 
Table 4.3 A database search on “functional foods*” 27  in WebSPIRS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                       
26  A data base search on functional food/ s was carried out in Libris, Affärsdata, BTJ 
Artikelsök and WebSPIRS by Christina Brundin, librarian at the Department of Economics 
at SLU, Uppsala, Sweden (March 1, 2001). 
27 The table shows the number of displays of Functional food/s (singular and plural) in the 
caption in articles in the database WebSPIRS. 
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These database searches show an increasing number of articles about functional 
foods in papers and journals. In reality, the number is much larger than these 
searches indicate. This is explained by the fact that only those with functional foods 
in the headline provided a display in the search. Nevertheless, this search shows a 
growing interest in functional foods. Looking in more detail the lists of publications 
show that an increase in articles in scientific and professional journals precede an 
increase in common papers and popular journals. This may indicate that the 
development process is driven as much by "technology push" as by "market pull".  
 
In attending food conferences, I also find a growing awareness of the area of 
functional foods. All food companies are not pursuing this avenue but they all keep 
track of consumer needs - and health related products are certainly in vogue. Some 
would argue that health values are perpetual, as a growing awareness, others argue 
that it is a trend. It is clear, however, that food companies are attentive to 
consumers’ needs. 
 
A growing interest in functional foods is partly stimulated in Sweden by financial   
support from governmental and industrial research funds (Ingvarsson, 2000). Most 
of this research is, as we will see in the cases, carried out at established universities, 
for instance in Lund, Göteborg and Uppsala, in collaboration with food companies. 
This financial support in Sweden is rather moderate compared to the investments 
made in, e.g., Japan and Finland.28 Investments in Finland and Sweden are, for the 
most part, motivated by forecasted industrial advantages. In Japan, on the other 
hand, the Health Ministry took the initiative and it appears as if the health effect 
among citizens was the primary driving force.  
 
The number of functional food organizations is also steadily increasing (Appendix 
4). The national center in Sweden is located in Göteborg  (Swedish Centre of 
Excellence and Innovation in Functional Foods, www.functionalfoods.nu). It is 
seen as an arena for the development where business interests meet research 
interests and societal needs. This center provides information, advice and lobbying 
for further development of functional foods.  One of the areas where this center fills 
an important role is in providing information about functional foods to the public 
and to representatives for food companies.  
 
 
                                                       
28 In Finland a long-term research project in the area of functional foods (300 million FM) is 
put forward by TEKES (the equivalence of NUTEK in Sweden) for joint projects at 
universities in collaboration with food businesses such as Fazer AB, Valio OY and Raisio 
OY (Ingvarsson, 2000, 20).   
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4.2.4 Well-informed consumers 
With the growing access to information through various avenues in IT, consumers 
shop around to satisfy their needs. This is, for instance, seen in medical care where 
doctors face patients well acquainted with their diagnosis and willing to discuss a 
treatment plan (Kollberg, 2000). Consumers have become increasingly concerned 
about the risks associated with food (Weinstein, 1987). These concerns involve 
worries with respect to the product itself (genetically modified organisms and 
pathogens such as BSE, E-coli, Listeria or Salmonella) and the diseases that are 
promoted by a certain diet. It is commonly known that cardiovascular disease, 
cancer and diabetes are major causes of death, and they are in part attributable to an 
unhealthy diet. Well-informed consumers are thus seeking alternatives. Health-
related products therefore constitute a pro-active alternative to sickness and 
treatment.  
 
In response to these fears the public responses to functional foods vary. Depending 
on food habits, life style and perceived risks, individuals are, to a varying degree, 
willing to change food habits and pay a premium price for a more healthy product 
(Figure 4.3). 
 
 
 
Prevention 
At risk 
”Sufferers” 
Mass market 
 
 
Figure 4.3 Market segments with different needs for functional foods (Mark-
Herbert & Nyström, 2000, 36). 
 
 
Assuming that the functional product is a food product (not a capsule or a pill) it is 
clear that taste to a large extent determines the success of a product launch in 
Sweden (Nyström & Edvardsson, 1980; Rune, 2001). Future functional foods thus 
have to be tasty and appealing in addition to having scientifically proven health-
effects. 
 
Consumers with the highest motivation to try new 
health related foods are those with symptoms of a 
disease, the “sufferers”.  
 
Those who are aware of a risk, for example 
hereditary cardiovascular disease, also show a 
high willingness to change food habits to decrease 
risk.  
 
The segment labeled as “prevention” refers to 
people who are health conscious, usually with an 
interest in how food and physical recreation may 
affect their health.  
 
Mass market refers to the average consumer with 
little or no interest in functional foods.  
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It is also an open question how consumers understand, relate to and believe in 
health messages for functional food products. Studies of consumers’ understanding 
of health information show that scientific health arguments are not comprehendible 
for a vast majority of consumers (Laser-Reuterswärd & Svederberg, 1999; 
Svederberg, 1997) Market investigations show that products sold with a “soft” 
argument are greeted with acceptance among the vast majority of consumers 
(personal communication, Wennström, 1999). An example of such arguments is 
used in marketing the products ProViva, “for a better stomach” – 
 ”your stomach will thank you”, and Oat Milk, “for a better heart”.  
 
 
 
4.3 A market analysis 
 
4.3.1 Functional food markets in 2001 
The functional food market is hard to quantify. This is in part explained by the fact 
that functional foods are diverse, which is problematic in defining this group of 
foods. Assuming that the definition of functional foods is restricted to foods and 
drinks, which are sold with a specific health claim on packages and in 
advertisements, the total market in Europe (1999) was approximately $1.79 billion 
(Hilliam & Young, 2000).  
 
Looking at international development, it is clear that different functional food 
segments are developed depending on regional food preferences as well as 
emerging regional developments of technologies (Table 4.4). 
 
 
Table 4.4  Functional food sales and trends by country/region  
 
Country/ 
region 
Sales in 1999 
($ billion) 
Comment on the market 
Europe  1.79  A highly developed market in dairy products, dominated 
by probiotic products.  
USA  1.80  A market in development, especially for breakfast 
cereals and fortified drinks. 
Japan  2.13  A large and rapidly expanding market, especially in 
probiotic and fortified drinks and spreads. 
Source: Hilliam & Young, (2000) 
 
 
Functional food markets have developed in different directions, with Europe seeing 
the area of ‘gut health products’ (Hilliam & Young, 2000), in particular probiotic 
drinks, as an important area (Table 4.5). The US market is characterized by much 
wider interest in anti-cancer products and the use of botanical raw materials. While  
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the Japanese market also has a strong focus on gut health products, the range of 
products makes it unlike any other market. 
 
 
Table 4.5 Functional foods by sector and country, 1999 (Hilliam & Young, 2000) 
 
 
Food 
segment 
UK 
Value (£M)   % share 
France                  
Value (FM)   % share 
USA                   
Value ($M)   % share 
Probiotic 
yogurt 
120  39  1 190  60  115  7 
Prebiotic 
drinks 
20  7  182  9     
Spreads  104  34  205*  11  22  1 
Cereals  60  19  400**  20  1 500  83 
Soft 
drinks 
3  1      166  9 
  307  100  1 977  100  1 803  100 
*   Probiotic ‘fromage frais’   
** Dietic biscuits 
% share refers to the share of total functional foods sold in each country respective 
!  Note the difference in currency in M (million) for each country (next to value) 
 
 
Cultural food habits are reflected in the food segments where functional foods are 
found in different countries (Table 4.5). The following countries are demarcated as 
important European markets for the functional food markets: the Netherlands, 
Spain and the Scandinavian countries  (Table 4.6). 
 
Table 4.6 Important markets in Europe for functional foods  
  
FOOD SEGMENT  KEY MARKETS 
Dairy products  France, the Netherlands, Spain, Scandinavia, Germany, 
UK 
Spreads  UK, Finland, the Netherlands, France 
Bakery and cereal  Spain 
Drinks  France, Germany, Scandinavia, Spain 
Confectionary  Scandinavia 
Source: Hilliam & Young, (2000) 
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The functional food industry is almost as fragmented and difficult to define as the 
markets. While some sectors, such as the functional drinks sector, is characterized 
by local brands, other sectors, like the yogurt sector, is dominated by major 
multinational companies like Nestlé, Unilever and Danone. 
 
 
4.3.2 Future markets  
The future functional foods markets are forecasted to continue expanding in most 
countries and regions of the world where there is an established processed food 
market (Heasman & Melletin, 1998). An optimistic prediction for the US market is 
provided by Dr. Rao at Con Agra, a large food producing company in the US. He 
estimated the American market for functional foods to a value of approximately 
$10-20 billion29 in 1998, with a forecast for growth of about 15 percent per year 
(Taylor, 1998). Even more optimistic predictions for the US, predicting a market 
value of about USD 40 billion, and a growth potential of 17-20 percent annually 
were presented the very same year (BioGaia, 1998, 9). In this market analysis the 
value of the world market for functional foods that contain microorganisms alone is 
estimated to USD 3 billion. Market analysis and any kind of prediction differ in 
outcome depending on what is regarded as functional foods and how the 
institutional conditions in different parts of the world will develop.  
 
A closer look at the development in the Swedish functional food market shows that 
most food businesses with an interest in the functional food area welcome a legal 
framework for marketing functional foods (Alsén-Eklöf, 2001). The allowed 
product-specific health arguments in marketing functional foods in Sweden apply 
to food products, not food additives. In the US marketing food additives is less 
legally restricted than marketing food products. Consequently, in marketing 
functional foods, the choice of launching a product as a food or food additive 
depends on the legal marketing restrictions as well as how these products are 
perceived by consumers.  
  
Many predictions are made about future food habits. Some appear more utopian 
than others. Yet, this is market investigation that provides information about 
consumers desired developments of food products. What consumers really purchase 
and need remains to be seen. It is worth keeping in mind that food changes are 
slow. Most individuals are only willing to change their food habits in minor ways 
(Feurst, 1991) unless they experience a health related trauma, such as a disease.  
 
 
 
                                                       
29 This forecast is based on a broad definition of functional foods, which include dietary 
supplements.  
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5 Empirical findings 
 
 
 
 
Three narrative cases about the development of functional food products are 
presented below (Proviva, Magiform and IgY-egg). The products, as they appear on 
the market in 2001, are shown on the accompanying bookmark. In these narratives 
the empirical material is chronologically presented. This material involves the 
development of products, a number of processes and businesses. The focus of these 
cases is on the innovation process as such. This means that the process is described 
in phases, from the viewpoint of different actors and various perspectives. 
 
In addition to these three cases a brief presentation of the development of a fourth 
functional food product is provided (dairy products with Lactobacillus reuteri).  
This presentation is not a full case, but it provides an interesting presentation, 
which demonstrates some contrasts to the three cases.  
 
 
5.1 ProViva  
 
This case has its origins in the need for a treatment of patients after abdominal 
surgery. The medical treatment requires a product to help the body recover the 
functions of the digestive tract (gut). In order to develop this product a process for 
genetically identifying bacteria is developed. The development of a product 
thereafter soon follows. The product concept is expanded and the market for this 
product changes, from a medical market to a vastly larger food market. As the 
product and processes are developed, a business takes shape. New markets are 
discovered and the business more ground for further developments. 
 
The following sections introduce the product, the major process and the business, 
before giving room for the case. 
 
A product  
ProViva, means the living (Lat.). It is a fruit drink, which is produced by the dairy 
Skånemejerier, and sold in paper beverage cartons. The drink (juice) contains oats 
and health promoting lactic bacteria (Lactobacillus plantarum 299v). The four 
different varieties of exotic drinks are: rosehip, blueberry, black current and 
strawberry.  
 
A process 
A technology for genetically identifying bacteria made it possible to differentiate 
these bacteria from other lactic bacteria. That technology serves as a base for the  
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patent, and for the scientific clinical studies of effects at a later stage in the 
innovation process.  
 
A business 
The grounds for Probi AB were formed in a small research project in 1986. A group 
of scientists and an entrepreneur challenged a problem. Partnerships to finance the 
project, as well as to provide technology input, changed several times. Probi AB 
was founded in 1990 and in 2001 it had two subsidiaries, Probi Food AB and Probi 
Feed AB. 
 
 
5.1.1 The idea for a new medical product  
The ProViva project started as a purely medical project, in which a need for a 
medical product was identified at the hospital in Lund. Prof. Jeppsson noticed that 
after what should be regarded as a successful extensive abdominal surgery (kidney, 
liver etc.) the patient was in poor condition. Unexplainable complications even 
resulted in total organ collapse (death). Part of the explanation appeared to be the 
fact that the patient was treated with antibiotics prior to the operation to counteract 
any possible secondary post operational infections. The antibiotics put the 
pathogens, as well as the normal and desired, microbiological intestinal flora, out of 
action. After the operation pathogens microorganisms re-colonize the 
gastrointestinal tract faster than the indigenous flora. Thus, the stomach needs help.  
 
The digestive tract harbors a microbial flora30, which helps the body to break down 
and absorb nutrients. The turnover time is approximately 3-5 days. If the digestive 
tract lacks bulk (food for it to digest) during a time when the patient is given 
intravenous fluids and antibiotics, a leakage may be a result, during which bacteria 
diffuse through out the abdominal cavity, which may cause organ collapse. 
 
A first attempt at preventing this post-operation condition led to the development of 
a tube, through which nutrients could be given. Although the tube was functioning 
satisfyingly, it was clear that the nutrient fluids were not. Professor Larsson, an 
expert in food technology at Lund University, was asked what would constitute a 
suitable nutrient solution. This question arose during the 1980s when lots of 
positive effects from oats were shown. For this purpose the oats would have to be 
finely ground and in a solution, since it could neither be chewed nor chemically or 
mechanically digested in the stomach. Grinding oats, adding water and fermenting 
them would give a suitable nutrient solution. 
 
The next issue was to find the bacteria for fermenting the oats. The primary 
objective for the bacteria was to digest the oats, leaving nutrients in an appropriate 
form to be absorbed in the intestine. A secondary objective for the bacteria became 
                                                       
30 A healthy person has about 1 kg of microorganisms in her gut  (800 g for a woman and 
1000 g for a man).  
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apparent in a later stage of the project, when it was thought that the bacteria 
themselves were essential for the digestive tract. If these bacteria colonized the 
intestinal mucus, this would provide protection against pathogens (undesired 
microorganisms). Most of the commonly known lactic bacteria (Lactobacillus 
bifidus, bulgaricus and acidophilus) are suitable for products based on milk, but not 
necessarily for a grain-based product. 
 
Early on in the research project it was thought that the research should be run in a 
traditional way. That would include listing the desired characteristics this bacteria 
should have, and screening for the bacteria with the best match with these criteria31. 
Very soon the leading researcher, Professor Nils Molin (in microbiology), realized 
that a more productive approach would start with the question: "where can we find 
healthy bacteria?" The research procedures were changed. A large number of 
biopsies (200) were taken from people with healthy digestive tracts.  
 
From these biopsies about 20 different strains of lactic bacteria were isolated, 
identified and cultivated. A second biopsy was later taken from persons after they 
had been given fermented oats, treated with these 20 strains of lactic bacteria. 
Again, strains were isolated and identified from the biopsies. A few of these strains 
appeared superior to others with regards to survival (among them L. Plantarum 299 
v). The mechanisms that may contribute to bacterial survival and other desired 
health related characteristics are still being investigated. Some of the identified 
characteristics and abilities of L. plantarum 299v are the following:  
 
* the ability to use oats as a substrate, 
* the capability to adhere to the intestinal mucus in the digestive tract, 
* the capacity to survive in general in a product (through production, shelf life until 
consumed, and in the product' s route through the stomach, with a low pH, to the 
digestive tract), 
* and the capacity of decreasing levels of blood cholesterol and fibrinogen.  
 
The health benefits from eating ProViva lie in its prophylactic effects in the 
digestive tract, for example by supporting the immune defense. ProViva is also 
known to have a curing effect in, for example, some cases of Colon Irritable and 
during certain critical abdominal post-operative conditions.  
 
The research project in which the probiotic idea grew was within the frame of 
several doctoral theses at the University of Lund. The university provided an 
environment in which knowledge from different areas could be combined. The 
research mainly concerned developing processes, a method for genetically 
                                                       
31 The desired characteristics of the bacteria include surviving a low pH in the presence of 
gallic acid, having the ability to colonize the intestine, survive treatment in production and a 
time in storage, inhibit pathogens, and last but not least, provide a good tasting product for 
oral consumption in a later, post-operational, phase.  
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identifying bacteria, and a method to technically handle the cultures of lactic 
bacteria. It was these technologies that later led to the possibility of filing for 
patents on the manufacturing process, and eventually on the bacteria in the product 
( L. plantarum 299, L. plantarum 299v and L. rhamnosus 271).  
 
Depending on the country, patents will have different emphasis that reflects each 
country’s legislation regarding proprietary rights. The patented process of 
genetically determining the strain of bacteria are for the most part similar in Europe 
and in the US. The bacteria, use of bacteria and the product (ProViva), on the other 
hand, are patented in different ways depending on patent traditions in different 
countries.  
 
A research project in a university setting is constantly exposed to the critical eye of 
other experts, and therefore it is continuously the subject of improvements and new 
solutions. So far, the research had been aimed at finding a solution to the problem, 
the need for a nutrient solution for the feeding tube, but a new idea was sprouting - 
that of a probiotic food product (ProViva). 
 
 
5.1.2 Partnerships and development 
A collaborative partner may fill a number of needs, for example that of providing 
financial support, of finding future customers or representing a source of expertise. 
In the case of ProViva there has been several collaborative partners along the way. 
As the project proceeded the needs changed. And as the partners were altered, the 
aim of the research project was slightly altered as well. 
  
1986 A small group of scientists at the University of Lund (Professor Jeppsson, 
Professor Larsson, and Professor Molin, with their respective doctoral 
students) worked on solving a medical problem. Kabi Invent (a 
pharmaceutical firm) was partly supporting the project. 
 
1987 Kabi Invent regarded the project as a future medical nutritional solution for 
probes. At this stage Cerealia, a major actor in the Swedish milling industry, 
was also part of the project, since the base for the product was oats.  
 
 When Kabi Invent was sold to Pharmacia, another pharmaceutical firm, the 
project was closed. Pharmacia assisted in finding a new partner. 
 
1989-1993 The new partner was found in a large Dutch pharmaceutical company, 
Nutritcia. The financial support was solid but Nutritcia' s belief in the project 
was insufficient. The contract, aiming to develop a medical product, was 
soon terminated. At that point, however, the research group felt that they 
were pretty far ahead with the development of a good product. 
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1990 Probi AB was founded, located in the science park in close proximity to the 
University of Lund. 
 
1990-1991 During the early nineties the first contact was taken with Arla, a major 
actor in the Swedish dairy-industry. The need for a product such as ProViva 
was rejected because Acidophilus (a yogurt functional food product) had 
recently been developed. Skånemejerier, a large dairy company in the south 
of Sweden, on the other hand, proved to be interested. Contacts with the food 
industry during that time did not conflict in interest with regards to Nutritcia, 
because their interest and contract concerned only medical processes and a 
medical product. 
 
1994 In February 1994 ProViva was launched, developed as a joint project, 
produced and marketed by Skånemejerier in Sweden. ProViva was lanuched 
in the south of Sweden (Skåne), and the market was gradually expanded to 
cover all of Sweden (in sales and distribution agreements between major 
dairies in Sweden). The ProViva market was also expanded to include the 
UK.  
 
1998 Probi AB finds another partner in development in SIA Glass AB, a family- 
owned ice cream dairy. A new ice cream, “god hälsa” (Good health) is 
developed,  launched and sold in three varieties: tropical, lemon/lime and 
black currant.  
 
1998 Probi Feed AB (subsidiary of Probi AB) launched a probiotic horse product, 
ProEquo. It was developed in collaboration with the Veterinary hospital in 
Helsingborg.  
 
2000  The ProViva concept was further developed by Skånemejerier and Probi AB. 
In August 2000 a new sports drink “ProViva Active”, a recap product with    
L. Plantarum 299 v, minerals, vitamins, carbohydrates and proteins, was 
launched.  
 
 
As of 2001 there is still no medical product on the market. It could readily be 
developed, however, when called for by the market. Plans are made for marketing 
pills (tablets or capsules) containing L. Plantarum 299v as a natural remedy 
product.  
 
 
A product - ProViva 
The business Probi AB was founded in 1990. It was the result of the efforts of a 
group of researchers over several years, which had led to the development of a 
product at the prototype stage. In 1991 the product (prototype and concept) was  
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presented to Kenneth Andersson, responsible for R&D at Skånemejerier. He 
showed a positive response and interest in cooperation for future developments. 
The product was considered a novel idea, unlike any other kind of known food or 
beverage on the market (see a comparison in Appendix 3). 
 
An agreement was reached as a formal contract between Probi AB and 
Skånemejerier, in which Skånemejerier became part owner of Probi Food AB 
(subsidiary of Probi AB). The financial support was not large, but sufficient to 
maintain research and development continued. Skånemejerier was not just a 
financial partner, but also a strong partner in the later stages of development of a 
food product and a possible future producer of the product. As a producer 
Skånemejerier had a number of advantages, that of great tacit knowledge, market 
channels and marketing experience, a well established sales organization, 
distribution net (cool transports and storage facilities) and last, but not least, a large 
production capacity. ProViva was launched in February 1994. 
 
ProViva proved to have good properties, the main property being health effects for 
the consumer. Furthermore, ProViva proved to be suitable for production and stable 
in transport and storage, before reaching the final destination, the digestive tract of 
the consumer. This stability and product uniformity, allows for a rather long shelf 
life. A positive consumer response to the product is illustrated in Table 5.1 as a 
growth in sales. In January 1998 about 200 000 liters a week were sold in Sweden, 
and the sales were still increasing.  
 
Table 5.1 Sales of ProViva 1994-2000 in Sweden  
P ro V iva Classic Sales Sweden (tons/year 1994-2000)
0
10 00
20 00
30 00
40 00
50 00
60 00
70 00
80 00
90 00
19 94 19 95 19 96 19 97 19 98 19 99 20 00
 
Source: Personal communication, Lönne (2001). 
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ProViva was also gaining new markets outside Sweden, mainly through license 
agreements with dairies in each respective country. In 1998 ProViva could be found 
in the following countries: Sweden, Poland, Finland, Iceland, Germany 
(PrimaVita), Belgium, Denmark and the UK. 
 
 
 
A business - Probi AB 
Probi AB is a research-based business, owning several patents and production 
rights. Prior to 1998 Probi AB was owned by seven scientific researchers, the 
director (Kaj Vareman) and the dairy Skånemejerier. In 1988 Probi AB went public 
on the Swedish stock market. The marketing was carried out in the subsidiaries, 
Probi Food AB and Probi Feed AB. Within Europe, Probi AB and Skånemejerier 
coordinate marketing, export and license agreements. Probi AB handles licenses 
while Skånemejerier is responsible for production, marketing and sales in Sweden 
and in the UK. 
 
Probi AB relies heavily on the knowledge and skills of each person who is a part of 
the organization. It is through this expertise in closely related areas and each 
individual’s contact network with other experts that Probi AB can be described in 
terms of unique knowledge and skills. Connections with experts in different 
medical fields and in different countries are made. In order to gain legitimacy, 
clinical tests are carried out in many different countries. A local scientific expert 
addresses consumer questions. These experts are preferably found in medical 
specialties, which deal with the digestive tract. They are found in Sweden, Spain, 
Italy, Germany, the US and in Korea. 
 
Experts within and outside Probi AB have contributed in the R&D process, which 
has resulted in ProViva. The parallel development of the business in which this has 
taken place has been managed mainly by the director, Kaj Vareman. It is his 
philosophy, which clearly marks the way for the development: 
 
 
“I never take on a new project without the knowledge of another market 
agent who shows enthusiasm and willingness to spend some money on the 
project“ (personal communication, Vareman, 1998). 
 
“My philosophy is that the researchers should make money on what 
they create and do. I want them to feel included in the whole business... 
That way the corporate culture is one where researchers want to, and 
will, try new ideas“ (personal communication, Vareman, 1998).  
 
 
The director’s role can be described as that of being a translator between two 
cultures, the scientific research and a financial market. The researchers lack in most  
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cases a product prototype, a given market, business connections, a budget, a finance 
plan and a financial language. These are the areas where Vareman’s knowledge, 
experience, skills, and contact network were crucial. His role also includes the tasks 
of analyzing the market, developing the business and its strategies, finding suitable 
partners and, above all, marketing Probi AB and its products.  
 
A collaboration partner in Skånemejerier 
Skånemejerier is by Swedish standards a rather large cooperatively owned dairy 
company (medium size by European standards). The owners are the farmers in 
Skåne, in the south of Sweden. The company is divided into three main business 
areas: fresh produce, cheese and raw materials & industry. Each director of a 
business area and of each managerial area reports directly to the Chief Executive 
Officer. 
 
The supervisor responsible for R&D, Kenneth Andersson, guides the different 
R&D activities within what he views himself as “chaos with a few steady routines“. 
The in-house R&D activities carried out within Skånemejerier are mainly that of 
development (in addition to production and marketing). This is perceived as their 
relative strength. The research, on the other hand, is conducted mainly by small 
university-bound research groups and businesses, which are in close contact with 
Andersson and his production personnel. 
 
Information about each R&D-project is kept in a so-called R&D-notebook. In this 
file the progress of each project is monitored, and ideas for new projects are saved. 
The ideas for a new project may originate from a Skånemejerier employee, an 
R&D-partner or from anyone else outside the company. Each project is regularly 
reviewed by the Development Committee and judged after certain criteria. If an 
idea for a project at some stage does not pass the screening process, it does not 
mean that it is forgotten for all future. It will remain in the idea database, to be 
reviewed at a later point. 
 
The Development Committee consists of the CEO, the respective director of each 
business area and the R&D supervisor Andersson. Each of the ideas are reviewed 
by Andersson. If an idea is perceived as interesting, it is carefully reviewed and 
sorted in to the most appropriate business area. In an ideal project the person in 
charge of the business area is involved from the start. This is desirable for many 
reasons, one of them being that it is easier to make major changes early in a project. 
Furthermore, it allows for the R&D-process to be carried out in part as parallel 
activities, rather than as sequential activities. These other activities include market 
testing, negotiations with business partners regarding sales and distribution, and, 
when required, development of new packaging techniques. It also enhances the 
acceptance of changes in technology, products and within the company as such. In 
the continued R&D process, meetings are held where Andersson, the director of the  
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business area, the research group or business, and specialized production personnel 
from Skånemejerier meet regularly to discuss the progress of the project. 
 
The R&D-activities within Skånemejerier can be seen as  “r&D“, where the 
relatively small r symbolizes the contact with research carried out at universities or 
in research-firms, such as Probi AB. The large D symbolizes the vast knowledge, 
skills and technology within Skånemejerier, related to handling raw materials, 
production, packaging, marketing, distribution and sales.  
 
 
5.1.3 Strategies and visions - continued R&D and new markets 
At Probi AB the strategies are based on the notion that a good idea and creative 
minds to solve problems may carry far, but not all the way for the successful 
commercialization of a project. Within Probi AB there is an awareness of the need 
to be farsighted in the R&D process. Such foresight requires resources. Some of the 
resources and conditions for the development to take place are: capital, strong 
business partners, contacts and patents (legal rights to the unique technology). In 
the early stages of development, the process was funded through business partners. 
At a later stage, when the product (patents) and business proves trustworthy, there 
were other ways to find capital, through a stock market introduction (1998). More 
capital would allow for Probi AB to grow in areas that have been given low priority 
thus far (a future Probi Med AB). 
 
As a small R&D-focused firm, Probi AB strives for finding partners who appreciate 
their relative strengths (technologies). Skånemejerier has proven to be the ideal 
partner in this respect, and also in many other ways. It is therefore not a 
coincidence that Probi AB chose Skånemejerier as partner in other development 
projects after the positive experiences in the ProViva project. The business partners, 
Probi AB and Skånemejerier, use each other as sources of expertise. These contacts 
(with special skills and knowledge in different areas) in addition to contacts with 
persons within certain medical fields throughout the world make up a network of 
experts, which can readily be consulted. The experts are mainly found in 
gastroenterology (in Sweden, Poland, Spain and the US), immunology (in Sweden 
and the US), surgery, microbiology, pediatrics (in Sweden, Poland and the US), 
cardiology (in Poland) and general medicine. 
 
Probi AB owns two kinds of patents: patents related to the process of making the 
product and patents on the bacterial culture themselves. The action of covering the 
process and product with patents was done in many small partial steps. Patents are 
costly, and may be regarded as an immaterial asset. The assets provide a sense of 
security and stability in the ownership of technology. It also means revealing an 
area of technology that may be regarded as an Achilles heal. Thus the main fear for 
Probi AB is that financially strong competitors will consume its scarce resources by  
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making legal patent claims, in which costly lawyers are hired to settle the 
disagreement.  
 
Market studies of the product show that the potential for ProViva is great. The 
consumption of ProViva 1997 was approximately 1 liter per inhabitant in Sweden/ 
year (Sweden has about 8,6 million inhabitants). The corresponding number of 
potential customers in Europe is approximately 400 million inhabitants. In addition 
to the promising European market, the US and other countries are viewed as 
interesting markets as well. 
 
Probi AB has chosen to cooperate with reputable and “strong” partners. Through 
this choice several advantages are gained, for example: covering market channels, 
production facilities, tacit knowledge regarding food habits, and established and 
well known brand names. 
Skånemejerier  
Before reasoning in terms of a technology and a market strategy, a clarification 
between research and development may be needed  (Table 5.2).  
 
Table 5.2 Differences in conditions for process and product development as opposed 
to process and product innovation (personal communication, Andersson, 1998) 
 
Comparison of/ 
dimension 
Process- and product 
 development 
Process- and product innovation 
(R&D) 
 
Cost and time 
 
 
Known 
 
Unknown 
 
Access to 
information 
 
Possible, relevant and 
complete 
 
Segmented, scattered, incomplete and 
unreliable 
 
Possible  
alternatives 
 
Known, few, “right 
alternative” easily found 
 
Many possible alternatives, few 
known, hard to find “a right one” 
 
Experts 
 
Previous experience indicates 
expert knowledge 
 
Many people regard themselves as 
experts, but few are 
 
Control 
 
Standards may be used, quick 
and easy evaluation of results 
 
No standards. It takes a long time 
before one knows how the project 
will develop and what the outcome 
will be. 
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Skånemejerier regard their strengths to be in the development of products, as well 
as in marketing, production, sales and distribution. The strategy for the R&D 
department is that of using the organization’s own strengths and being an attractive 
partner for organizations which have their strength in research. This is clearly stated 
in the business strategy: 
 
“ Our customers should regard us as a partner with a sensitive ear and 
an innovative capacity. Through cooperation with other actors, we want 
to achieve increased competitiveness.“ (translated from Skånemejerier, 
Annual Report, 1997, 2) 
 
Building a research organization within Skånemejerier does not appear as a 
strategically fruitful alternative. The organization would be hard to manage. 
Instead, keeping in close contact with different research teams at several 
universities gives an idea of what is new in research in the area. The joint projects, 
such as ProViva, are kept independent, but yet in close contact with Skånemejerier. 
This is a strategic objective in itself.  
 
“ As a r ather small business, in an international perspective, there are a 
few different strategic ways to go. We have not chosen rationalizations of 
different kinds, but rather putting our resources into R&D, in building 
nets of contacts, strategic alliances and a general awareness of R&D“. 
(personal communication, Andersson, 1998) 
 
Cooperation is regarded as especially important in certain strategic areas, such as 
bacteria, enzymes and polar lipids32 (Figure 5.1). 
 
“ We build networks. We don' t have all the technol ogy or skills within the 
organization; strong partners carry a long way“ ( personal 
communication, Andersson, 1998). 
                                                       
32 Polar lipids are fatty acids with ability to mix in water-based solutions (polar solutions).  
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Figure 5.1 Skånemejeriers R&D organization, a schematic figure. Their R&D is 
conducted as a number of joint projects between Skånemejerier and research 
groups (R) located at near-by universities. 
 
 
In the process of developing new products, Skånemejerier' s role is mainly seen as 
paying attention to new ideas. Some of these ideas come from researchers 
conducting basic research. This is where most ideas for radically new products are 
developed, as an early part of the innovation process. Once a pilot process or 
prototype is developed, much of Skånemejerier' s technology comes to use in the 
continued development. In what may be regarded as refined development of the 
products (further improvements of an existing product or new varieties), the taste of 
the product becomes the critical issue. 
 
As a part of a network, Skånemejerier strives for strategic alliances within as well 
as outside Sweden. Presently, many of the alliances are with companies of 
comparable size to that of Skånemejerier (Hansa Milk in Germany, Klöver Melk in 
Denmark, Milka in Finland, Säntis in Switzerland and Leima in Spain). Products 
are for the most part produced by the local dairy, as a license agreement.  
 
Legal contracts regarding sales and distribution with other dairies within Sweden 
may also be considered as parts of the network in which Skånemejerier is a part. 
Major Swedish dairies, e.g., Arla, NNP, Norrmejerier and Milko have agreements 
with one another to sell and distribute products, which are produced by the other 
dairies. These agreements are constructed as many different contracts, for each 
product and geographical area, and they need to be re-negotiated intermittently. 
 
Success in terms of prosperous new products that are not based on the traditional 
raw material, milk, has provoked thoughts regarding the future business for 
Skånemejerier.  
 
 
Skånemejerier 
development of products, 
production, sales 
 & distribution 
 
 
R 
R 
R 
R 
R 
R  
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“ Being a part of creat ing something new stimulates new ways of 
thinking throughout the entire organization”  (personal communication, 
Andersson, 1998). 
 
A good example is ProViva which is based on oats, water and bacteria with a fruit 
addition. This is well illustrated in a quote from the 1997 annual report:  
 
“ Our business has developed  - from being a dairy on a small market, to 
being a food producing company in Europe”  
(translated from Skånemejerier' s Annual Report, 1997, p 2).  
 
The development of ProViva is an example of the changes, which are taking place, 
leading the way, in incremental steps, towards awareness of a new strategy. The 
previous goal of maximizing the price of milk to the farmer is history. Such aims 
and thoughts belong to a time when Skånemejerier was a dairy on a geographically 
smaller market. 
 
A contemporary goal is to produce added value in production of mainly milk-based 
food products. Functional foods are a part of that strategy and they constitute about 
10% of Skånemejerier’s annual turnover in 2000/2001 (Olsson, 2001). As a well-
established company with many well-known brands, Skånemejerier is very aware 
of the value of their image. Serious conduct in research is therefore a prerequisite 
for a long-term engagement in the area of functional foods.  
 
 
5.1.4 A market in the US  through ConAgra Inc.  
The following paragraphs are based on interviews with Stirling and Rao (personal 
communication, 1998), who are supervisors in the development of a new business, 
CAG Functional Foods in Con Agra Inc. The aim with this outlook is to give an 
idea of how ProViva may fit into ConAgra functional food strategies. ConAgra 
enters the innovation process in a phase when new market alliances are sought in 
licensing agreements by Probi to cover the American market. 
 
 
CAG Functional Foods 
ConAgra was founded in 1919 when four flourmills consolidated and formed a 
corporation in Grand Island, Nebraska Consolidated Mills (NCM). In 1922 the 
headquarters moved to Omaha, NE and in 1971 NCM changed its name to ConAgra 
Inc. The name ConAgra was derived from the Latin roots “with” and “land” 
signifying the partnership with the land.  
 
ConAgra is one of the largest food companies in the US, with annual sales of about 
$ 24 billion (1998, Annual Report). It is a diversified food company, which  
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operates across the food chain, from basic agricultural inputs to production and 
sales of branded consumer products. ConAgra consists of roughly 180 independent 
operating companies, each having their own business areas and brands. Some of the 
well known brands are: Hunt’s, Healthy Choice, Wesson, Orville Redenbacker’s, 
Singleton, Van Camp’s, Peter Pan, Knott’s Berry Farm, La Choy, Butterball, Inland 
Valley, Santa Fe Style and Country Pride. 
 
The mission of ConAgra is simple: to increase stockholders’ wealth. This is 
achieved through growth of long-term earnings where the sales of branded food 
products account for well over half of these earnings (ConAgra Inc., 1998, Annual 
Report). 
 
CAG Functional Foods is an independent business unit under ConAgra Trading and 
Processing Companies. It was started in 1996 by Stirling and Rao, to develop and 
market proprietary supplements and future functional foods to health conscious 
consumers. The main interest is in grain-based functional foods. Stirling entered the 
company with a good background in sales of OTC products (Over The Counter, 
pharmaceutical products that are sold without a prescription) as well as other health 
related products for consumers at large. Dr. Rao was at that time well established at 
ConAgra, leading the R&D for the Trading and Processing Companies.  
 
Functional foods are seen as a possibility to promote health through diet rather than 
to cure a disease already developed. The area of probiotics is of particular interest; 
these are in the form of food supplements that contain health promoting bacteria for 
the digestive tract. The newly introduced brand is Culturelle. It is a capsule, which 
contains granulated bacteria. Thus far, one kind of bacteria is marketed 
Lactobacillus GG. Marketing rights have been established for the US and the UK 
markets with the Finnish company, Valio. After further testing in the US a second 
variety of Culturelle, containing  Lactobacillus 299 V  is expected to be launched as 
well.  
 
The marketing of functional food in the US market is regulated by the FDA (Food 
and Drug Administration). The claims in any kind of consumer information are 
carefully screened (ads, labels, the internet, spots on the radio). In general, no food 
products can be said to cure or prevent a disease.  
 
 
A business strategy 
CAG Functional Food' s way of answering to legal demands as well as to consumer 
needs and to company objectives is by working according to the a specific strategy 
and operating model shown, Figure 5.2.                        .   
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These three cornerstones may provide a sustainable competitive advantage, which 
will result in continued growth with sales and profits to meet the financial 
objectives. The proprietary ingredient or product gives exclusive rights to sales for 
a certain time. Through the use of branded products consumer recognition is 
gained, along with consumption traditions. Testing the product provides a basis for 
experts in the health field to evaluate the product in a scientific way. The three 
factors are interdependent and closely connected to the business model, which is 
essentially how CAG Functional Foods is implementing its strategy. In other 
words, this is how it operates.  
 
A business model  
For the American market, which is the main target for these products, the business 
model for probiotics is based onbuilding awareness (Figure 5.3). A primary step, 
which is not part of the figure, of acquiring the proprietary rights to the product or 
ingredient. In the case of Culturelle, this was done through a contract with the 
Finnish dairy company, Valio, and the Swedish company, Probi AB. These rights 
are formalized in continuous contracts for certain phases and time periods.  
 
In the case of functional foods, marketing relies heavily on each phase taken prior 
to the one in focus in the innovation process. This is illustrated in Figure 5.3. An 
example of this is how the advertising phase is dependent on previous phases, 
public relations and clinical studies. In the public relations phase medical facts 
from the clinical studies are communicated in news on TV and radio. This process 
is essentially building awareness in different consumer groups.  
 
Clinical studies are associated with rather large investments. Once the phase of 
clinical studies is started it would be of great consequence if the proprietary rights 
were jeopardized. Therefore, prior to such investments, contracts to guarantee 
proprietary rights are drawn up. 
Figure 5.2 CAG Functional Foods, a business strategy (personal communication, 
Stirling, 1998). 
Proprietary  
ingredient/ products 
Clinical  
studies 
Building a brand  
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Figure 5.3 The US Business Model of CAG Functional Foods for selling probiotics  
             - building awareness (analysis of interview with Stirling, 1998).  
 
 
Clinical studies are usually carried out at reputable American universities and 
hospitals. Some of the studies may have taken place outside of the US, but would 
still carry weight if they were published in internationally recognized peer-
reviewed journals (a thorough state-of-the-art summary can be found in 
Vanderhoof & Young, 1998). The studies, must to show effects on humans, using 
the actual product or ingredient, as opposed to effects on experimental animals. In 
the case of Culturelle, an entire supplemental issue of Nutrition Today  was devoted 
to such studies, conducted both within and outside the US (Nutrition Today, 1996). 
Clinical studies of the same type as those conducted for Lactobacillus rhamnosus 
GG, are conducted at present for Lactobacillus plantarum 299v, with hopes of 
making a second variety of Culturelle.  
 
Public relations  include a number of programs in which different segments of the 
market are targeted. Channels for these programs include, for example, TV, radio, 
magazines, newspapers, brochures and samples in direct mail, toll-free telephone 
numbers, web sites, conventions and newsletters. Much of the PR activities are 
related to consumer’s interest in these new health-related products. National as well 
as local TV channels may interview a doctor who has conducted the research in the 
clinical studies to share experiences from these studies - millions of viewers are 
reached.  
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“T he ‘free press’ is o f enormous value, not only because it does not 
bring a direct cost, but more so because product information from 
‘non paid media’ is far more reliable in the eyes of the consumers” .   
(personal communication, Stirling, 1998) 
 
Consumer research conducted parallel to PR programs, , which gives a picture of 
how the previous information is perceived, and to what kind of food product the 
consumers could see the supplement added (yogurt, juice etc.). Different concepts 
are tested in terms of "newness", probability of future consumption and beliefs in 
the health effects from the product.  
 
The segment, which is labeled “sufferers” (chronic intestine diseases), is most 
inclined to try a new product to relieve symptoms from the onset of a disease. This 
is often done through advice from a doctor or a pharmacist. Consequently, one of 
the first target groups for CAG Functional Foods is the medically skilled 
professionals. They are reached at conferences, seminars, in meetings and personal 
letters. They are made aware of the results from published articles on clinical 
studies. Samples are provided for their own testing as well. The medically skilled 
professionals are also key persons to success in the following programs.  
 
For the "at risk" segment the program looks similar to that of the sufferers, except 
that this group is approximately twice as large as the sufferers segment (estimated 
to 50 and 100 million people, respectively). The “at risk” segment includes persons 
who take antibiotics for some reason, or live a stressful life. They are generally also 
aware of the risks of illness, and they often seek ways to minimize the risks, ideally 
without changing their lifestyle at all. Health related news and talk shows on TV 
are one way of finding information. Culturelle information, for example, reached 
about 60 million viewers in one month during the fall of 1998 (personal message, 
Stirling, 1998). In magazines, such as "Prevention- Americas # 1 choice for Healthy 
Living"  doctors and journalists tell of new products as well as other ways of 
maintaining good health. In this magazine one could also find coupons (“save one 
dollar”) for buying Culturelle (October, 1998, p 42).  
 
Positive personal experience from any of the above consumer segments also helps 
spread the news to the "prevent" segment and the broader market. The prevent 
segment includes people who take vitamins, minerals and herbs - people who are 
aware of health in general. This brings us one step further in the model (Figure 5.3), 
to advertising. Through advertisement in magazines and papers, and spots on radio, 
a broad range of consumers are reached. Efforts are made to target health 
magazines and papers to raise the general awareness of the product and its benefits. 
 
At this time (1998) the product was sold in a pharmacy, not in a general food store. 
The product, a capsule, will remain as such until awareness has reached a certain 
level. Once this level of awareness among consumers is achieved the product may 
take on a new shape. A medical product thus become an ingredient in a food  
76 
product. A capsule and a dietary supplement is the entry point of this product, 
around which a brand name is built up. As a dietary supplement, a research-
supported claim can be made in product information. Once awareness is built up 
about the effects of the ingredient, the following step is to make it available in a 
food form, for example a yogurt, a juice or in ice cream. Consumers then know to 
look for that specific ingredient in the food product, to get the health benefits. 
 
Advertisements and marketing 
What may and may not be said about a product, in any kind of product information 
(label, spot on TV, radio, on the wide world web or on a package), is strictly 
regulated and screened by the FDA (Food and Drug Administration). As a part of a 
large food business, ConAgra Inc., CAG Functional Foods has to act in a 
responsible way (Taylor, 1998). This is yet another explanation for the importance 
of conducting reliable clinical studies. To their assistance, CAG Functional Foods 
gets scientific expertise through the R&D department, led by Dr. Rao, legal 
expertise though ConAgra Inc., and PR and marketing services through marketing 
consulting firms.  
 
CAG Functional Foods relies on market pull  for information about these new and 
health associated products. One way of providing this information to consumers is 
through video releases to TV stations. A video typically include clips about product 
information, as well as clips from interviews with doctors, pharmacists and other 
medical experts, who have knowledge of the effects of the product.  
 
A product - Culturelle 
The product is a dietary supplement, a capsule, which is sold in packages of 30 
capsules per package (at a price of $15/ package in 1998).  Inside each capsule is a 
white, granulated substance, so far Lactobacillus casei rhamnosum GG (for history 
on the discovery, see Sherwood & Gorbach, 1996).  
 
Lactobacillus GG (LGG), is the short name for this bacteria, after the two 
discoverers Drs. S. Gorbach and B. Goldin, who isolated the strain at Tufts 
University, Boston in 1985 (Salminen, 1996). A patent was issued in 1987 and 
shortly thereafter Valio, a Finnish dairy business, acquired the rights to 
commercialize the bacteria. In 1996 CAG Functional Foods licensed the marketing 
rights for the US and the UK from Valio. Time was gained through a number of 
successful clinical studies, conducted in the US as well as in Europe prior to the 
licensing. These results published in scientific journals enabled CAG Functional 
Foods to readily start building awareness, and a strong brand name. This occurred 
in 1997/98.  
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In 1999 further studies of L. Plantarum 299V were planned to provide similar kinds 
of evidence, to provide a basis for a second variety of Culturelle. Plans were made 
for developing a functional food product, for example a fruit drink or a yogurt. This 
future food product has to be marketed without a health argument. That explains 
the need for CAG to build an awareness of the product / ingredient as long as it is 
sold as a dietary supplement.  
 
American markets for functional foods  
All humans need foods. Practically anybody can consume functional foods, but it 
takes awareness to see the need. From a business standpoint the consumer market 
can be divided into segments, as shown in Figure 5.3; the sufferers, the at risk 
group, people who are acting in a preventive way and the mass market. Health 
awareness decreases with each of these groups, but it is not a static division. As 
awareness grows in one group, it continues to the next, like ripples on the water.  
 
Another way of reaching the consumers, in a more indirect way, is through Health 
Maintenance Organizations (HMOs). The HMOs interest is to keep down the cost 
of medical care. This does not imply denying people their rights, which are a part of 
their health plan, but rather, if possible, avoiding complications to medical 
treatments. An example may be side effects of taking antibiotics, such as diarrhea 
or vaginal infections. If a product has proven effects that counteract side effects of 
medical treatment (a product like Culturelle, for instance) it may become a part of a 
subsidized recommendation in a health plan.  
 
One might question whether people need functional foods or not. ConAgra does not 
make it their role to decide if there is a need for consumers at large, only to provide 
information and safe healthy products for those who request it.  
 
“ It is just an evolution... We are not trying to change what people eat. 
Consumers are the ones changing the course. We want to go to ingredients 
that can do some wonderful things to your body in really small quantities 
(in a way) that doesn' t change taste or texture” .   (Rao, in Taylor, 1998, 2) 
 
 
Primary groups of consumers with needs for functional foods are seen as groups of 
people who in different ways abuse their bodies (stress, alcohol, medicines), people 
with an expected onset of certain diseases (diabetes, for example) or people who 
live in environments where they are subjected to a vast flora of pathogens. 
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5.1.5 An epilogue (Probi AB in 2001) 
Looking back at the development since 1999/2000 the present CEO, Monica 
Wallter33, reveals that Probi AB has clarified its technological and marketing 
strategies. Starting with a major market investigation for probiotics, a strategic 
analysis was conducted (2000). In this analysis information about key markets was 
gathered and strategic areas for future research were identified. Future strategies for 
research are aimed for developments in the following four areas: gastrointestinal 
disorders, positive effects on the immune system, physiological stress and recovery, 
and risk factors for cardiovascular disease. Although each of these areas are vast 
and the areas of application many (foodstuff, sports and health beverages, medical 
products and feed products), the new strategies have focused Probi’s business idea 
(Annual report, Probi AB, 2000).  
 
The new marketing strategies refer to finding strategic partners in development as 
well as in production and sales. Strong partners are identified as international actors 
on the food market, pharmaceutical market or feed market. In some instances 
national or even local food producers with large market shares prove to be 
interesting partners as well. Skånemejerier with annual sales of 10 M liter of 
ProViva/ year34 is the Swedish strategic partner in production as well as in sales 
(Probi AB, half year report 2001). In meeting new and potential licensees and 
partners in development, the presentation of Probi AB becomes essential. Clear 
strategies, good results in research and good experiences in collaboration in the past 
are all important parts of a good business image. In terms of changes, the contract 
with Skånemejerier was re-negotiated. Skånemejerier is now responsible for the 
sales in England and on the Nordic markets. Probi, on the other hand, manages 
collaboration agreements in the rest of the world. The collaboration with Con Agra 
was terminated.  
 
Experiences and contacts from previous collaboration becomes a part of Probi’s 
network. The new CEO brought in a wide net of experiences and contacts from the 
pharmaceutical industry. With new contacts, focused technological strategies and 
identified partners, the new CEO lays the foundation for continued successful 
developments.    
 
                                                       
33 The epilogue is based on a telephone interview. More information about Monica Walter’s 
view on functional food is provided in “Hennes levebröd är folk som inte hinner äta rätt” by 
Andersson (2001). 
34 The sales of ProViva are 10 M liter/year in Sweden, which is an 11% increase compared 
to the half year annual report in 2000  
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5.2 Magiform 
 
This case concerns the development of a new line of cereal-based products using a 
new technology. The development has been staged by a new business, BioDoc AB, 
and its growing network. Here is a brief presentation of the product, the major 
process and the business. 
 
A product 
"Magiform" (translates as ' stomach in shape' ) is the name of a line of cereal -based 
products (müsli, biscuit, pasta, bread and crackers). These products are primarily 
sold to consumers with a chronic inflammatory gut problems (for example Mb 
Crohn and IBS35). 
 
A process 
The development of the production processes has involved a lot of know-how in 
cereal processing. Developing ways to assure a premium quality of the raw material 
has also been an important part in the development process. Prior to product 
development, basic research has been carried out in the area of gut immunology. 
Basic research, for example in identifying Protein AF, was a condition for filing a 
patent and thus for the innovation process. 
 
A business 
The company, BioDoc AB, is a virtual organization with only three people on a 
regular payroll. The network that these three persons maintain, however, is vast and 
well developed for their needs.  
 
 
5.2.1 Background 
The innovation process in this case is basically grounded in research concerning the 
function of the gut immune system and in the development of pig feed in the 1980s 
(in Sweden). This new special-processed cereal feed was needed when the 
antibiotic treatment of piglets was prohibited in 1986. Research showed that the 
piglet’s immune system was activated by a special-processed cereal-based feed. 
More piglets, especially piglets of young sows, thus survived without antibiotics.  
 
The research and development of the new feed was a joint activity where Dr. 
Göransson at Sveriges Svincenter (The Swedish Pig Center) and two medical 
researchers, Ass. Professors Lange and Lönnroth (at the Gothenburg University / 
Salgrenska hospital), cooperated. The research, in which the function of the gut was 
studied, resulted in finding protein AF. This protein was isolated and structurally 
described.  
                                                       
35 IBS,  Inflammatory Bowel Syndrome, is a chronic gut infection.  
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A patent was filed in 1989 and granted in 1991 for Sweden and other perceived 
major markets (over 30 countries, including the EC, Japan, the US and Japan). This 
patent is based on the effect of the feed, in other words the elevated concentration 
of protein AF in the gut, which indicates that the immune system is activated.  
 
It is commonly known that the pig and the human gut system are quite similar in 
their functions. With this in mind the head of Sveriges Svincenter, Lars Sjöstrand, 
pursued a new avenue for a technological achievement - that of a human food for 
people with chronic gut problems. The base for a new business, BioDoc AB, was 
founded in 1993, albeit all the challenges were not yet defined.   
  
 
5.2.2 Developing an idea -  from pig feed to high-tech human food 
The development of a product, a pig feed, and at a later stage a human food 
product, is based on years of research in immunology. Lange and Lönnroth study 
the immunization process in rats during the 1980s. They found indications that the 
immunization process takes place in the pituitary body36, which is shown by an 
elevated concentration of Protein AF. 
 
Animal studies, at Sveriges Svincenter in collaboration with Lantmännen 
Foderutveckling AB, showed that special processed cereal based feed for pigs was 
associated with activation of the immune system. This was indicated by an elevated 
production of Protein AF.  
 
In summary, the idea for a food product was derived from experiences in 
developing a feed for piglets. Radically new technologies, such as the isolation and 
structural definition of the protein, made it possible to identify the protein and thus 
to study the effects of immune system activation.  
 
 
5.2.3 Realizing a strategy   
In retrospect it may look rational to develop a functional food product, given the 
vast knowledge in the area, and a patent. It took an entrepreneur, Sjöstrand, 
however, to make reality of the business idea. 
 
“  At first it was an exciting idea. It inspired me and my intuition told  me that this is 
an opportunity. It was something new and unknown... A challenge.... One has to be 
a bit of an entrepreneur to see the possible, not the impossible! If I meet an obstacle 
I try to see beyond it. It is all about apprehension - about perceiving possibilities 
and not problems”. (personal communication, Sjöstrand, 1999)  
 
                                                       
36 The pituitary body (hypofys) is a small hormone-producing organ in the middle of the 
brain.   
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Sjöstrand and the researchers decided to form a joint venture business, BioDoc AB 
in 1993. It is a subsidiary of a large farmer' s cooperative, SLR, partly owned by the 
following farmer’s cooperatives: AB Cerealia (25%), Skånska Lantmännen (15 %), 
Odal Lantmännen (5%) and Lantmännen Invest AB (55%). 
 
The perceived advantage of a joint venture is mainly the access to financial strength 
and expertise in certain areas.  
 
“The ownership structure does not really affect us a whole lot. The main thing is 
that the owners are financially strong. Developing functional foods is costly. I 
would say that the development of a product ranges somewhere around 10-15 
million SEK. BioDoc acts independently but we have experts in production, sales 
and distribution close at hand” .  (personal communication, Sjöstrand, 1999) 
 
The organization is small. It is a virtual organization where a few people each have 
access to a large network (illustrated in Figure 5.4). The entrepreneur in this case 
has carefully hired persons with capabilities, experiences and contacts that are of 
use for organizing the development and marketing of functional foods. The 
management style is seen as that of creative management: 
 
“I see myself as a strategic person - and a creative person. If I want to do 
something new, to manage a new business in a new area, I can' t manage the 
operation in a ' business as usual’ way. New businesses require new ways of doing 
things -  new management styles!”. (personal communication, Sjöstrand, 1999) 
 
 
D e v e lo p  
c o n c e p t s  
S jö s t r a n d  
P r o d u c t i o n 
r e s p o n s i b i li t i e s  
L in d h o lm  
M a r k e t  
r e s p o n s i b i li t i e s  
E r h a r d t  
 
 
Figure 5.4 BioDoc AB, a virtual organization. It consists of three persons, each 
with an extensive network  (personal communication, Sjöstrand, 1999). 
 
 
Sjöstrand: “In this figure, my job is to develop concepts for functional foods. The 
business idea is to develop functional foods. It does not mean we have to 
develop and produce the products within the business. On the contrary, we 
have strategic partnerships to purchase most functions, production, sales  
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and even R&D. That way we don' t have to have a large organization to 
conduct business.” 
 
 “ ...  Well, I think my most important role is to be enthusiastic towards 
people I meet, within BioDoc as well as in my contacts outside BioDoc. I 
' sell the idea'  and if I do it well changes happen more easily... It is 
incredibly exciting!” (personal communication, 1999)   
 
Lindholm:“ Much of my job is to solve problems. I make sure the development of 
new products, production, sales and logistics works out well. My 
experience in the food business comes in handy in many ways. I have a lot 
of contacts that I need to help me solve problems.”  
 
 “ ...In my previous job, I could use standard ways to solve problems. The 
problems were distinct and repetitive. This job is different. Everything is 
new and we have to find new ways of doing things. Of course, when I can 
I use standard ways of doing things, I do, but for the most part I make use 
of my network in finding new routines.” (personal communication, 1999) 
 
Erhardt: “I think I was hired thanks to my experiences in the pharmaceutical 
industry. When I came here I recall thinking that this job is so flexible. 
Nobody told me what to do. Decisions were made quick and easy, in a 
spontaneous conversation between the three of us.”  
 
 “ ... we all have our own networks, but we also cover for each other when 
one of us is out of the office. We actively try to share our contacts with 
each other so nobody is irreplaceable” .  (personal communication,  2000)  
  
 
Strategic partnerships in R&D, production, sales and distribution are all part of 
BioDoc' s network. Most of the partners are contacts from previous experiences. In 
qualifying for continued business, however, business partners are regularly 
evaluated: 
 
“When I came to BioDoc, a marketing firm was used that I did not care for. 
The person did not at all seem interested, creative or organized. So, I 
changed to a consultant I have worked with in my previous job. I simply 
extended the network a bit ... It is important that we trust our partners in 
work since we are depending on their work for our own survival.” 
(personal communication, Erhardt, 2000) 
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5.2.4 Developing new products 
The "Magiform" products are all cereal-based products that can be a part of a 
healthy diet for most consumers. The development of these functional foods 
includes developing new technologies and new markets. Three products were 
developed  (müsli, pasta and bread) for tests in clinical studies. 
 
The first product that was developed was the müsli, where the major challenge was 
to conceal the after-taste that the special processing of the cereal produced. The 
resulting mix was so appealing that it has not been modified since the time of 
development. 
 
Pasta was developed as the second product. The minimum batch is 20 tons, so a 
failure would have been a gigantic failure. The vast technical know-how provided 
grounds for successful development of a new pasta product.  
 
The previous successful development of new products was a comfort when it came 
to developing a bread. Once the bread was acceptable, it was decided that the 
packaging was not. It was a time-consuming and effort-filled process. Still, the 
bread did not turn out well. The taste was altered and the bread moulded. Finally, 
Hattings (in Denmark, owned by Cerealia) was able to produce the bread. It was 
sold (as frozen bread) by a health chain, Notana AB.   
 
Positive results in clinical studies of the magiform products stimulated further 
development of other products; biscuits and crackers.  
 
“I think our partners'  know -how in production saves us a lot of time and 
money. They know the raw material and the technical aspect of 
production.” (personal communication, Lindholm 1999) 
 
 
5.2.5 Markets for new products 
In marketing Magiform products BioDoc concentrated on consumers that were 
interested in health (Figure 5.5). The primary targeted segment is consumers with 
chronic gut problems. They are willing to try and pay for a new product, instead of 
using medicines.  
 
The next market segment is health-conscious consumers. They are also willing to 
consume products to promote their health. Compared to consumers with chronic 
gut problems these consumers are somewhat less willing to pay premium prices.  
 
People at large are not interested in consuming an expensive product unless it is 
tasty and provides a perceived added value.   
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Market segmet  Segment size  Willingness to pay 
People with gut 
problems 
People who are 
interested in health 
People at large 
10% 
45 % 
45 % 
High 
Low 
 
Figure 5.5 Marketing strategy, illustrating different consumer segments’ expected 
willingness to pay for added value in Magiform products (personal 
communication, Sjöstrand, 1999). 
 
 
Marketing the Magiform products as medical products is possible due to scientific 
research and publications that support the health effects. The marketing activities 
have included, for example, participating in medical conferences and 
communicating a scientific health message to medical experts. These experts in 
turn test the product in their clinical work and share their experiences with 
colleagues. Patients (the chronic gut problems segment in the Figure 5.5) also 
provide an important marketing channel as they not only share their experiences 
with friends, but also provide feed-back on the product for BioDoc.  
 
Marketing functional foods, such as Magiform products, is regulated by Swedish 
food and drug laws. The recent directive from the EU (1999/21/EG - March 25, 
1999), however, makes it possible to market functional foods of this type as food 
for medical use. The legal system appears to have limited the development and 
marketing of new functional food products: 
 
"...We have a food with desired health effects but we are not able to tell 
consumers about it. It is important that we act in a responsible way, with 
well documented research. Everything relies on this research - and being 
able to talk about the results". (personal communication, Sjöstrand, 1999) 
 
The Magiform products are sold in health food stores. In the future it is possible 
that the pharmacies (Apoteket in Sweden) may sell a concentrated version of the 
product and the food stores a less concentrated product. In addition to traditional 
food stores, Magiform is also sold on the internet (from 2000) where consumers 
may also find scientific information about the clinical studies of protein AF and 
Magiform.   
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5.2.6 Creating new markets 
New markets are created in contacts with consumers as well as businesses. The 
awareness of the health effects is growing locally among consumers. The scientific 
studies become known through medical experts and the product is requested by 
health conscious consumers.  
 
The Magiform products are primarily sold in Swedish health stores (2000). Using 
the health store distribution channel has the advantage that it is easier to enter the 
market with a new product.  Sales volumes, on the other hand, are small and a good 
proportion of potential customers never even enter a health food store. A planned 
market expansion in Sweden involves the pharmacies and, in a second step, food 
stores. A more concentrated version of the product, for people with IBS and Mb 
Crohn, may be sold in pharmacies, whereas in a food store people are for the most 
part interested in health maintaining foods (a less concentrated version of the 
product).  
 
Once products have a strong home base, marketing is less demanding in new areas.  
Medical experts are informed at conferences and in research journals. BioDoc has 
numerous examples of consumers sharing their experiences after visiting Sweden:   
 
“ We have had contacts with consumers from, for example, Spain, Belgium 
and France who are asking, after a vacation in Sweden, where they can 
find the product in their home country.” (personal communication, Erhardt, 
2000) 
 
Market expansions are not planned far ahead. Possible interesting markets have 
been sought out by extensive market investigations and patents are filed in 
countries that are seen as interesting.  A market expansion will be made based on 
experiences from the home market. Countries in close proximity to Sweden are 
seen as possible markets for export. The advantages are, for example, a larger 
production volume and the possibility to slightly vary the taste of the products for 
different markets. In Denmark, for example, consumers like a sweeter müsli than is 
preferred in Sweden. For markets that are located geographically far away, a strong 
licensing partner, for example a multi national company such as Novartis 
Consumer Health, is seen as the most desired alternative. 
 
5.2.7 Strategies and visions - continued R&D  
Based on the business idea, “to develop, produce and market products with health 
effects”, BioDoc continues to develop functional food products. Another example is 
”100% oats”, which is a product line of cereal products which are free of the 
protein “gluten”. These products and processes are not protected by patents. They 
are, however, associated with other competitive advantages, such as a great deal of 
technical know-how and access to pure raw material.   
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Continued development of products is grounded in consumer needs: 
 
“T he starting point for our projects is the consumer, the problems a 
consumer has, and what kind of product we can develop to counteract 
these problems. It may sound trivial but, really, that is what we aim for.” 
(personal communication, Lindholm, 1999) 
 
“ Ideas for new products are developed in contacts with medical experts 
and consumers and in conversations within BioDoc. A source of 
inspiration for future functional foods is nature itself ... I also think that 
experience from developing food products is important. It takes knowledge 
in both these fields - and the ability to perceive the possibilities in new 
things (!), to succeed.” (personal communication, Sjöstrand, 1999) 
 
BioDoc AB continues to carry out research in areas where they have identified 
needs among consumers. These needs are found in ways to counteract common 
diseases that are widely spread in society, such as diabetes, obesity and allergies.  
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5.3 IgY - egg 
 
This case is about the development of chicken eggs for use in immune therapy, 
which refers to preventing and treating certain infections37. It started as a group of 
scientists’ shared thoughts one late night during a conference. These ideas were 
seen as projects no one had taken the time to pursue. In reasoning about the 
marvelous creation of life (egg cells and sperm) the discussion narrowed to entail 
the properties of bird eggs and their abundance of antibodies (IgY). This is where 
the story started...    
 
The product 
Eggs and egg powder are the products in focus in this case. These eggs look just 
like any chicken eggs we would find in a food store. The medical effects, however, 
differentiate these eggs from other eggs. The medical effect of particular interest 
here is the prevention of an infection with a common pathogen (a bacteria), 
Pseudomonas aeruginosa. For a group of patients with Cystic Fibrosis (CF), these 
bacteria constitute a serious threat to health and even to life (CF is further explained 
under 5.3.5 Using immune therapy).  
 
It would also be possible to develop eggs that would protect individuals from other 
bacterial infections as well (such as Tuberculosis), fungal infections (Candida 
albicans.) or even viral infections. It is possible that this technology could be used 
for most infections38.  
 
The process 
Production of IgY- antibodies involves keeping hens and exposing them to an 
inactivated form of an infectious agent39, the pathogen of interest. These hens lay 
eggs with high levels of antibodies against the pathogen. Eggs are naturally rich in 
antibodies, in the yolk. If the IgY-antibodies are required for medical treatment 
they are purified in a large-scale purification process (Jersenius et al., 1981) 
providing a powder for oral intake (as a capsule or a pill).  
 
                                                       
37 Oral immune therapy (boosting the human immune system) with these special eggs is 
used for prevention and treatment of enteric infections (Carlander et al., 2000).  
38 For treatment of local infections the IgY- antibodies are in physical contact with the 
pathogen. “A systemic disease, however, would probably not be possible to treat with this 
kind of immune therapy” (personal communication, Kollberg, 2000). “However,  since most 
systemic diseases start as a local infection it would be possible to prevent the onset of such a 
disease” (personal communication, Larsson, 2001).  
39 Inactivated infectious agents are, for example, bacteria that have been killed in a des-
infection process. These bacteria therefore do not infect the hen – but the hen develops anti-
bodies (IgY) against this agent. See Figure 5.7.   
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A functional food product or a medical drug with preventive effects could be an egg 
as it looks when we find it in the store. This egg could be consumed like any other 
egg, as a part of an ordinary meal. The antibodies are active even when the egg has 
been partly denatured (for example, cooked up to 6 minutes). This means that the 
medical effects would be lost when using these eggs in a baked product ( for 
example, a pound cake/ sockerkaka), since the cake is in the oven for well over 6 
minutes. The egg would, however, still have a nutritional value.   
 
The business 
A group of scientists formed a jointly-owned business, Immunosystems IMS AB in 
1984.  In their spare time these scientists wanted to develop egg antibodies (IgY) 
primarily for diagnostic use. The business idea was later expanded to include a new 
application for IgY, that of immune therapy. Several collaboration partners have 
participated in the development process. The numerous perspectives and ideas for 
research and new application areas have resulted in plans to create a center for IgY 
research.  
 
5.3.1 An idea for a medical product 
The story begins with the entrepreneur, scientist and farmer, Wejåker, going to 
IFS’s (International Foundation for Science) conference in Thailand in 1982. One 
late night a group of researchers in different fields came to talk about their ideas 
that never had been explored. They shared ideas (and whiskey). After talking about 
the difference in immune systems for different species the conversation narrowed 
to revolve around the properties of eggs. An egg carries nutrition, a well-developed 
immune defense and much more for a new chicken to evolve. Hens cannot, as 
mammals can, support the developing life with nourishment, or immunity against 
infection agents, throughout the embryonic development, or in feeding procedures 
after birth. This explains the abundance of antibodies, IgY, in the yolk. These 
antibodies thus protect the chicken until it has a sufficient immune system of it’s 
own.  
 
Having worked with hens for medical production for many years40, Wejåker had a 
vast knowledge about avian production and an extensive net of contacts in medical 
research and in the pharmaceutical industry, as well as in poultry production. The 
idea that Wejåker took to heart was essentially to further explore the usefulness of 
avian antibodies (IgY) for medical purposes. One answer to why Wejåker perceived 
this idea lays in the label he uses for himself, “a scientific farmer”.    
 
“I am an entrepreneur. I see things differently from most other people. It’s like 
thinking widely instead of deeply… I get my inspiration in every day meetings 
                                                       
40 Wejåker worked with hens in a medical project with a large pharmaceutical company, 
Pharmacia. The medical product was Healon®, made from rooster’s combs.  
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and in problems I face… Researchers think vertically, deeply in a specific 
area, whereas I think horizontally. I see challenges and conceivable solutions 
to problems I face”. (personal communication, Wejåker, 2000) 
 
 
Filled with enthusiasm and a general feeling that this was worth exploring, Wejåker 
returned to Sweden. In meeting researchers in medicine and poultry the idea was 
further developed.   
 
A group of five scientists, including Wejåker, was formed. They reviewed the field 
of avian antibodies for further information. It was concluded that avian poly-clonal 
antibodies had desirable biochemical properties, that would make them attractive 
for medical use (Larsson et al., 1993). During the 1980s this group of scientists 
continued, in their spare time, to learn more about IgY. A small-scale laboratory 
experiment was set up. The hens were kept at Funbo-Lövsta41, and the laboratory 
procedures were at first carried out in the home of one of the scientists, and later in 
the laboratory of one of the medical scientists. A doctoral student, Larsson, carried 
out and documented the progression of the research (Larsson, 1988).  
 
“ Anders and I worked very closely together during this phase. We did all 
kinds of crazy things at the time; we tested everything - and it was great 
fun!” (personal communication, Wejåker, 2000) 
 
The group of five scientists continued exploring the idea in their spare time. A 
business was founded42, Immunosystem IMS AB (IMS), in 1984. The basis for the 
business was a sincere interest in exploring the possibilities for using avian 
antibodies (IgY). 
 
 
5.3.2 Using IgY antibodies for diagnostic use 
The primary application for these antibodies was diagnostic use, to determine 
concentrations of hormones (Larsson, 2001). It was also concluded in review, 
however, that IgY-therapy was another possible medical avenue. It had been used 
successfully for animal production (chickens and piglets) in scientific studies 
(Larsson et al., 1993). The main reason for choosing to develop a medical 
diagnostic application, rather than a feed or food product, is mainly explained by 
the experiences and contacts of scientists in the company. 
 
                                                       
41 Funbo-Lövsta is an avian research center for the Swedish University of Agricultural 
Sciences in Uppsala. 
42 The business Immunosystems IMS existed as a private dormant side business for one of 
the scientists. It was activated in 1984 and made into a jointly owned business for the five 
scientists working in the project.   
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“ At first it was all research. I used IgY antibodies for research in my 
dissertation…” (personal communication, Larsson, 2000). 
 
“We tried many different things, and we learned a great deal in doing that… 
The thought was to develop knowledge, and in a second step to find ways to 
explore this in a commercial way. The research was presented in Anders' 
dissertation. We also wanted to find a market application. The IgY-area is a 
very general research area... Diagnostics – it is a field we had experience 
from and it just seemed like the natural way to go… But really - it is just our 
thoughts that sets the limit for the use of IgY…” (personal communication, 
Wejåker, 2000) 
 
 
Methods and results were developed and accounted for in a dissertation (Larsson, 
1988). The following step involved finding customers with needs that could be met 
by IgY-antibodies. Most medical applications (kits and supportive products) are 
built on mammalian antibodies. Even though IgY (chicken) antibodies have 
biochemical43, economical44 and ethical45 advantages over mammalian antibodies 
the difficulties in selling these antibodies lie in the development of products (kits 
and supportive devices) that are based on this radically new technology.  
 
“ … Antibodies are somewhat like perfume. You don’t buy it because it is 
cheap, but because you believe in the effect. The price is secondary. To sell 
antibodies cheaply does not work at all. On the contrary, if you have a high 
price that indicates hard work in development. This is interpreted as a 
guarantee for good quality. This business is all about building trust to make 
sure customer satisfaction.” (personal communication, Larsson, 2000)  
 
 
In commercializing antibodies for diagnostic use the price is secondary. Chances of 
high revenues are, in other words, high. With increased experience and knowledge 
in the area it became increasingly clear, however, that a business partner was 
needed.  
                                                       
43 One of the important biochemical properties of IgY is that “they do not activate 
mammalian complement or Fs receptors, that could mediate an inflammatory response”  
Furthermore, there is “…practically no risk of toxic side effects of IgY” (Carlander et al. 
2000, 4). This advantage, using IgY for medical treatment of humans, is explained by the 
evolutionary distance between humans (a mammal) and birds.  
44 One hen produces approximately 10 times the amount of antibodies a rabbit would 
produce in the same amount of time (Larsson et al., 1993, 1807). Hens are, furthermore, less 
costly to keep, compared to rabbits (Larsson, 2001, 26). 
45 Mammalian antibodies involve bleeding a rabbit (taking blood through a vein in it’s ear). 
Chicken antibodies do not cause any harm to the hen.   
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5.3.3 Finding collaboration partners 
Looking at the development process several collaboration partners have contributed 
in the development process. Contacts and networks from previous projects 
constitute technological resources as well as possible partners in development.  
 
1982 Wejåker meets with researchers in poultry, veterinary sciences, and clinical 
chemistry to investigate in the IgY area.  
 
1983 A small-scale pilot study for research is set up at Funbo-Lövsta (a poultry 
research center at the Swedish University of Agricultural Sciences).  
 
1984 Immunosystems IMS AB (IMS) is founded by the five researchers. One person 
works part time and the rest of the researchers work on their spare time. 
Antibodies for research use are developed and sold. A vast technological area 
is built up in addressing problems to develop these antibodies. 
 
1984 Contacts with businesses in the diagnostic area were made with little result. 
None of the six approached businesses seemed to take the invitation 
seriously. This is in part explained by difficulties to communicate the 
technical advantages with using IgY-technology. This radically new 
technology did not match the existing R&D strategies for the approached 
businesses.  
 
One company however, Pharmacia, contacted IMS for help in solving a 
problem with a diagnostic kit46. A contract was set up where IMS developed 
antibodies for research use by Pharmacia. The project dragged out in time 
and it became apparent that the provided antibodies were not used for 
research but rather for commercial purposes. This undermined the trust and 
the project was terminated. Pharmacia shortly thereafter started developing 
IgY antibodies independently. 
  
1988 starts the era of great beliefs in biotechnology in society in general and in the 
pharmaceutical industry in particular. A pharmaceutical company, Procordia 
Nova/ Kabi was in search for small research businesses in biotechnology, 
which could be an acquisitions to gain core competencies in this area. IMS 
met their needs. Contracts were drawn up and plans were made for Procordia 
Nova to purchase shares in IMS. Based on expected future value, expressed 
in speculative business plans which refer to sales in areas where the products 
did not yet exist, a price was set.  
 
1989 Procordia Nova purchased 40% of the shares for 1.5 MSEK. A traditional 
CEO from Procordia Nova was responsible for marketing and sales.  
 
                                                       
46 A diagnostic kit for testing TSH (Thyroid Stimulating Hormone)  
92 
1992 Procordia Nova withdrew their engagement in biotechnology, focusing on 
health care. They sold their 40% of the shares back to the researchers for 0.1 
MSEK. The joint venture did not result in the expected revenue drawn up in 
the speculative business plans.  
 
1993 Contacts are made with Kollberg, at the hospital in Uppsala, a pediatric doctor 
with a special interest in Cystic Fibrosis (CF). Research in a new area of 
application, immune therapy, is further explored. (See 5.3.5 for more details). 
A part time CEO is made partner in IMS. 
 
1993 An agreement is made with BioPool AB, a small business working in 
diagnostics (located in Umeå). BioPool markets the antibodies that are 
produced by IMS. The patent which is the base for this production is owned 
by two of the scientists in IMS.  
 
1999 A joint business, Immunonativ AB, is set up with BioNativ AB for developing 
IgY-based products against respiratory infections (immune therapy). 
Scientists in IMS own the patent, and BioNativ AB carries out development 
of products.   
 
 Plans are made for an IgY- center.   
 
2000 IMS is in search for partners in exploring new animal feed application areas. 
Contacts are made with Kjällbergs Ind. AB, specialized in making egg 
powder.  
 
Looking back at the development, several conclusions can bedrawn. Two of these 
conclusions deal with communication, the difficulty to communicate a radically 
new technology and the challenge of making a joint venture a truly joint venture 
with communicated and shared visions.  
 
Communicating something radically new can be seen as persuasion. Wejåker was 
enthusiastic about the research idea. A good track record and personal relations 
with researchers may in part explain his successful transfer of a radically new and 
vague idea. With a group of researchers to support the project the prospect was 
strengthened. Yet, when it came to setting up the pilot study at Funbo-Lövsta, it 
was time for two research traditions to meet: 
 
“We met with Martin Wilhelmsson, who was responsible for the Funbo-
Lövsta research center at the time (1983), to talk about the project. We 
talked and we talked.. . Martin seemed interested and yet hesitant to give it a 
‘go’. As it turns out he was concerned about having a buffer of only 1000 
animals. He thought we would need hundreds of animals – when, really, we 
had only three or four in mind. This shows how differently you can perceive 
things. We talked different languages. He was used to LARGE studies and  
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we had a very small one in mind. I have a feeling he thought we were a bit 
odd.” (personal communication, Larsson, 2000)  
 
With positive research results at hand from the pilot study the group was up against 
yet another communication challenge, that of a suitable time for a new technology. 
 
“T he timing is a key factor. You have to enter a system at the right time when 
people are ready for the new thing. At the time we presented our IgY 
[polyclonal antibodies] it was monoclonal antibodies that were in vogue… 
Our timing was ‘off’, to put it simple.” (personal communication, Wejåker, 
2000) 
 
 
Even with a partner at hand communication becomes a crucial factor. In the joint 
venture between IMS and Procordia, there was a need for a common language to 
communicate shared visions. These visions were expected business plans using 
Procordia language. IMS tried to project future sales of not yet developed products 
on not yet created markets to come up with an estimate for the value of the sold 
shares in IMS.  
 
“ Within Procordia there are scientists  and economists47, but few bridges 
between them. The people we were in touch with were mostly economists. 
They need a value on things, but how do you put a value on a research 
business?!  … We had to come up with a projected expected value. It was 
very hard. Needless to say we provided a much too detailed (!) prognosis 
based on the prevailing optimism in biotechnology and it was certainly 
colored by our own positive connotations” .  (personal communication, 
Larsson, 2000) 
 
 
The joint venture between IMS and Procordia did not provide access to desired 
markets for IMS. Nor was it an investment in a strategic and lucrative area that 
Procordia hoped for. A traditional CEO entered an entrepreneurial system with 
expectations to run business as though it had been an established business.  
  
 
“…We should have sat down and discussed the plans with Procordia [1989]. 
We might have realized the importance of producing more scientific 
documentation. That would have given us arguments to show potential 
customers. As it was, we had not enough to show.” (personal communication, 
Larsson, 2000)   
                                                       
47 Larsson explains later on in the conversation that he refers to managers, administrators 
and finance departments as “economists”. Their language differs from the scientist’s 
language, hence the division.   
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Having learned about some difficulties in developing a market, IMS is again a side 
business for the researchers (2001). Plans exist for continued research and 
development of a platform for IgY research.  
 
 
5.3.4 An IgY-center for further developments 
A project proposal was presented for an IgY-center in Heby (Figure 5.6). The 
project could be partly financed by an EU program (Mål 2 - Tillväxtavtalet) if the 
EU financing was matched equally by Swedish investments. So far it has not been 
matched. 
 
The main objective for this center would be to constitute an arena where 
researchers from different backgrounds could meet in cross-disciplinary studies of 
IgY. Ongoing projects would serve as a start for a network as well as provide 
experiences for planning future projects.  
 
 
 
  
 Antibodies and 
diagnostic kits 
Research 
accomplishments 
Costly R&D 
Very expensive 
products 
Knowledge 
An IgY-center 
for  continued 
research 
Medicine -  
For humans 
Costly R&D 
Expensive 
products 
Food - 
Development of 
tasty products  
Large volumes 
Lower price 
Feed - 
Continued research 
Very large volumes 
Low price 
? 
 
 
Figure 5.6 Possible areas of application for IgY technologies. The R&D process is 
based on research, which is conducted in a multi disciplinary, planned 
IgY-center in Heby. The identified areas of application so far are; 
antibodies and diagnostic kits, medicine, food and feed. The “?”  
resembles future areas of application. (This illustration based on 
interviews with Larsson, Wejåker & Kollberg, 2000). 
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The IgY-center could furthermore support the development of results from basic 
research to the industrial production of medical devices, medicines, food and feed 
products. A strategic geographical position, in Heby, with several major hospitals 
(in Stockholm and Uppsala), universities (in Uppsala, Stockholm, Västerås, 
Eskilstuna and Gävle), pharmaceutical industry in the region and an FDA- 
approved avian business (OVA poultry production) in near proximity, further 
support the strategic value of this center.  
  
 
5.3.5 Using IgY in immune therapy  
Using IgY in immune therapy refers to an oral distribution of specific antibodies to 
establish protective immunity against pathogens. For a specific group of patients, 
with the hereditary disease Cystic Fibrosis (CF), this is especially interesting. 
People with CF suffer from malfunctioning mucus-producing glands. Their mucus 
is too thick and these patients are highly susceptible to infections in the respiratory 
tract. The main infectious agent is Pseudomonas aeruginosa, a common bacteria, 
which does not constitute a serious threat to a healthy person.  
 
There are approximately 450 CF patients in Sweden. The disease is hereditary. CF 
patients are mainly found in Europe and in North America. A few decades ago 
these children died young, due to lack of treatments. Now, chances of survival 
increase with each year of research in the area. The CF patients are well organized 
and their patient’s organizations constiture a lobbying force. (Kollberg, 2000) 
 
If a person with CF gets prophylactic treatment with IgY (gargling an egg powder 
solution with ½ an egg/day) a chronic infection with P. aeruginosa can be avoided, 
or the onset can at least be delayed (Carlander et al. 1999). The gains are seen in the 
quality of life, for the patient as well as in lowered costs for treatment of these 
patients. The cost of treatment of a CF patient with a chronic infection in Sweden is 
seen in hospitalization 2-12 times a year for one or two weeks to get treatment, 
mainly antibiotics. The medical cost for these treatments can amount to 160 000 
SEK/year for one patient.  This is not taking into account the personal suffering, 
societal loss and massive amount of additional indispensable costly medicines this 
person has to take. Hence, the gain for these patients is large in financial terms as 
well as in quality-of-life factors.   
 
Additional possible areas of immune therapy are illustrated in Table 5.3. Some of 
these areas are pursued at present as a part of a medical strategy to lessen the use of 
antibiotics at the University hospital in Uppsala. The immune therapy includes 
preventive measures as well as treatment after an onset of a disease. It has been 
proven, for instance, that oral immune therapy with IgY-antibodies may prevent 
and treat enteric infections (Carlander et al., 2000 A). 
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Table 5.3 Possible areas of immune therapy using IgY antibodies  
 
Bacteria, virus, 
fungus 
Disease  Treatment 
Pseudomonas 
aeruginosa 
-Cystic Fibrosis (CF) 
-burns (brännskador) 
-leg ulcers (liggsår, bensår) 
-ear infections 
-urinary tract infections 
Gargling 
compress/ dressing 
compress/ dressing 
ear drops 
“rinsing” in the bladder  
Drug resistant 
pneumococci 
-pneumonia  gargling 
 
Enterobact 
cloacae 
-diarrhea for new-born children  milk additive 
Toxin producing 
Escherichia coli 
-enteritis*48  swallowed capsules 
Salmonella and 
Shigella 
-gastroenteritis*  swallowed capsules 
Rotaviruses  -diarrhea among children  drinkable solution 
Helicobact pylori  -ulcer (magsår)  drinkable solution 
Bacillus antrax*  -anthrax (mjältbrand)   swallowed capsules 
Tuberculosis  -pneumonia  gargeling 
Candida albicans  -candidacies (secondary infections for 
patients with a suppressed immune 
system – i.e. cancer/ AIDS patients) 
-vaginal infections 
gargling 
 
 
vagitory capsules 
Source: A proposal for a IgY research center, (2000, 8). 
 
It is clear that range of possible medical applications is vast. Clinical studies in 
some of the areas mentioned in table 5.2 are carried out in a medical treatment plan 
at present (personal communication, Kollberg, 2000).  
 
Although the possible areas of application are numerous, the network of contacts 
within the hospital is considerable, and this technology is in agreement with the 
hospitals’ strategy to find alternatives to using antibiotics – the process of changing 
procedures is slow. One reason for the slow change is that the positive results need 
to be ensured before a general practice can be changed.  
 
 “ Good ethics is a condition for conducting clinical research. We want to 
carry out as many clinical studies as possible to be sure of our results. At this 
point we have a number of studies going on and, for the time being, I doubt we 
                                                       
48 * Refers to alterations in the original table as it is presented in the report. These 
alterations are made by Dr. Bernardh Claesson, who is an expert in clinical microbiology at 
the Central Hosptial in Skövde (personal communication, 2001). A short comment is 
provided by Dr. Claesson in the epilogue (p96).   
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could tend to more studies. … We have, however, seen an increased interest in 
society, among industry and governmental agencies in supporting this 
research.” (personal communication, Kollberg, 2000) 
 
So far we have discussed IgY-products mainly for medical use in a medical setting 
in Sweden. This is where the needs are palpable and the alternative procedures are 
costly.  Once these products are developed - a vastly larger market may want a part 
of these added value products, modified to meet their needs.  
 
 
5.3.6 Markets for IgY 
Looking at the products used for medical care, these are developed with the needs 
of Swedish CF-patients in mind. The hens are exposed to a dead (sterilized) 
cocktail of the strains of Pseudomonas that are regarded as the main risk for 
Swedish CF patients. The production procedures are illustrated in Figure 5.7.  
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Figure 5.7 Production of IgY antibodies in the egg yolk against, for example, 
common strains of Pseudomonas aeruginosa (personal communication, 
Larsson 2000; Wejåker, 2000 & Wall, 2001). 
 
 
Bearing in mind that the common strains of Pseudomonas vary slightly in different 
geographical areas, this very product may not fit the needs of CF patients in the US 
or even in Germany. To satisfy different needs the sterilized cocktail of 
Pseudomonas may need to be altered; albeit, the procedures for making the egg 
powder would be just the same.  
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The development and marketing efforts so far have resulted in antibodies for 
research use, for pharmaceutical use (kits) and in immune therapy using antibodies 
for CF-patients. The possible area of application of this technology is vastly larger, 
as seen in table 5.2. It is worth keeping in mind that the table illustrates possible 
medical applications in Sweden. Looking at markets in close proximity, especially 
the Baltic countries and the former Russia, reveals the needs for proactive treatment 
against Tuberculosis. Drug-resistant Tuberculosis is a major problem in these 
countries. In other parts of the world Cholera and Typhoid fever are serious threats 
to health. All of these diseases could be proactively treated with IgY antibodies in 
eggs.  
 
Looking into the future it would also be possible for functional food products, such 
as eggs developed against throat infections or the common flu. Such products could 
be an egg drink or a spray dried egg component in a ready-to-go meal (personal 
communication, Larsson, 2001). Contacts are made with Kjällbergs Industri AB for 
production of egg powder. Their production capacity is high and the CEO, Rosén, 
is investigating a possible use for IgY in food and feed products (personal 
communication, Larsson, 2000). The potential markets for food and feed remain to 
be further explored.  
 
 
5.3.7 An epilogue 
It is clear that there are several possible medical applications for this technology. 
After reading the case Dr. Claesson, a medical expert in clinical microbiology, 
comments that this technique may offer a potential in proactive treatment of 
patients with a suppressed immune defense (such as patients that undergo cancer 
treatment for example). For people with a normal immune defense, however, it is 
hard to improve the status of a functioning immune system without a specific 
immunization (personal communication, Claesson, 2001). 
 
In this day and age, with a world spread fear of Bacillus anthrax, the interest in 
proactive treatment of people at risk of contracting anthrax appears to another 
interesting medical area of application. There are three ways of contracting anthrax, 
pulmonary, orally and through the skin (Örn, 2001). The orally contracted anthrax 
could theoretically be proactively treated with oral intake of special eggs.  The 
anthrax that resides in the skin is less invasive and possible to treat with known 
medicines. The pulmonary anthrax, however, has a rapid development and the 
treatment is successful only in the cases where a correct diagnose was made at an 
early stage (Ibid). The reason that an aerosol (such as used for asthma patients, for 
example) with egg-powder would not be possible to use lies in the risk for allergic 
reactions due to the egg base in the powder that would meet the pulmonary tissue.   
99 
5.4 Lactobacillus Reuteri49 
 
This case presents a Swedish research-based business, BioGaia Biologics AB 
(BioGaia). A scientific discovery in 1985 was further developed and it is today a 
research business on the stock market. BioGaia owns patents on the use of a 
complete family of lactic acid bacteria (L. reuteri). These patents form the base for 
licensing agreements with food and feed producing companies all over the world.   
A product 
The functional food product is a dairy product with lactic bacteria. In Sweden a 
license is held by ICA-handlarna, that sell milk with lactic bacteria, so-called 
“BRA”-milk (Bifidus, Reuteri, Acidophilus). 
 
Working with probiotics, it was evident that these products require special 
packages. BioGaia is also responsible for a patented radically new packaging 
concept for freshness in probiotic drinks, Life Top
TM. This packaging concept, a 
capsule on a bottle that allows for the probiotic bacteria to mix with the food when 
the package is opened, has several advantages. First and foremost it increases the 
stability of the bacteria and thereby lengthens the shelf life of probiotic functional 
drinks. 
A process 
The research process has included methods for bacterial identification, chemical 
characterization of substances (for instance, reuterin) and methodological 
development for testing probiotic effects. Testing probiotic effects include methods 
for detecting prophylactic (proactive health) effects. 
A business 
BioGaia Biologics AB is a research based company with operations in Sweden, the 
US and Norway (Figure 5.8).  
 
BioGaia 
Biologics Inc. 
USA 
Bio Gaia 
Biologics AB 
Sweden 
FermentationAB 
Sweden 
Biosentrum AS 
Norway 
10% 
10% 
100% 
100% 
 
Figure 5.8  Organization of BioGaia AB (Annual report, 1998, 2). 
                                                       
49 This case is shorter and less detailed than the three previous cases. As a business on the 
stock market the CEO, Rotschild, felt that it was unappropriate to talk in detalil about 
technological and market strategies. The case is, therefore, based on two interviews, one 
presentation of BioGaia at a conference and official written materials about the business.    
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BioGaia’s vision is “to be instrumental in bringing about a change in emphasis, 
from treating illness with only medicines to improving the natural protection 
against disease through preventive measures” (Annual report, 1999, 2). 
 
 In 2000 their operations are divided into four business areas:  
- Animal health, 
- Functional foods, 
- Health care, and  
- Fermentation (BioGaia Biologics AB, press release, “year-end report for 2000”). 
The fermentation business area is organized as a separate whollyowned subsidiary.  
 
The focus in this case is primarily on the area of functional foods. It is clear, 
however, that technologies used in one business area provide valuable input for 
development in other business areas as well.   
 
 
5.4.1 From basic research to products on a market 
Looking at the development process, from findings in an experiment to the 
development of a market application, several unexpected turns have been made. 
Basic research provided knowledge that was further developed and explored on a 
market.  
 
1984 In the lab at the department of Microbiology (at the Swedish University of 
Agricultural Sciences) two scientists, Lindgren and Dobrogosz (on  
sabbatical leave in Sweden) make a discovery. One strain of lactic bacteria 
produces an antibacterial substance (Reuterin), given anaerobic conditions 
and when certain nutrients are present. This means that this substance 
inhibits the growth of other bacteria. 
 
1985 A patent was filed based on their findings which caught the attension of an 
American venture capital business, PBI. They purchased the patent rights for 
a planned development of a Herpes zoster medicine50.  
 
1989 The development of a Herpes medicine did not turn out to be what PBI had 
hoped for, so when the two Swedes, Rothschild and Annwall, declared their 
interest in the patents rights they were readily sold. Rothschild and Annwall 
wanted to find a technique for increasing the durability, qualities for 
maintaining freshness of organic vegetables when these were transported. 
This was the primary intended use for these bacteria.   
 
A friend of theirs, Möllstam, pointed out a new possible area of application, 
using the bacteria in animal feed. Healthy bacteria, such as L. Reuteri, would 
                                                       
50 Herpes zoster is a virus. Once a person has contracted Herpes zoster it is chronic, with 
dormant periods between outbursts (blisters).   
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thus constitute a probiotic, an alternative to antibiotics for piglets and 
turkeys.  
 
Research was also conducted on the possibility of using these bacteria in a 
food. Dobrogosz returned to the US and his group showed that L. Reuteri had 
positive effects in food products as well as in feed products.  
 
 
1990  BioGaia Biologics was founded. 
 
1991 A food product, BRA-milk (BRA-mjölk & BRA-fil), was launched in 
Sweden. 
 
1993 The “BRA-milk” is licensed out to ICA-handlarna in Sweden. A patent for 
the Canadian market was gained.   
 
1995 The patents were further extended to cover other interesting world markets. 
 
1996 Licensing agreements were signed with large dairy producers in, for example, 
Japan, Finland, the US and Switzerland for production of dairy products with 
L. Reuteri.   
 
1997 Fermentation businesses, MultiFerm AB (in Lund, 100%) and Biosentrum AS 
(in Stavanger, 20%), were acquired. In these production facilities process 
know-how is further developed and the bacteria are produced that are needed 
for the products (for example in the “BRA-milk”).  
 
1999 MultiFerm’s services include any kind of production from small-scale models 
to large-scale production. Customers are mainly seen in the pharmaceutical, 
biotechnological and veterinary medicine disciplines. MultiFerm AB changes 
name to Fermentation AB. 
 
1999 A strategic alliance with Christian Hansen A/S is formed regarding marketing 
and sales of food ingredients. 
 
 
The R&D process is based on the notion that BioGaia is good at research and that 
licenses, in the four business areas, will provide financial grounds, as well as 
additional know-how, for continued development of products and processes.  
 
 
5.4.2 Research as a business idea 
The base for the business, BioGaia, started in basic research, the discovery of L. 
reuteri by the two microbiology professors Sven Lindgren (the Swedish University 
of Agricultural Science in Uppsala) and Walter Dobrogosz (North Carolina State  
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Univ. in Raleigh). They found that under anaerobic conditions and in the presence 
of glycerol L. reuteri bacteria produced an antimicrobial substance (reuterin51). 
 
In scientific studies52, the positive effects in the gastrointestinal tract are manifested 
in a histological healthy gut53 and the absence of pathogens. The patents (well over 
20) that protect the right to use these lactic bacteria are regarded as strong patents 
(Möllstam, 1998). This is attributed to the fact that reuterin is easily chemically 
detected and thus defended.  
 
With production facilities and a strong set of patents at hand, the development of 
functional food products revealed that the shelf life of the bacteria in the dairy 
product was limited. The need for a package that would allow for the probiotic 
bacteria and the food product to mix when the product was consumed became 
increasingly apparent. A bottle, Life Top
TM, and a straw, Life Top
TM Straw, were 
developed to keep the bacteria separated from the drink until it was consumed. The 
Life Top
TM and the Life Top
TM Straw are patented as well. Licensees are thus offered 
the use of L. Reuteri and a premium packaging for a probiotic product.   
 
Another area of research and development that is prioritized is that of developing a 
method for evaluating probiotic effects. These probiotic effects are mainly 
preventive effects, as a compliment to the established methods for evaluating 
medical effects in pharmaceutical products.  
 
“ Probiotics should be evaluated in terms of the effects of prevention against 
an onset, or the delay of an onset, of a disease, not in terms of a cure when 
symptoms of a disease are diagnosed”   
(personal communication, Möllstam, 1998). 
  
These studies54 are extremely costly for a number of reasons. The main reason is 
that they involve a large number of persons (a large sample as a test group and a 
“blind” group in a double blind study). Furthermore, the studies would have to be 
of longitudinal type to ensure that each person at some point would be exposed to 
                                                       
51 The substance reuterin occurs in three dufferent forms, as a monomer, as a hydrated 
monomer and as a dimer form of ß-hydroxypropionaldehyde. 
52 Scientific studies show that reuterin is produced by an entire family of lactic bacteria, L 
reuteri. These bacteria are found among numerous animals, for example cattle, turkeys, pigs, 
mice, rats, hens, turkeys, ostriches and humans. The human strain of L reuteri that is used in 
functional food products was isolated from a Peruvian woman living in the Andes.  
53 A histologically healthy gut shows a stimulated epithelial cell development, resulting in 
long intestinal villi, deeper crypts and hence a more efficient nutrient uptake.  
54Most methods for evaluating medical effects have been developed in a pharmaceutical 
tradition. The main objective has been to find efficient substances to treat a disease. In the 
case of functional foods the challenge is to find new methods for evaluating preventive 
effects – preferably in studies on humans (as opposed to rats or mice).    
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pathogens. Another challenge is to find indicating measures, markers that could be 
used to determine an individual’s immune status. The development of methods for 
the evaluation of probiotic feed products is seen as technological development that 
might benefit the functional food area as well.    
 
 
5.4.3 Licensees and partners in development 
BioGaia has licensing agreements with a number of strong business partners. These 
licensees/ partners are listed in Table 5.4 (on the following page). Most of these 
licensees and partners produce and market consumer products, where BioGaia 
receives revenues in royalties from sales of these products. The licensees are 
offered a product package. 
 
“ We have realized that R&D is what we are good at  – so that is what we do. 
We don’t offer our customers the free use of a technology, however, we offer 
a product. A complete product concept, including packaging, is the ideal 
offer to make to a customer’s marketing department. That way the customers 
own R&D department may not get engaged in the business proposition.” 
(personal communication, Möllstam, 1998)  
 
 
The alliance with the very large company, Christian Hansen A/S, differs from the 
license agreements described above. In this strategic alliance the products are bulk 
products, produced to meet the needs of the food industry, and the dairy industry in 
particular. The alliance with Christian Hansen A/S is a part of a strategy to access 
food industry markets for ingredients and food-related know-how. 
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Table 5.4 Licensing agreements and partners in development in the four business 
areas for BioGaia 200055  
 
Business area/ 
product 
The use of the products  Licensee and partner in 
development 
Health care/ 
Tablets & capsules 
 
 
 
 
 
Clinical nutrition 
products 
 
-for people with an in-balanced 
micro-flora in their gastrointestinal 
tract or for persons with a reduced 
resistance 
-a joint venture in developing a 
“mother’s milk replacement” 
product for children with allergies 
(trademark: Profylac) 
- an agreement with the Danish 
company regarding the rights to 
sell PreKUnil (for treatment of the 
metabolic disorder PKU) 
McNeal Consumer 
HealthCare, a subsidiary of 
J & J (USA, Canada), 
Victus (South America) 
BioPro Pty. Ltd. (S. Africa) 
 
ALK Abelló A/S a 
subsidiary in the Christian 
Hansen group  (Germany) 
 
Semper (Sweden) 
 
Nila A/S  (Europe) 
Functional foods 
Milk, cultured milk 
products, fresh 
cheese, ice cream, 
food additives and 
baby food products. 
 
 
Ingredients for the 
dairy industry 
 
- a part of a healthy life style. The 
L reuteri supports the immune 
system and the nutritional uptake 
in the gut. 
 
 
 
 
-a strategic alliance in marketing 
food ingredients 
ICA-handlarna (Sweden),  
Chichiyasu Milk Co Ltd 
(Japan) 
Ingman Foods Oy Ab 
(Finland) 
Kraft Jacobs Suchared 
Iberia (Spain, Portugal) 
germany (Benelux) 
Nature’s Way (USA) 
Christian Hansen A/S 
(Denmark/Europe) 
Animal products 
“ReuterIn Ovo” 
 
 
“Reuteri Chicken 
Soluble” 
 
– An injecting eggs technique that 
is used in broiler production is a 
patented product. 
– is a product for chicken 
production. It is administered via 
the drinking water. 
 
A very large chicken 
producer  (USA) 
Fermentation 
Production capacity 
and know-how 
 
The plant in Lund, Fermentation 
AB, offers capacity that include 
production as well as development 
of new products.  
 
Possible industrial partners/ 
customers are seen in 
industries out-sourcing the 
fermentation part of their 
production. 
  
                                                       
55 This table is based on information in press releases from BioGaia 1999-2001 (Internet: 
biogaia.se)  
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In the business area fermentation, BioGaia shows a clear wish to find industrial 
partners in production as well as in development. They market production capacity, 
experience in the field of fermentation and quality authorization for production of 
pharmaceutical ingredients.  
 
 
5.4.4 An epilogue 
Are lactic bacteria of any help for healthy people? We know that they play an 
important role in the function of the gastrointestinal system, including immune 
functions. Do more lactic bacteria bring better health? Are we more sensitive to 
lactic bacteria in certain phases of our lives than others? Studies of probiotics do 
not provide any simple answers. 
Studies of allergies in young children show that, in certain environments, the 
children show less signs of allergies (Alm, 2001; Wickman, 2001). These children 
and their families are exposed to an environment with factors that stimulate the 
immune system. One of these factors is the presence of  lactic bacteria. Recent 
clinical studies of oral intake of lactic bacteria capsules during the late phase of 
pregnancy demonstrate an inverse correlation with signs of allergies in the newborn 
children (Kalliomäki et al., 2001). These studies would indicate that it would be 
possible to strengthen the immune system with probiotics as capsules or in food 
products. 
 
Other researchers (Cedegård & Widell, 2001) agree with the possibility to enhance 
health by intake of probiotics. In good health or poor, the GI-tract requires a 
continuous re-establishment of healthy bacteria (probiotics) and food for these 
bacteria (prebiotics). Ideally, they argue, new functional food products should 
therefore not only contain probiotics but also prebiotics,  in so called symbiotic 
products. 
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6 Discussion 
 
 
 
 
In analyzing the innovation process, a number of questions, connected to the main 
research question, are raised. The main question is “How do Swedish food 
companies develop new high-tech functional food products?” This question is 
partly answered in the empirical material, as conveyed in chronological case 
narratives (Chapter 5). The market analysis, in Chapter 4, also provides general 
grounds for understanding the developments in the food industry.  
 
In this chapter, the discussion evolves from a comparison of the innovation process 
in the cases. It continues in terms of an analysis of vital contextual factors. Building 
on the analysis of the cases and a contextual analysis, conclusions are presented 
along with speculations for future development of functional foods.   
 
 
6.1 A model for technological and market upgrading 
 
In the management literature most models for NPD (New Product Development) 
have been developed to describe the technological and market upgrading of existing 
products. Models for developing radically new products, however, have hardly 
been described at all. This refers to models that allow for the dynamics of going 
from low-tech to high-tech, as revealed in the case studies.  
 
In the following chapter it is therefore worth keeping in mind that most food 
businesses do not engage in this high-risk endeavor of developing functional foods. 
The common strategies within food production aim towards an efficient production 
of established products. This refers to standardized bulk products, such as vegetable 
oil, starch and sugar. Development of functional food products, however, requires 
strategies for change (Figure 6.1).  
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Low    
Low     High    
Production and distribution of  
standardized raw material     
(e.g vegetable oils, starch, sugar)    
Production and  
marketing of  
differentiated products  
using new technologies  
(e.g functional foods)    
Production and marketing 
of differentiated products  
with established  
technologies (e.g a new  
taste of an existing yoghurt  
brand or a new cereal mix)    
LEVEL OF 
MARKET 
INNOVATION 
  
LEVEL OF TECHNOLOGICAL  
INNOVATION    
High 
     
 
Figure 6.1 Product development strategies gives rise to products with varying levels 
of innovation (after Nyström & Liljedahl, 1994, 7). 
 
 
Strategy A and B are strategies for commercial NPD. Strategy A refers to the 
development of new products in an incremental change process. These products are 
often the result of a market-driven development process. Using existing products 
and products with minor alterations existing and new markets are explored. 
Strategy B, on the other hand, shows a strategy for a high level of technological and 
market innovation. This refers to the development of radically new products for 
new markets. 
 
6.2 Grounds for a comparative analysis 
 
In each case, the process of innovation is in focus. Thereby new products, new 
processes and new businesses are developed. The comparative analysis is limited 
with regards to which phase the innovation process has reached for the functional 
food product in each case (Figure 6.2). 
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Figure 6.2 Phases of the innovation process using the general model presented by 
Albernathy & Utterback (1988, 27) for illustration of the development in 
the case studies. The dotted line is an addition to the model. It refers to 
the development of a new business, which is interdependent on the 
development of new products and new processes.  
 
 
Traditionally, this model (Figure 6.2) is used in discussions of industrial 
development. It is assumed that the rate of innovation follows a general pattern 
over time (Albernathy & Utterback, 1988). Using the model as an illustration of 
product and business development at a company level allows for a comment about 
the interdependency of these processes. The model shows that the development of a 
product precedes the development of a process. Looking closely at the cases it 
seems that a condition for the development of a product (in for example the 
ProViva and the Magiform case) has been the development of processes (for 
identifying bacteria and processing grain). We will assume in further discussions 
that the development of a product and a process are interdependent processes.  
 
Furthermore, the development of a product includes the development of production 
techniques for this new product. The development of a process, on the other hand, 
refers to the development from a small lab-scale experiment to an efficient large-
scale production process. This may in turn motivate questioning if the curve for the 
rate of process innovation should be as high as that for product innovation. A 
reason for regarding it as lower would be that the objectives for the process 
development are pre-determined by the desired product outcome.   
 
It is assumed that product and process development are seen as two parts of the 
same process (Albernathy & Utterback, 1988). It has been argued, however, in a 
recent study of European food businesses that companies are either process or 
product oriented (Traill & Grunnert, 1997). In Traill and Grunnert’s proposed 
model the orientation towards process or product development has a major 
influence on the innovation process components that are outsourced and what is  
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developed in-house. In this empirical material these processes are intimately 
connected. A clear focus on an orientation towards product or process development 
is not seen in the analysis of these cases. Furthermore, the distinction between what 
is developed in an in-house activity vs. in an outsourced activity is unclear in the 
cases. This is further discussed under “Organizing for innovation” (6.4). What is 
very apparent, on the other hand, is that the development of new businesses is also 
seen as a result of the innovation process. These new businesses are research 
oriented, entrepreneurial, flexible and consist of skilled and specialized people, in 
accordance with Utterback’s (1995) model.  
 
The innovation process, in terms of functional food products, has reached different 
developmental phases in each case (Table 6.1). In the IgY-egg case, a functional 
food product is not yet developed whereas for the ProViva case, a second-
generation health related food product, ProViva Active (a sports recovery drink) has 
been launched as a brand extension.   
 
Table 6.1 Developed products in each case 
Case  Functional food product  Additional functional foods  
or other product/s 
 
ProViva  ProViva (a fruit drink)  ProEquo (a horse feed) 
ProViva Active (a sports drink) 
 
Magiform  Magiform, a product 
line: 
müsli, pasta, bread, 
biscuits 
 
“100% oats” (gluten free oat flakes)  
IgY-egg  ---  Medical products for patients with, for 
example, Cystic Fibrosis or burns 
 
L. reuteri  BRA-milk and cultured 
milk 
“Profylac” (a pill, clinical nutrition) 
“LifeTopÔ” (a bottle for drinks)  
“ReuterIn Ovo” (animal product)  
 
 
With these products in mind we will make a cross-case comparison with the focus 
on technological and market strategies. Starting where the innovation process 
commences as a strategic intent, often viewed as a problem that needs to be 
resolved, we will follow the development of these products to a market.    
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6.3 Strategic intent 
 
Developing a radically new product is preceded by a strategic intent. In this 
framework these strategies are referred to as intended strategies. These intended 
strategies are revealed in the cases as visions of the destination of technological and 
marketing strategies (Table 6.2).  
 
Table 6.2 Intended strategies expressed in terms of visions  
Case  Vision statement 
ProViva  “From having been a small dairy on a minor market we want to become an 
actor on the European food market…Our customers will perceive us as a 
keen and innovative partner in development. Through cooperation with other 
actors we will achieve increased competitiveness” (Annual report 
Skånemejerier, 1997, 2). 
“Probi will develop into an internationally recognized leading biotech 
company in the area of probiotics” (Annual report, Probi AB, 2000, 6). 
 
Magiform  BioDoc’s business concept is to “develop, produce and market products with 
health effects” (BioDoc, business brochure, 1999, 3). 
 
IgY-egg  A business oriented vision statement is not found for this case. The 
interviewed researchers share a research oriented vision of building an IgY-
center for continued research, where their role would be technological 
development (R&D). 
 
L. reuteri  BioGaia’s vision is “ to be instrumental in bringing about a change in 
emphasis from treating illness with medicines to improving the natural 
protection against disease through preventive measures” (Annual report 
BioGaia Biologics AB, 1999, 2). 
 
 
But, of course, most of these statements are expressed with hindsight, with 
continued developments in mind. In the IgY-case a business oriented vision is not 
expressed. This is primarily explained by the early phase of development in this 
case. This may in turn be attributed to the fact that the business, Immunosystem 
IMS, consists of full time working scientists with limited time and incentive to 
drive the innovation process into a marketing phase.  The area of application, other 
than as medical products, is not yet clear and therefore difficult to communicate in 
a vision statement.  
 
Assuming the vision statements are not perfect measures of the strategic intent, but 
rather an after-the-fact rationale that directs future developments, what could 
explain the development? Starting where the innovation process in each case starts, 
we can compare initial sources of inspiration (Table 6.3). A practical problem 
seems to have been the initial source of inspiration in all the cases but the IgY-egg 
case. The problem that inspired the innovation process provided a request for a  
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solution and, in other words, a “market pull” situation. Looking at the IgY-egg 
case, it could be regarded as a “technology push” situation where a visionary 
entrepreneur’s interest in science motivated researchers to engage. 
 
 
Table 6.3 Information and problems as inspiration for the innovation process 
Case  Initial inspiration for the innovation process 
ProViva  A medical problem after abdominal surgeries 
 
Magiform  A need to find an alternative to using antibiotics in animal husbandry 
 
IgY-egg  Discussions of a scientific entrepreneur’s ideas with a group of scientists 
 
L. reuteri  A need for a technology to keep vegetables fresh during transport 
 
 
 
The development of ProViva is the result of a desire to resolve a medical problem. 
Little was known about what the final product would look like or how it would be 
developed. From the case it is clear that a number of actors have participated in the 
development of this product. It is also clear that the procedures have been radically 
changed several times. Furthermore, the final product is not even what was 
imagined or needed. The end product was not the expected medical product for a 
medical market, but rather a health related food for a broad consumer market. 
 
Developing products with L. reuteri  (i.e. BRA-milk) is another example of a new 
avenue that was not the initial objective. The need for a technology for keeping 
vegetables fresh lead the way to other areas of application (functional foods, health 
care products and animal products).  
 
When the use of antibiotics during the weaning of piglets was prohibited a need for 
a feed that would support the immune system for the piglets was evident. One of 
the persons involved in the development of this feed for piglets was an entrepreneur 
who recognized a new market for this technology, as functional food products 
(Magiform).  
 
It was through an entrepreneur’s sincere interest in science, his previous 
experiences in research procedures, and his know-how in poultry production, that 
information was transformed to an idea, in the IgY-case. This idea was not an 
immediate solution to a problem. The idea was rather intuitive, based on scientific 
experiences, with no immediate commercial application.  
  
We can conclude the analysis of strategic intent as follows. The creative process, in 
each of these cases, shows entrepreneurship as the visualization and realization of 
new ideas. Information is thus transformed to an idea and an innovation. As the  
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unfolding of experience gradually leads the process towards a possible solution to 
the problem or an area of application, the process gets more focused and thus 
possible to plan. Once a prototype of a product is developed, the development 
continues as technological development and marketing. The marketing strategy 
involves a plan for how the product can be marketed to existing markets and how 
new markets can be developed.  
 
The innovation process is further discussed below in terms of organizational 
conditions that allows for flexibility and emerging technological and marketing 
strategies, a leadership for the creative process, and administrative routines that 
have promoted the progress. 
 
 
6.4 Organizing for innovation 
 
Strategies for new product development include organizational arrangements for 
managing the innovation process. The organizational structure for developing, 
producing and marketing functional foods ranges from in-house R&D, joint 
ventures and alliances, to the acquisition of firms. Table 6.4 illustrates a 
comparison of the organizational arrangements found in the case studies. 
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Table 6.4 Organizational changes in structure to promote flexibility 
Case  Changes in organizational structure throughout the innovation process 
ProViva  A cross-disciplinary research project at Lund University Þ a science-based 
business is founded collaborating with a number of partners in development 
Þ a joint venture for development and marketing is formed with 
Skånemejerier Þ Probi goes public Þ an alliance in production and 
marketing with Skånemejerier and licensing agreements with other 
production and marketing partners. 
  
Magiform              A   A joint research project with Sveriges Svincenter and Gothenburg Univ. for 
developing a pig feed Þ a joint venture business (BioDoc) and a virtual 
organization, owned by: Cerealia, Skånska Lantmännen, Odal Lanmännen 
and Lantmännen Invest  Þ a search for strategic marketing partners. 
 
IgY-egg  A cross disciplinary research project at Uppsala University and the Swedish 
University of Agricultural Sciences Þ a science based business is founded, 
Immunosystem IMS, collaborating with pharmaceutical businesses Þ a 
strategic alliance is formed with BioPool, another science-based business 
working in diagnostics Þ a joint business, BioNativ is set up between 
Immunosystem IMS and BioPool Þ a search for partners for the 
development, production and marketing of functional foods. 
  
L. reuteri  A research project at the Swedish University of Agricultural Sciences Þ an 
American venture capital business, PBI, purchase the patent rights Þ the 
patent rights are sold to become the foundation for a science based business, 
BioGaia Biologics Þ BioGaia Biologics goes public and acquires 
fermentation plants  Þ Licensing agreements are set up with food production 
partners through out the world and a strategic alliance is formed with 
Christian Hansen A/S for marketing food ingredients to the food industry.  
 
 
Different organizational arrangements in these cases appear to have promoted 
changes. They have allowed for exploring unexpected avenues and changing the 
direction when the traditional procedures did not serve the needs. In reading the 
cases these changes are expressed as, for example, new product applications, new 
markets, new procedures in the R&D-process and as new partners throughout the 
innovation process. What is needed in early phases (flexibility and access to certain 
resources) is gradually replaced by other needs (resources for production and 
distribution and communication) in later phases. To accommodate for these 
different needs, the organizational arrangements need to allow for change. 
Organizational aspects of different collaboration arrangements in the cases are 
illustrated in Figure 6.3.  
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Figure 6.3 Organizational and managerial implications of different forms for R&D 
collaboration in the cases. (* = Planned sales) 
 
 
In the four cases the progression of the innovation process56 – from research 
projects to manufacturing and distribution of products – has required organizational 
changes.  The simplified illustration of these changes in Figure 6.3 shows that these 
strategic changes allow for some comments.   
 
In the study by Chiesa and Manzini (1998) and other studies of organizational 
forms for innovation (e.g Ford, 1988) businesses are analyzed at one point in time. 
It is rarely discussed how the organizational form may change in different phases of 
a creative process. A closer look at the cases reveals that the organizational 
arrangements change throughout the innovation process. What starts as a research 
project with different collaboration partners and formal contracts, turns into 
alliances and joint ventures in the case of ProViva and IgY-egg.  
 
The ProViva research project has several collaboration arrangements with partners 
in development (as negotiated outsourcing). The organizational arrangements for 
collaboration were rather formal and regulated by contracts in the introductory 
phase. This is also the case for the collaboration with Skånemejerier. What started 
as negotiated outsourcing became an acquisition and later a joint venture. The 
                                                       
56 Collaborative arrangements can be discussed at great length in deciding the differences 
between negotiated outsourcing, an alliance or a joint venture. Therefore, the terms used by 
the respondents serve as basis for the discussion.    
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reasons for a more formal arrangement in the early phase of the joint activities is 
illustrated in Figure 6.3 as low start up time and costs, high reversibility, low risk, 
and low impact on a firm’s resources. Successful collaboration between Probi and 
Skånemejerier stimulated a closer collaboration arrangement as a joint venture in 
the development, production and sales (Figure 6.4). Less successful collaboration 
arrangements (for example with ConAgra) were terminated. The engagement 
continued to grow between Probi and Skånemejerier in development of additional 
products. Their organizational collaboration arrangements changed, from a joint 
venture to an alliance. In this alliance the ownership of the brand name, the patents 
and the markets are carefully divided. The change from a joint venture to an 
alliance is seen as a clarification of roles in the collaborative activities (Figure 6.4).   
 
In the case about the development of the Magiform products, the organization is 
described as a virtual organization. Each member of the organization has an 
extensive net of professional contacts, i.e., partners in the development. The applied 
strategy is seen as negotiated outsourcing, ranging from research to production and 
distribution of products. Theoretically the arguments for this arrangement are low 
commitment and high reversibility. In working with the case, however, it is clear 
that it is a strategy to build viable and long lasting relations with collaboration 
partners. The collaboration provides benefits for both parts involved. The main 
argument that supports this strategy is rather that of efficiency, where a 
collaboration partner performs one part of the innovation process with more 
experience and resources at hand. The BioDoc company regards itself as a 
coordinator of all these activities. Although BioDoc is jointly owned, it is managed 
rather autonomously. 
 
The development in the IgY-egg case started as a cross-disciplinary research 
project. A science-based company was founded. In order to gain access to a market, 
as well as a partner in development, a joint venture was formed. This joint venture 
with a pharmaceutical industrial partner did not prove to be fruitful. High costs, 
high risks and low reversibility did not provide the needed flexibility for the 
innovation process to proceed. A strategic alliance and later a joint venture was 
formed with a company in the same field. Strategies for the future include 
continued R&D and production of functional foods with strategic partners. 
 
The case about the development of L.reuteri shows organizational arrangements 
where acquisition has been an important way to access resources and gain control. 
The patent rights were purchased and they became the base for a biotechnology 
firm, BioGaia Biologics AB. The development involved a joint venture between 
researchers in the research phase and an acquisition strategy for the newly-founded 
biotech company (where patents as well as production facilities are acquired). The 
company went public and acquired plants for fermentation. Licensees are offered a 
product concept based on the development that has been staged and patented by 
BioGaia. The acquisition is associated with high commitments (impact on 
resources, control over activities, risk and start up time and costs) and low  
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reversibility. As a company on the stock market, in a high-tech area, BioGaias 
strategy for ownership of intellectual properties as well as production facilities 
appears to be a way to communicate commitment. This commitment may in turn 
result in stable finances and investments for continued research as negotiated 
outsourcing. This organizational arrangement allows for continued development in 
strategic fields as well as strategic partnership in marketing products.  
 
An analysis of how the organizational form has changed in these cases further 
supports the need to understand the conditions for supporting the innovation 
process. For a food business, for instance, this implies finding procedures and 
organizational forms that allow for collaboration, thereby accessing resources and 
building competencies that strengthen the competitive position on the market. 
 
A close look at the collaboration condition shows that it is unclear what parts of the 
R&D process take place within the company between collaboration partners, and in 
contacts with other actors in the surrounding network. Unclear boundaries for 
technology development and transfer is an explanation for difficulties in discussing 
the development in terms of where the R&D process takes place - as an “in house” 
activity or an activity mainly outside the organizations. A more productive 
approach is to look at how companies perceive their strategic roles in the 
innovation process (Figure 6.4).  
 
Marketing   
A research-
based business 
A manufacturing 
business 
Marketing  Sales  Distribution  Manufacturing  R&D 
 
 
Figure 6.4 Strategic roles in the development and marketing of functional foods 
(modified after Annual report for Probi AB, 2000, 11). 
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The innovation process, i.e. the development of functional food products, has its 
origin in research and in most cases a problem or a genuine interest in science 
(Table 6.4). Understanding scientific research is thus a condition for being able to 
make a strategic choice in collaboration partners. Hence, the functional food actors 
take strategic roles with regards to their business idea. The chosen roles for 
research businesses and food manufacturing businesses are further discussed and 
analyzed as technological and marketing strategies. 
 
 
 
6.5 Technological strategies 
 
Technological strategies are not just words on a paper, or a creative person’s 
visions. It is how things are done, patterns of behavior (Mintzberg, 1976). 
Technological strategies refer to the acquisition and use of knowledge in different 
phases with regards to a technological life cycle (Nyström, 1990, 77). In the early 
stage of the life cycle model the technology is more implicit. Its use is not yet clear 
and describing it is rather that of conveying an image of possible outcomes. At a 
later stage, the technologies become more explicit. The technology has at that point 
an accepted name, and the application is a product concept.  
 
Technological strategies are seen as mechanisms for creating more knowledge and 
skills. This includes all kinds of knowledge: technical, market, administrative and 
social knowledge. A technological strategy reveals the future aims of a business 
(see Strategic intent, 6.3). The case narratives are mainly concerned with realized 
technological strategies, but in historical and in contemporary actions lie 
possibilities for tomorrow’s intended strategies.  
 
 
6.5.1 Strategies  for technology development 
Strategies for technology development are seen in for example organizational 
arrangement and administrative routines. These strategies for R&D and acquisition 
of technologies are discussed below. Figure 6.5 illustrates strategies for technology 
development from the IgY-egg case. Similar thoughts are conveyed in the other 
cases.   
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Figure 6.5 Possible areas of application for new technologies. New knowledge is 
developed in cross-disciplinary research projects (from the IgY-case). 
These areas of application for new technologies; research, medical, food 
and feed appear in each of the cases.    
 
 
A vision is created for continued development in the case of IgY. Keeping the 
R&D entity in an IgY-institute is a solution to the experienced problem of not 
taking the time for documentation prior to exploring a new technology. The 
institute would ensure creative freedom, intellectual properties and academic 
quality. These new technologies would become the basis for continued 
development in four different areas of application. At present, the reason for the 
development so far in research applications is, of course, the fact that this is a 
familiar avenue for the researchers.  They have medical contacts in their every day 
routines. Finding collaboration partners for development in the food and feed areas 
is thus a critical technology in this case. Ideally, the institute would also provide 
partners in development and production.   
 
In the ProViva case Skånemejerier views the R&D process as a semi-structured 
phenomena. It starts as a project with time limits and go/no go points. It is 
perceived as a process in which scattered information is brought together and 
analyzed by a group of experts. Sometimes a vision of a new product or process is 
the outcome of this time and resource-consuming process. Skånemejerier has 
chosen to form joint ventures with groups of experts, often from the nearby 
university science park in Lund. These groups of experts become a part of their 
network.  
 
In practical terms, the process is described as “structured chaos”. Skånemejerier 
follows research projects in the food area conducted at universities, and sometimes 
these projects become a joint R&D project. The scanning and reviewing of projects 
is carried out regularly at Skånemejerier. Strategic aims, financial possibilities and 
a general judgment of how commercially successful a product might be, puts the 
project in financial order of priority.  
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The American partner in collaboration, ConAgra, entered the innovation process at 
a time when the development of a product and a process had taken place. Their 
strategy was mainly that of clinically testing and selling the product. Thereby, an 
access to a new market was provided for the product (ProViva). In return, ConAgra 
received access to critical technologies. This was accomplished through license 
agreements between the patent holders, Probi AB, and ConAgra Inc.  
 
In the case studies, the technological strategies are also reflected in organizational 
arrangements with many collaboration partners and openness towards possible 
areas of application. Open technological strategies may in part be explained by the 
cross-disciplinary approach and the many skills that have been required for the 
innovation process to proceed (Table 6.5).  
 
Table 6.5 Technology development  
Case  Technology development 
ProViva  Identification of bacteria, methods for screening for appropriate bacterial 
strains, application areas, products and processes. 
 
Magiform                     Processing cereal to develop a feed that would activate the immune system in 
piglets, understanding the mechanisms behind protein AF, application areas, 
products and processes 
 
IgY-egg  Production of IgY-antibodies, areas of application for specific IgY-
antibodies, mechanisms behind the immune system supporting effects and a 
product for CF-patients (immune therapy as an area of application) 
 
L. reuteri  Identification of a bacterial strain and a chemical substance, functions of this 
substance, areas of application, products, processes, methods for evaluating 
prophylactic medical effects, packaging for probiotics. 
 
 
 
Table 6.5 illustrates significant technological development in all of the cases. For 
the development, it should be noted that all of the above cases have resulted in 
numerous immaterial rights, mainly patents. In the Magiform case, however, it was 
shown that technology development to increase know-how may play just as an 
important role as patents in developing functional foods. The comment alludes to 
the development of another product where the know-how and production quality 
control provide a company position that yields increased competitiveness.  
 
 
6.5.2 Creating an innovative culture 
Technological strategies are also expressed as conditions that make individuals and 
organizations engage in a creative process.  
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“ My philosophy is that the researchers should make money on what they 
create and do. I want them to feel included in the whole business... That way 
the corporate culture is one where researchers want to, and will, try new 
ideas.” (personal communication, K. Vareman, 1997, the ProViva case) 
 
“ Our customers should regard us as a partner with a sensitive ear and an 
innovative capacity.” (Skånemejerier, annual report, 1997, 2, the Proviva 
case) 
 
“ Anders and I worked very closely together during this phase. We d id all 
kinds of crazy things at the time; we tested everything – and it was great 
fun!” (Personal communication, Wejåker, , 2000, the IgY –egg case) 
 
"… I think my most important role is to be enthusiastic towards people I 
meet, within BioDoc as well as in my contacts outside BioDoc. I ' sell the 
idea'  and if I do it… well, changes happen more easily... It is incredibly 
exciting!" (Personal communication, Sjöstrand, 1999, the Magiform case)   
 
A closer look at organizational structure reveals that a non-hierarchical structure 
may provide the needed freedom, which is associated with creative production.  
 
“ In my previous job, I could use standard ways to solve problems. The 
problems were distinct and repetitive.  This job is different. Everything is 
new and we have to find new ways of doing things. Of course, when I can I 
use standard ways of doing things, I do, but for the most part I make use of 
my network in finding new routines". (Personal communication, Lindholm, 
1999, the Magiform case) 
 
“I think I was hired thanks to my experiences in the pharmaceutical 
industry. When I came here I recall thinking that this job is so flexible. 
Nobody told me what to do. Decisions were made quick and easy, in a 
spontaneous conversation between the three of us.” (Personal 
communication, Erhardt, 1999, the Magiform case) 
 
This reasoning about organizational structure opens up for a comment on overall 
corporate culture. Most of the interviewed persons have their background and 
experiences from a university setting, where freedom is considerable and output is 
not measured strictly in monetary terms. It is accepted that the cost and outcome of 
process and product innovation is to a large extent unknown. This uncertainty of the 
outcome of the research project is also reflected in a number of partnerships 
throughout the R&D-process. Hence, difficulties in evaluating and forecasting a 
research program appear to be an accepted part of the innovation process.  
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6.5.3 An entrepreneur as a manager of technology development 
It has been shown that the creative process, in any kind of organization, is often 
driven by an entrepreneur (Gaddefors, 1996; Howell & Higgins, 1990). It is 
through his or her insight that information is transformed to an innovation, and 
thus, a new idea is visualized and realized (Nyström, 1990, 55).  
 
In each of these cases an entrepreneur has acted as a manager of technology 
development. Vareman at Probi AB, Andersson at Skånemejeriner, Sjöstrand at 
BioDoc, Vejåker and Larsson at Immunosystems AB and Rotschild at BioGaia 
Biologics AB – they all have the role of ‘a translator between two cultures’, the 
scientific research community and the market. It is through their eyes and in their 
management that information is interpreted, technology is developed and new ideas 
are developed and exploited.  
 
Through personal contacts the entrepreneur meets a challenging problem. In finding 
solutions to this problem the entrepreneur’s experiences of solving problems 
through research, and access to technologies become key factors for innovation 
success. Since the innovation process is not an individual achievement previous 
experiences of cooperation with a group of researchers has proved to be of 
particular value. 
 
The entrepreneurs have developed several “good ideas” into businesses (i n addition 
to the innovation process described in the cases). It is not through responding to an 
awaiting opportunity (Kirtzner, 1973) that the entrepreneur contributes in a creative 
process. He rather creates a technological and market innovation. Despite 
difficulties and restrictions, the entrepreneurs create the setting in which the 
innovation process can take place. It is in challenges from problems and ‘horizontal 
thinking’ that the entrepreneur envisions future possibilities. The concept of 
‘horizontal thinking’ is used by Vejåker, in the IgY-case, when he describes how he 
thinks of an idea (personal communication, 2000). It refers to thinking in ‘wide’ 
and practical terms, making use of experiences and common sense. In contrast, 
‘vertical thinking’ is what the researchers do, according to Vejåker, when they 
structure problems and look closely in detail at a limited problem for cause and 
effect. By associating and assembling technologies, individuals and resources, a 
stage is provided for the act of innovation.  
 
 
6.5.4 Critical technologies 
The potential for technological and market uniqueness is found in the handling of 
critical technologies. This refers to recognizing areas of strategic value, where the 
technologies are regarded as critical for the future development of processes and 
products. Many of these strategic areas correspond to the technology development 
described in Table 6.4. Some businesses spell out what their strategic areas are, 
such as Skånemejerier’s recognition of the areas of bacteria, enzymes and polar 
lipids. Other businesses reveal their areas of critical technologies in patents and the  
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development of know-how. An example of this is seen in the BioGaia case, where 
packaging is developed (and patented) parallel to their probiotic products.  
 
Accessing critical technologies is a strategic matter. It ties organizational aspects of 
development to the development of technologies and markets. A virtual 
organization, such as BioDoc, relies on their network of partners in the 
development as well as in the production and sales of products. In the ProViva case 
it is especially clear that Skånemejerier has chosen a strategic partnership strategy 
to access the identified critical technologies. 
 
“ We build networks. We don' t have all the technolog y or skills within the 
organization; strong partners carry a long way.” (Personal communication, 
Andersson, 1998, the ProViva case). 
 
Critical technologies are reflected in the product itself as well as in the processes. 
During the different phases of the innovation process certain technologies appear 
more critical than others with regards to the development of a product, a process 
and a market. It appears as if the development is not a process in even and 
incremental steps, but rather of breakthrough and uneven phases.  
 
These leaps in development are seen in the cases as, for example, technological 
break-through and market establishments. The method to genetically determine the 
strain of lactic bacteria, in the ProViva case, is an example of a major technological 
breakthrough. A published article with clinical results in a well-known journal may 
be another manifestation of a technological breakthrough (The gut, in the Magiform 
case). A certain technological development is critical in a particular phase, and as 
the innovation process proceeds, other technologies come into focus for the process 
to continue.  
  
As a part of business strategies, technological strategies also reflect the maturity of 
a market. The general domain of the food industry is a mature market, which is 
signified by consolidated and closed technological and marketing strategies 
(Nyström, 1990). Most critical technologies are therefore seen as efficient 
production techniques and market strategies, designed to erode the position of 
existing brands.  
 
 
 
6.6 Marketing strategies  
 
Marketing strategies are ways to develop and find customer segments. In each of 
these cases, technological strategies lead the way to increased knowledge, 
immaterial rights (seen in, for example, patents) and products with added value. 
Developing markets for these products are discussed below. Commercialization of  
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technological strategies is also seen in terms of licensing agreements (see 6.6.5 
Licensing agreements). 
 
Depending on how the product is defined, the customer segments in focus will 
vary. If the functional food product is seen as, on one extreme, a cure for a disease 
or, on the other extreme, a traditional food, the marketing strategy will vary. These 
strategies are manifested in the selection of targeted market segments, the use of 
marketing arguments and in the choice of distribution channels for the product 
(Figure 4.2).  
 
In the model in Figure 4.2 for marketing strategies, a number of possible strategies 
for functional food products are presented. It is not assumed that products by 
themselves necessarily determine the category in which they belong. It is rather the 
marketing argument by which they are sold that determines their categorization.  
 
Unprocessed (natural) functional foods, such as garlic, broccoli, citrus fruits and 
beans, are labeled as “traditional foods”. They are sold with little or no health 
argument (Edgeson & Marber, 2000). It is assumed that customers are aware of 
their health effects. Health nutrition would be products, in many cases food 
additives, that have a preventive medical effect, for example cholesterol-lowering 
margarine. These are sold with product information about the health advantages. 
Medical nutrition products refer to tube feeding and special foods for medical 
conditions. Consumers in need of these products are, for the most part, well 
acquainted with their needs and the product properties. OTC is a vast group of 
products that are seen as drugs that can be purchased without a prescription. 
Information about these products varies from vague health arguments to strict 
information of dosage and effects (for example on headache medicines). 
Prescription drugs are sold in pharmacies with information on dosage and side 
effects. 
 
 
6.6.1 Distribution channels 
Depending on the strategy, distribution channels will vary for sales of a functional 
food. If a functional food product is sold as an OTC, for example, the distribution 
channel (in Sweden) would be a pharmacy or possibly “Naturapoteket” (a store for 
natural remedies) or health stores. The marketing strategy would include 
information to medical professionals and marketing activities on for example 
medical congresses. If, on the other hand, a product is sold as a normal food/ health 
food the expected distribution channel would be the retail market, where consumers 
would find the product in a food store, or possibly a health food store.  
 
Selling a product through a food retail channel assumes large volumes and a 
willingness to compete for exposure in the shelves. Consumers will compare prices 
with existing products that may fill their needs equally well. Hence, this strategic 
choice results in a low price margin but a larger volume. If the distribution channel  
124 
is a medical professional (a doctor or a pharmacy), on the other hand, the volumes 
are smaller and it is expected that the price margin is higher.  
 
The distribution channel will also have an effect on the revenues through a 
differentiated taxation. Food products are burdened with a 12% VAT57, whereas 
medicines are burdened with 25% VAT. This difference may amplify the effects of 
difference in sales volume depending on the choice of marketing channel.  
 
 
6.6.2 Targeted market segment 
The choice of targeted markets is closely related to the choice of distribution 
channel. Which markets are the targets for these functional food products? Who is 
the consumer? In Sweden the chosen distribution channel will to some degree 
automatically limit the market. Consumers go to the pharmacy mainly to purchase 
medicines, and possibly hygiene products.  At the pharmacy consumers might 
expect to find functional foods as capsules or tablets. These products are not 
possible to evaluate in terms of personal benefit from an added value for most 
consumers. Many consumers, if convinced of medical benefits will, however, 
probably be willing to pay a premium price for the expected added value of this 
product.  
 
In a food store, on the other hand, consumers expect to find food products;  
products that the consumer recognizes as ‘food’ with many competing products and 
relatively low prices compared to medical products. The functional food product in 
a food store would thus have to taste well, be priced as a food product and be 
recognized as a food product.  
 
Looking at the rapid changes in the food retail market, it is clear that not only the 
food industry, but also the retail market is changing towards fewer and larger actors 
(Traill, 1997; Lagnevik & Kola, 1997). The stores become larger supermarkets and 
they are fewer in number. In these stores, it is also possible to find aisles with an 
extended health food assortment compared to average food stores in Sweden. In the 
US, large food stores commonly have a pharmacy within the store in addition to a 
wide assortment of natural remedies and health foods. It is possible that in the 
future this kind of integrated supermarkets where one can find a pharmacy and 
other services within the store will be more common in Sweden. If this is the case, 
it will enhance the possibility to market functional food product as illustrated in 
Figure 6.6. 
 
 
                                                       
57 VAT Value Added Tax, for food 12% and for medicines 25 %, in Sweden (2001)  
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Figure 6.6 Marketing functional food products for targeted markets (from the 
ProViva case, CAG Functional Foods). 
 
 
The model in Figure 6.6 shows graphically, in the center, how the size of different 
targeted markets may vary. It also shows that the channel of distribution affects the 
consumer’s expectations for the product.  The curve at the left in the model shows 
an increasing awareness among consumers of the new product throughout the 
process of innovation. CAG Functional Foods  (in the ProViva case) builds 
consumer awareness by targeting the “sufferers” first. They are the primary market 
segment, in need of a product and willing to pay a premium price for it. As the 
awareness increases, new products containing the functional food ingredient (lactic 
bacteria in this case) are introduced. The dietary supplement, a capsule, thus 
becomes an ingredient in a food product. 
 
The IgY-case appears to show the same type of marketing strategy as CAG 
Functional foods. A medical application for ‘the sufferers’ has been introduced. 
Products for broader markets are not yet developed.  
 
In the other case studies, the products (ProViva, Magiform and BRA-milk) have all 
been introduced as a food product sold in food stores. Positive results in clinical 
studies have stimulated the development of a more concentrated version of the 
product, for example in the ProViva and Magiform case. How these products are 
going to be marketed remains to be seen. Furthermore, in all of these cases 
continued efforts are aimed at developing a medical product (a capsule or a pill).  
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6.6.3 Marketing arguments  
An analysis of the products in each case shows that the functional food products are 
sold as normal food products with limited scientific information on the products  
packaging (Figure 6.7).  
 
In the IgY-case a functional food product is not yet developed, so it was labeled as 
a drug (a prophylactic treatment for patients with a disease). In the future, an egg, 
as natural as those most of us consume today, with an immune supporting effect 
could be sold as a normal food, with a positive health image. This is further 
discussed below.  
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Figure 6.7 Marketing strategies for the functional food products in each of the 
cases.   
 
Clearly, all of the products in these cases could be sold with ‘heavy’ health 
arguments, providing solid scientific results of positive medical effects. In the past 
the food industry has argued for the need to inform the consumer of the scientific 
results in marketing arguments and yet none of the products remotely touches on 
the science behind the development, in the consumer information58. At a first 
glance this seems like a waste of resources (costly R&D) if the consumers are not 
informed. What could possibly explain these strategic choices? An analysis of each 
case provides interesting possible explanations for the findings.  
 
In the ProViva case the product is sold by Skånemejerier, a large food producing 
company with many other health-related products (milk-based products providing 
calcium and healthy bacteria in fermented products). The choice of selling ProViva 
as a “normal food” with a soft argument “ Your stomach will thank you” does not 
interfere with the company image or sales of other products. 
                                                       
58 An internet address, with more information about the product, the scientific results and 
possibility to make inquiries, is provided on the packages of these products.   
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A soft marketing argument “Enjoy it and feel good” (Skånemejerier, 2001) is also 
the main message in the advertisement for ProViva in ICA-handlarna’s paper. The 
heading for this advertisement is “Swedish research offers the Swedish people 5 
crowns discount”. It continues as: “ It took eight years. Plus nine doctoral 
dissertations and thirty clinical studies. By then we, at Skånemejerier, and the 
researchers in Lund, had managed to develop a natural fruit drink with the healthy 
bacteria that provides protection, Lactobacillus Plantarum 299V (pardon, but that 
is the name for researchers)...” In this advertisement the extensive research in 
developing the product is given attention. The main message is still, however, the 
health effects that the product brings to the consumer. The sales arguments for 
ProViva Active also conveys a positive health message: ”Drink it afterwards. The 
Swedish elite does”.  (“Drick den efteråt. Det gör den svenska eliten”).  
 
BRA-mjölk is sold by ICA-handlarna as a private label and the reason for selling 
BRA-mjölk as a normal food product is, of course, the fact that ICA-handlarna is a 
large food retail chain. No advertisements have been found to promote this product, 
but that is the case for many other private brand products that are sold by ICA-
handlarna.  
 
The Magiform products (müsli, biscuits, pasta, bread and crackers) all have food- 
like appearances with regard to how they look and taste. The packages have a 
picture of a tanned and healthy looking stomach with the text “Developed for you 
who want to feel better in your stomach and in your gut”.  
 
The IgY-egg case does not have a functional food product on the market yet. For 
comparison, however, an egg product, which is sold in the UK under the name 
“Columbus’ eggs”, is popular amo ng consumers. These eggs have a high content in 
omega three, which is associated with preventive effects in the area of coronary 
heart disease. The sales argument for these eggs is not focused on preventing a 
medical condition. It talks of hens that are fed a natural, wild and nutritionally 
balanced feed, and thus making a health association.  
 
We can summarize that these products all have sales arguments that are ‘positive 
health messages’. They do not talk of threats, limiting risks and complicated 
scientific studies. Instead they focus on making the consumer feel good about 
purchasing and eating these products. An example of a product that has chosen to 
use a “negative health message” is Benecol. The information about lowering the 
cholesterol is, of course relevant and scientifically solid and many consumers are 
aware of the risks associated with a high level of cholesterol in the blood, but the 
message has a negative connotation. It makes consumers feel at unease about 
themselves and about eating food. 
 
The motive for choosing positive health messages in these cases is probably 
explained by a number of reasons.  One of the most important reasons is the  
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positive health image for the product as such and the business at large. Lack of a 
legal framework for marketing health effects is another important institutional 
factor but even in Japan, where it is legally recognized to make a scientific claim in 
sales of “Fochu” (Japanese for functional foods), about 90% of the products are 
sold with soft health arguments rather than scientific facts (Wikström, 2001). The 
marketing strategies are focused on developing a positive relation to the customers. 
The institutional conditions are further discussed in “Marketing functional foods in 
Sweden” (6.7.1). 
 
6.6.4 Branding 
A brand name is a carrier of beliefs, an image of a product and, in many cases of 
the entire company. It provides grounds for firm image marketing and product 
differentiation where the consumer shows his or her identity by purchasing certain 
products.  
 
The brand names in these cases are: ProViva (for life), Magiform (stomach in 
shape) and BRA-mjölk (good milk). These names, logos and illustrations on 
packages, all give health associations. Assuming that is desired by the food 
company, what are the underlying reasons? The main reason is that reputable brand 
names provide confidence that allows customers to differentiate these products 
from other products, and they are thereby willing to pay a premium price for the 
value added product. It is assumed that the brand names create grounds other than 
the function of the product (taste, nutritious etc) for making a choice of a product. 
 
The strength of a brand name can be determined in a customer survey in terms of 
recognition and purchasing patterns. Another dimension of the strength of a brand 
name is the elasticity of the name (how much the name can be stretched). The brand 
name Nike, for example, is a considerable asset with high elasticity as it is 
associated with a large number of good quality (highly priced) products. Examples 
of how the brand names are stretched in the cases are seen in the development of 
ProViva Active and a product line, Magiform. 
 
A brand positioning strategy is based on the values that each product are meant to 
support as a part of a company image. These images are illustrated in the cases in 
Table 6.2, as self-images. The positioning strategy is also a means to strengthen the 
competitive position by attracting interesting partners in development and 
licensees.  
 
 
6.6.5 Licensing agreements 
Licensing agreement is another way of gaining pay-back on R&D investments. In 
the cases, Probi AB (ProViva) and BioGaia Biologics AB (L. reuteri) have pursued 
this avenue. Both these companies are on the stock market. They are internationally 
renown and dependent on a positive company image.  
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In looking at the innovation process it is clear that both companies have patents and 
brand names to protect their intellectual properties. BioGaia Biologics have offered 
licensees a complete product, including a brand name and a package, which, in this 
case, is also associated with major R&D efforts (LifeTopÔ, a bottle for drinks).  
 
A licensing agreement requires trust. A condition for sharing technologies or know 
how, such as a secret recipe, is some kind of assurance of control and trust. This 
condition for trust is expressed in rigorous contracts and legally binding 
agreements. Another way of gaining control is to maintain the dominion of a 
critical part of the production process, for example in production of a ‘starter 
culture’. In both of these cases (ProViva and L. reuteri) the starter cultures are 
produced in their own biotechnology plants. The production facilities (Multiferm 
AB in Lund and Biosentrum AS in Stavanger) have the capacity to meet the needs 
of the licensees. Keeping the production know-how within the company is a way of 
ensuring long-lasting customer relationships and dependencies. 
 
  
 
6.7 Marketing functional foods in a societal context 
 
Functional food products are developed in a context of politics, legal systems, 
norms and values, finances and other societal factors. In earlier studies of 
functional foods the lack of a legal definition and system for functional foods has 
been pointed out as major problems for the food industry (Mark-Herbert & 
Nyström, 1993). Yet, the institutional conditions have allowed for development of 
functional foods in these case studies.  
 
 
6.7.1 Marketing functional foods in Sweden 
In the presented cases, the lack of a legal system has not hindered the development 
of functional foods. The National Code of Practice, though not a law but rather an 
agreement, has provided guidance as to how products with health effects may be 
marketed. Investments in R&D, resulting in products with medical effects, have 
been launched thanks to a close cooperation between state authorities and 
companies. Since Sweden has become a member of the EU, in 1995, however, it 
has become increasingly clear that harmonized legal systems for food and 
medicines would facilitate production and trade with these products.  
 
In Sweden the majority of functional foods are launched as food products. They are 
sold with a health image at a premium price. The image is to a large extent created 
by consumers and professionals in the medical field, spread by the internet and by 
the word of mouth. The interest for health has increased in the 1990s among people 
at large. Nowadays we commonly find a health issue page, column or even an 
entire section of a paper devoted to health issues on a regular basis.  
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If we look at societal interest expressed in terms of financial support it is apparent 
that governmental funds for research in this area are rather moderate compared to 
the financial support for similar activities found in for example Finland and Japan. 
In Japan, it is societal interest in limiting costs for medical care that motivates the 
financial support. In Finland, however, like in Sweden, these investments are 
motivated by forecasted industrial competitive advantages.  
 
 
6.7.2 Marketing functional foods in the US 
The food industry at large shows interest in pff in the US. Several large companies 
have started R&D programs of their own, or alliances with other businesses such as 
seen in the case in this study. Functional foods face many problems, which may be 
explained by their relative newness to the market to the FDA (Food and Drug 
Administration) as well as to customers. 
 
For the sake of beliefs, as well as for legal reasons, ConAgra' s goal (from the 
ProViva case) is to build strong science to back up the product.  It serves as a base 
for their business strategy. This means scientific, well documented double blind 
tests on people using the product or ingredient, and preferably studies conducted in 
the US. Their reasoning is that if the FDA is not convinced, the consumer might not 
be satisfied either.  
 
If a claim and the product become an object of investigation for the FDA, 
experience shows this may be a time- and resource- consuming process. It took 
eleven and nine years respectively for Johnson & Johnson to get approval for their 
Sucralose sweetener, and for Procter & Gamble to get approval for Olestra (a 
calorie free fat replacement).  Consequently, marketing the product as a dietary 
supplement, as opposed to a food-additive, is a faster way to reach awareness, i.e., 
to reach the consumer market.  
 
 
6.8 Strategies to meet the future 
 
The food businesses have traditionally been regarded as rather low tech, producing 
bulk products for a traditional market. It is commonly labeled as a raw material-
driven strategy. With contextual changes, new strategies for meeting the future are 
emerging. Interest in gaining financial return on the products as well as a strong 
market position may account for developing new and more specialized products as 
well as finding new markets. These new strategies are driven by market values.  
 
 
6.8.1 New strategies 
These new strategies require new organizational forms, new management styles and 
new definitions of business raison d´être. We have discussed the strategies revealed 
in these cases as different ways to allow for the development of radically new  
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products. But what about all other companies that have not been subjects of this 
study? What are their options if they want to engage in development of functional 
foods? Three strategies are theoretical options, for the existing food businesses.  
 
One option is developing a variety of healthy substances, protected by immaterial 
property rights, and formulating products that meet existing consumers needs. A 
second option is to extend product lines by combining the portfolio of existing and 
new product forms with innovative new substances. The third option is to follow a 
strong trend, to identify emerging growth opportunities that can be accelerated into 
the mainstream market through competencies in marketing and distribution. As 
pointed out by Teece (1986) a fast second mover or even a slow third might 
outperform the innovator. They may have access to the complimentary assets that 
are needed to commercialize an innovation. “Innovating firms without the requisite 
manufacturing and related capacities may die even if they are best at innovation” 
(Ibid, 285). 
 
Some of the success factors required for each strategic option would be the ability 
to develop and identify healthy substances, accessing consumer behavior 
information, capacity to build brands, partnering skills and a strong distribution 
base. Time to market will vary with the strategic pathway chosen, as will the risk. 
There is no guarantee for success in either of these strategies. A suitable strategy, 
however, is based on a thorough analysis of the company competencies, willingness 
to take risks and the fit with the overall business strategies. 
 
In theoretical terms, as shown in Figure 2.4 (and 6.1), strategies for development of 
functional foods can be illustrated as changes from the lower left corner outwards 
in the quadrant. What is illustrated as a strategy for development with high 
technological uniqueness (strategy C) may be of little commercial value in a short 
time perspective but it may provide grounds for strengthened future market 
competitiveness. Developing a high uniqueness on the market, on the other hand, 
(strategy A) is most commonly used as it involves less investment in R&D. The 
strategies in the cases would serve as examples of a strategy for development of 
high technological and market uniqueness (strategy B). This upgrading process, 
development of new technologies, is commonly carried out in different forms of 
collaboration agreements.  
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6.8.2 Access to technologies 
One of the reasons for collaboration is to reduce costs and risk. One way of 
managing risk is to protect the technology tied into this product or process through 
proprietary rights, for example patents. These patents may cover several 
applications of a technology and use of, for example, a strain of bacteria. A 
common understanding among the interviewees, in the cases, is that patents, as well 
as strong brands, are vital. This perception also dominates in the field of 
pharmaceuticals where the production of certain medicines is discontinued when 
the time for the patent is running out, even though the product is not replaced with a 
superior one (Gustavsson, 2001).  
 
Baring these perceptions of the importance of proprietary rights in mind, one might 
ask if the food and pharmaceutical industry has something to learn from the 
computer operative system industry? It was in the development of Linux, a 
computer software, that the concept of open source development received increased 
attention (Wayner, 2000; Meliam 2001). Open source development refers to a 
situation where technologies (knowledge) are shared within a community while still 
maintaining commercial potential. The contrary would be a more closed strategy 
for development of technology, which is used by, for example, Microsoft Windows. 
The key to development in the open source strategy, in development of Linux, was 
creating something together and taking pride in the peer recognition that resulted 
from each addition to the program. The open source tradition also reflects the kind 
of environment that presumably is characteristic for an academic environment.  
 
Assuming that scientists get their schooling in an academic community, where 
technologies are developed in collaborative arrangements with openness towards a 
larger community, why do proprietary rights become so essential in food and 
medical applications? A possible explanation is that in an open source development 
the innovation process is difficult to manage. Some scientists will argue that the 
innovation process in itself, independent of strategies and organizational 
arrangements, is “a nonlinear dynamic system” better described with chaos theory 
than any planning models (Van den Ven, 1999, 5). If that is the case, an open 
source development could be an option given the appropriate context and resources. 
If the innovation process, on the other hand, is linear and possible to plan, an open 
source development would certainly make the coordination of contributions and the 
direction for development arduous tasks.  
  
The other possible explanation to rejecting an open source development is the 
question of financing these developments. In the case of Linux many private 
persons devoted their spare time at home to contribute to the program. For the 
development of functional foods, however, it would require resources that are not 
accessible to most individuals. 
 
The last, and perhaps most important, reason for rejecting an open source 
development for functional foods is lack of motivation among people at large. In  
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the case of Linux many individuals were frustrated with the monopoly situation that 
Microsoft had acquired. There were simply too few alternatives for people who did 
not want the highly-priced Microsoft products. In the development of functional 
foods, although radically new, other food products do exist. Consumers rely on 
food and medical authorities to act in their interest. So far these interests have been 
communicated in collaborative arrangements between industries and authorities.  
 
In Japan, state funds were directed towards the development of technologies that 
ultimately would provide lowered costs for health and medical care in society and a 
commercial potential for the food industry. In an on-going open source 
development of technologies as collaboration arrangements between industry and 
state universities, these objectives are met.  
 
Albeit, the open source development is probably not a likely developmental path in 
the area of functional foods in Sweden - at least not the way we have defined it 
here. If, however, the term open is somehow limited to a smaller and well-defined 
community, such as the collaborative arrangements illustrated in the cases, the open 
source development might be a fruitful conceptual model assuming there are well-
allocated resources and trust among collaborative partners.  
 
 
6.8.3 Industrial marriage 
The future market for functional foods also depends on the willingness of food 
companies to invest in R&D. When major food companies decide to close down 
their R&D departments it raises the question of future development and the need 
for skilled labor (Leife, 2001, 6). Swedish Meats decided to close down the R&D 
department in 2001. As one of the largest food businesses in Sweden, in an industry 
that strives to attract people with higher education, it raises a question of a choice 
of strategy that has led to this decision. 
 
Swedish food manufacturers spend less than two percent of their annual turnover on 
R&D (Mark-Herbert & Nyström, 2000 B, 22)59. Compared to the pharmaceutical 
industry (with nineteen percent of their annual turnover on R&D), which very well 
could play a major role in development of functional food markets, this seems very 
low indeed (Ibid). Where the pharmaceutical industry has an advantage, in a strong 
R&D tradition, the food industry seems to have a need. The food industry, on the 
other hand, is more focused on consumer marketing; it has shorter development 
                                                       
59 The figure, 2% of annual turnover, for R&D in the food industry (Mark-Herbert & 
Nyström, 200B) seems low, yet it reflects a wide definition of R&D, including 
environmental development and new product development. In the most recent edition of 
“ Fakta 2001. Pharmaceutical market and healthcare ” the comparative figures are even 
more differentiated; where the pharmaceutical industry spends 26,8% of their annual 
turnover and the corresponding figure for the food industry is 0.4% 
(Läkemedelsindustriföreningen, 2001, 23).  
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cycles and it is less stringent on safety and efficacy evaluations. These areas are all 
shortcomings of the pharmaceutical industry in the area of functional foods.  
 
It seems reasonable that partnerships would benefit food and pharmaceutical 
companies. These collaboration agreements, such as joint ventures, are seen in for 
example the strategic agreements between General Mills / Protein Technologies 
Inc. and Novartis Nutrition / Quaker Oats (reported in New Nutrition Business, 
2000). Collaboration may provide advantages such as access to critical 
technologies, as in the case of General Mills / Protein Technologies Inc., or new 
markets, as in the case of Novartis Nutrition / Quaker Oats. 
 
In a recent presentation by one of the CEO for a leading pharmaceutical firm in 
Sweden he clearly stated that the strategic aims for future developments were 
leading the way for products that impede, delay or all together prevent the onset of 
a disease. The business idea is thus extended from products for treatment and 
alleviation to include proactive and preventive products. These products are 
especially interesting in the area of weight reduction, allergies, cancer and coronary 
heart diseases (Personal communication, Hassan, 2001). 
 
The closing of an R&D department in a major food company, mentioned above, 
could signify that new strategies for collaborative R&D activities will be the new 
way of managing the innovation process. Skilled, experienced and well-informed 
managers will simply have to build on networks of experts and coordinate the 
development process, as a part of the new economy. This will be an interesting 
field for studies in the future. 
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7 Conclusions and reflections 
 
 
 
 
In addressing the research question How do Swedish food companies develop 
radically new food products?, several factors appear to have explanatory value. 
Some of these factors are described in the cases, in a contextual analysis and in  
discussions in the preceding chapters. These factors are also summarized below in 
terms of conclusions, a re-visitation with the research question, and a future 
outlook. 
  
 
 
 7.1 Conclusions 
 
7.1.1 A new product category 
On a relatively stable market, such as the traditional food market, changes are 
gradual and slow. The consumers are conservative and thus contribute to preserving 
of prevailing conditions. In that environment, a strategic plan works well. It 
provides conditions to achieve efficiency and a direction for future 
accomplishments. New products and processes are developed with minor 
alterations from those currently in use.   
 
Radically new functional foods differ greatly from the vast majority of established 
food products is the. They are radically new products in a new product group. That 
is why developing these products is such a challenge. The development of 
functional foods involves managing the innovation process and marketing products 
with added value. A planned strategy thus has to be replaced by a strategy that 
allows for flexibility. These strategies evolve over time and they change throughout 
the innovation process.  
 
The functional food market is a rapidly expanding market. It has characteristics of a 
changing market where flexible strategies are reflected in strategic collaborative  
development that is ahead of the development of a legal frameworks, on the market 
as well as in individual companies.  
 
Businesses that want to succeed in this market will have to find new ways of 
conducting management, in particular in identifying critical technologies. This 
refers to building internal skills, employing innovative external sourcing, 
developing new markets, establishing alliances, developing packaging, building 
strong brands and finding venture capital for new developments. The strategic 
options also include strategies of communication.  
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A summarizing figure is presented to capture some of these strategic choices 
(Figure 7.1). One of the underlying assumptions is that the food industry is facing a 
challenge of changing attitude towards food production. In this perspective a faster 
moving market requires a strategy that combines market pull and technology push 
as driving forces for the innovation process.  
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1 Three corner stones for creating added value in developing functional 
foods; technological development, clinically tested medical effects and 
building a market position.   
 
 
These strategic choices are summarized below in terms of technological 
development (technological and marketing strategies), clinically tested medical 
effects (organizational collaboration in the innovation process) and building a 
market position (the use of market channels and brand names).  
 
 
7.1.2 Technological development 
In the past decades the Swedish food market has become more exposed to 
competition.  With increased competitive pressures, low prices and large volumes 
may not suffice as strategic advantages in a long-term perspective. One way of 
gaining competitive advantages requires finding new ways of creating added value. 
Added value, as it is seen in these cases, is based on technological development.  It 
is a technological upgrading process that refers to making use of technologies 
(knowledge, illustrated in Figure 6.1). In these cases the technological upgrading 
leads to the production of value added products, profits from licensing agreements 
and a boost for the company image.  
 
These new technologies are protected by proprietary rights, that serve as an 
assurance of ownership. They also provide grounds for a reinforced image for the 
company. For a company on the stock market the image is reflected in the expected 
future value of the shares. A company that is not noted on the stock market may 
still receive benefits from a strong image as it may attract other successful business 
partners to collaborate in sales or future development projects. 
 
Technological 
development 
Clinically tested 
medical effects 
Building a market  
position and a brand  
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7.1.3 Clinically tested medical effects  
In this study the innovation process is seen as technological and market 
development. The development of new products and processes are dependant on 
one another. A successful innovation process, where a radically new product is 
developed, requires that these processes are well coordinated.  
  
The technological development, as it is carried out in these case studies, is not an 
in-house achievement where one company has all the needed technologies and 
skills. It is rather a collaborative accomplishment between research groups and food 
companies. During the collaborative process, partners were changed several times 
and the organizational forms changed to meet the new conditions throughout the 
process. A virtual organizational arrangement provided a high degree of freedom 
in, for example, the selection of collaboration partners. Alliances and joint ventures 
signified a need to collectively manage the innovation process. Acquisitions, on the 
other hand, required a large capital investments and it provided a situation of 
integrated management.  
 
In the technology development, the knowledge in itself and the proprietary rights 
play central roles. These proprietary rights, for example patents and brand names, 
provide an assurance of greater payback on the invested resources in the 
development process. The knowledge in itself is expressed in scientific studies to 
back up medical claims (Eliasson & Bergqvist, 2001) and an awareness of different 
areas for application. The companies in this study did not settle for using a newly 
developed technology in one area, for example food (functional food). All of the 
cases reveal plans for using new technologies in different areas of application, for 
example in developing feed, medical products and even products for research 
purposes (Figure 5.6).  
 
The added value, and thus the revenues, in different areas of application will vary 
depending on prices, volumes, taxes and the cost of developing and marketing 
products. However, very few food businesses in Sweden express a business strategy 
that includes making use of technological skills through licensing (Mark-Herbert & 
Nyström, 2000 B, 29-30). These businesses are simply food producers with little 
ambition to explore new avenues.  What Wejåker refers to as “thinking 
horizontally” (personal communication, 2000) could lead to new areas of 
technological application, even for established technologies where patents and tacit 
knowledge provide assurance of ownership within collaborative arrangements.  
This avenue is not possible to take unless the raison d’être is re-defined for most 
food businesses.  
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7.1.4 Building a market position and brand  
It seems reasonable to assume that many more functional food products will appear 
on the market in the near future. Consumers with high expectations of health, 
comfort and appetizing products will pay a premium price for these products.  
 
Depending on how these products are marketed the revenues may vary, as will the 
marketing channel and marketing arguments (Figure 4.2). If a product is sold as a 
medical product (prescribed drug, OTC or a medical nutrition product) the sales 
volumes will be smaller and the price higher. The sales will depend on medical 
professionals. If a product is sold as a food product with a health image, the sales 
volume will be larger and the price lower. These products can be found in food and 
health stores.  
 
These strategic decisions also affect product design and the marketing arguments 
used. Looking at food products in general, it is evident that sales arguments have 
changed drastically the past three decades, even if some of the food products are 
basically the same. Prior to the 1970s sales arguments were often built on a strong 
brand name alone (and the face of a happy house wife in her home). In the 1970s 
and 1980s the health related arguments were based on "absence of negatives", for 
example fat, sugar, salt, in information such as: “ This product is 96% fat free”.  In 
the 1990s these arguments have changed to positive information, "presence of good 
stuff", for instance, fibers, minerals and ‘good-for-you-bacteria’. Increased 
awareness and interest in health among consumers at large has certainly facilitated 
the marketing of functional foods. 
 
The marketing strategy in each of these case studies reveal two very different 
strategies – either targeting the “sufferers” with a specific medical product or the 
mass market with a food product (Figure 6.6). Marketing a product of a medical 
kind (capsule, pill or concentrated version of a product) means that the “sufferers” 
are targeted as the primary segment. Medical effects in scientific clinical studies 
provide grounds for research reports and “hard facts” in marketing these products. 
Positive experiences from this group provide a spillover effect in the “at risk” and 
“prevention” segment, consumers with a high awareness and priority of health. The 
broad mass-market is eventually targeted with a food product where the active 
substance is an ingredient.  
 
Another possibility is marketing a food product without medical claims. Instead, 
soft marketing arguments like, “ X will make your stomach happy”, provide a 
positive association between health and the product. In the cases where the product 
has started as a mass-market product continued development may lead the way 
towards medical products.   
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7.2 Revisiting the research question 
  
Looking back at the research process, several choices were made along the way. 
Some were mine and deliberate, other choices were intuitive or my advisors’. 
Having tried different theoretical perspectives my choice was a creative 
management perspective. Other perspectives did not provide grounds for 
understanding the entire process, the development from idea to a product on the 
market, including both technological and market development.  
 
I choose to focus on the process of innovation as it is seen in managing changes. In 
studying the process, conditions that are necessary to cause an outcome were 
discussed. It is the combination of these conditions that reveal the story and how 
the outcome occurs. The case studies, however, were selected on the basis of the 
outcome. A creative management perspective refers to the development of 
technologies, markets and new businesses. My perspective also includes a choice of 
model and method for conducting the study.    
 
 
7.2.1 A theoretical perspective ex post 
In my theoretical understanding of the innovation process one step leads the way 
for the next in the development of a radically new product and process. It is a 
learning process in a new territory, followed by processes of refinement and 
efficiency. This perception has affected my theoretical focus and my crafting of the 
narratives (Barry & Elmes, 1997, 434).  
 
During the interviews a story is told of how something new was developed. For 
reasons of logic and rhetoric a story is often told as a chain of chronological events. 
Detours are forgotten, mistakes are suppressed and uncomfortable situations are 
neglected. In addition, constructive vagueness allow for a number of 
interpretations. That is why we often get a rational story ‘on the expressway’ 
instead of a winding trip on a countryside back road. The story may therefore seem 
more linear than it was, but careful interview technique will uncover some of the 
detours and winding trips taken.  
 
Crafting case narratives with a sense of novelty is a careful balancing act between 
making the too familiar mundane and the unfamiliar lacking in credibility (Barry & 
Elmes, 1997). A new area of studies, such as that of functional foods, thus creates a 
sense of novelty that has to be balanced with familiar wordings and structure to 
achieve credibility.  
 
In these cases it was sometimes hard to clearly separate the different phases of the 
innovation process. The collaboration was carried out in such a way that it was hard 
to draw lines between phases and the allocation of labor in the innovation process. 
It became increasingly clear to me, however, that product, process and business  
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development are highly interdependent processes, all of which are needed for living 
up to tomorrow’s expectations.    
 
 
7.3 Future developments and research 
 
In these cases, the innovation process is discussed as it is carried out by research 
businesses in collaboration with food businesses. The outcome of the successful 
collaboration is radically new products with high technological uniqueness and a 
high degree of uniqueness on the market. The market for functional food is 
forecasted to continue expanding. It remains to be seen for how long the functional 
food market will continue to be dominated by food businesses. Research shows that 
pharmaceutical and biotechnology firms do considerable research in for example 
probiotics (Childs, 1997). Another area of interest for the pharmaceutical industry 
is phyto-chemicals as future ingredients in functional foods (internet, Leatherhead, 
2001, foodlineweb…). Pharmaceutical companies also demonstrate strategic aims 
that go beyond treating symptoms and curing diseases.  Pharmaceutical and 
biotechnological companies have the capacity and perhaps an interest in making an 
entrance on the functional food market. 
 
There are over 20 000 launches of new food products in Europe alone each year 
(Internet, Leatherhead, 2001, foodline…60). Faced with an increasing 
competitiveness, food manufacturers are under pressure to find products with added 
value. Added health benefits is one option and convenience is another. Ideally, 
many consumers want both of these added values. These products are developed for 
‘cash-rich and time- poor’ consumers. Their snacking habits are linked to an active 
life style with little time to cook and many meals ‘on the go’. An awareness of 
major changes in life style and eating habits is a condition for the successful 
development of new food products. 
 
These conclusions raise a question of the interest of society at large in these foods. 
Assuming these products delay the onset of a disease, offer a cure or a better 
treatment of a disease61, does this make the development of these products a 
societal interest? A person eats on average 50 tons of food in a lifetime (Sandberg, 
2001). The composition of this food and life style in general will to a large extent 
                                                       
60 According to Leatherhead (internet, 2001, foodline…) the number of new food product 
launches in 2000 in Japan and Europe is about 20 000 respectively. The corresponding 
number in the US (for 2000) is about 12 000 products per year.   
61 The diseases that functional food products may prevent, or be a part of the treatment of, 
are for example AIDS (Coghlan, 2000), Diabetes Type 2 (Hellénius, 2001, Tuomilehto et 
al., 2001),Crohns disease (Almer, 2001), Cystic Fibrosis (Carlander et al, 1999), cancer and 
cancer treatment (Rafter, 2001; Tingåker-Johansson, 2001 A, 8), coronary heart disease 
(Saldeen, 2001; Anonymous in Kemivärlden, 2001) and allergies (Alm, 2001; Tingåker-
Johansson, 2001 B, 3-5).  
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determine the risk for so called welfare diseases (for example, cancer, coronary 
heart disease, diabetes and osteoporosis). Many of these diseases can be proactively 
treated by choice of food products and lifestyle.  
 
 
Since the costs of medicines and medical care in western societies are very high, 
and rapidly increasing (Axelsson, 2000; Grewin, 2001; Carrey & Barret, 2001), we 
may expect these products to benefit both the food industry and society at large62. 
After all, rather than subsidizing the treatment of a disease it seems more logical to 
support prevention in a proactive strategy for health. If society does not subsidize 
the products, should the development be funded through research grants as is the 
case in Japan and Finland?  
 
The area of novel foods, foods containing genetically modified raw material, is also 
an area of growing concern. The techniques to enrich products with certain 
components and give products desired characteristics are available. Is this 
development desired and needed by consumers? Consumers’ attitudes will have an 
impact on the development of legislation and the acceptance of new products 
(Bech-Larsen et al, 2001; Bredahl et al, 1998). The ethical aspects of food 
production and health will increase in importance as the boundaries between food 
and medicines, traditional processing and genetic techniques, and information and 
marketing, are fading.  
 
 
Let the food be your medicine and the medicine be your food. 
                                                                            (Hippokrates) 
 
 
 
                                                       
62 According to The Swedish Association of the Pharmaceutical Industry (Anonymous, 
2001,8) the sales of medicines in Sweden has increased significantly. In 1980 the sales of 
pharmaceuticals per capita was 453 SEK. Twenty years later, 2000, the sales, per capita, is 
2822 SEK.  
142 
 References 
 
 
 
 
Books and articles 
 
Adler, N. 1999. Managing complex product develoment. Three approaches. 
Stockholm School of Economics, EFI, Economic Research Institute (ISBN 
91-7528-542-2). 
 
Agriculture Canada, 1991. Task force on competitiveness in the agri-food industry: 
Growing together, Report to Ministers of Agriculture, Agriculture Canada, 
Ottowa. 
 
Albernathy, W. & Clark, K. 1985. Innovation: Mapping the winds of creative 
destruction. Research Policy, 14, 3-22.  
 
Albernathy W. &  Utterback, J. 1978. Patterns of Industrial Innovation.  
Technology Review,  80, 7:40-47. 
 
Albernathy, W. &  Utterback, J. 1988. Patterns of industrial innovation. in  
Readings in the management of innovation , 25-36, Tushman, M. & Moore, 
W (eds), Ballinger Publishing Company, Cambridge, Massachusetts.  
 
Ali, A. 1994. Pioneering versus incremental innovation: Review and research 
propositions. Journal of Product Innovation Management, 11, 46-61. 
 
Alm, J. 2001. Atopy in children: Association to life style. Doctor’s thesis from 
Karolinska Institutet, Stockholm (ISBN 91-628-4919-0). 
 
Almer, S. Genetiskt genombrott vid inflammatorisk tarmsjukdom. Läkartidningen, 
98; 33, 3795. 
 
Alsén-Eklöf, E. 2001. Klart för hälsopåståenden till sommaren. Livsmedelsteknik, 5, 
7. 
 
Alvesson, M. & Deetz, S. 2000. Doing Critical Management Research. Sage 
Publications Ltd, London. 
 
Alvesson, M. & Sköldberg, K. 1994. Tolkning och reflektion. Vetenskapsfilosofi 
och kvalitativ metod. Studentlitteratur, Lund. 
  
143 
Andersson, K. 2001. Hennes levebröd är folk som inte hinner äta rätt. Svenska 
Dagbladet, July 30, Näringsliv, 6-7. 
 
Anonymous, 2001. Finsk funktionell korv. Kemivärlden med Kemisk Tidskrift, 3:7. 
 
Anonymous, 2001, The Swedish Association of the Pharmaceutical Industry, Fakta 
2001. Pharmaceutical market and healthcare. (Box 17608, 118 92 
Stockholm), 8. 
 
Anonymous, (TT), 2001. Svensk mat på väg bort. Alger och sjögräs ersätter. UNT, 
February 14, A 10.   
 
Asp, N.-G., 1999, Egenåtgärdsprogrammet bör utvidgas snarast! Scandinavian 
journal of Nutrition/ Näringsforskning, 2: 92-93. 
 
Axelsson, L. 2000. Den svenska hälso- och sjukvårdens styrning och ledning. En 
delikat balansakt. Doctoral thesis, Göteborg: Nordiska Hälsovårdshögskolan.  
 
Balachandra, R. & Friar, J. 1997. Factors for success in R&D projects and new 
product innovation: A contextual framework. IEEE Transactions on 
Engineering Management.  44: 3, 276-287. 
 
Barnard, N. 1993. Food for Life. How the new four food groups can save your life. 
Random House, New York. 
 
Barry, D. & Elmes, M. 1997. Strategy retold : Toward a narrative view of strategic 
discourse. Academy of Management Review. 22: 2, 429-452. 
 
Bech-Larsen, T., Grunert, K. & Poulsen, J. 2001. The acceptance of functional 
foods in Denmark, Finland and the United States. A study of consumers’ 
conjoint evaluations of the qualities of functional food and perceptions of 
general health factors and cultural values. Working paper 73, Centre for 
Market Surveillance, research and strategy for the food sector, Århus, 
Denmark. 
 
Berhow, M., Hasegawa, S. & Manners, G. (eds) 2000. Citrus limnoids. 
Functional chemicals in agriculture and foods . American Chemical Society 
(758), Washington, DC. 
 
Birgerstam, P. 2000. Skapande handling – om idéernas födelse. Studentlitteratur, 
Lund.  
 
Bolman, L. & Dale, T. 1995. Nya perspektiv på organisation och ledarskap. 
Studentlitteratur, Lund. 
  
144 
Bredahl, L., Grunert, K, & Frewer, L. 1998. Consumer attitudes and decision-
making with regard to genetically engineered food products – A review of the 
literature and a presentation of models for future research. Working paper 
52, Centre for Market Surveillance, research and strategy for the food sector, 
Århus, Denmark. 
 
Briggs, G & Calloway , D. 1984. Nutrition and physical fitness. 11
th ed. CBS 
College Publishing, The Dryden Press, NY.  
 
Brown, S. & Eisenhardt, K. 1995. Product development: past research, present 
findings, and future directions. Academy of Management Review.  20:2, 343-
378. 
 
Capell, K., Tromben, C., Echikson, W. & Zellner, W. 2001. Rengade Ryan Air. 
Bussines Week, 14 maj, 38-43. 
 
Caragay, A. 1992. Cancer-preventive foods and ingredients. Food Technology. 
April 1992, 65-68. 
 
Carlander, D., Sundström, J., Berglund, Å., Larsson, A., Wretlind, B. and Kollberg, 
H., 1999. Immunoglobulin Y (IgY) – A new tool for the prophylaxis against 
Pseudomonas aeruginosa in cystic fibrosis patients. Pediatr. Pulm. Suppl 18, 
240. 
 
Carrey, J. & Barret, A. 2001. Drug prices, what is fair? How can we encourage 
research and still keep prices within reach? Busniness Week. December 10, 
46-53. 
 
Cedegård, L. &  Widell, A. 2001. Probiotika återställer tarmens bakterieflora. 
Dagens levnadssätt har utrotat även de’goda’bakterierna.  Läkartidningen, 98; 
50, 5753. 
 
Chiesa, V., Coughlan, P. & Voss, C. 1996. Development of a technical innovation 
audit. Journal of Product Innovation Management.  13, 105-136. 
 
Chiesa, V. & Manzini, R. 1998. Organisational forms for accesing external sources 
of technology (67- 83) in Technology strategy and strategic alliances. 
Selected papers from the 1998 R&D Management Conference, Foundación 
Cotec para la Innovación Tecnológica, Madrid. 
 
Childs, N. 1997. Foods that prevent disease: Consumer attitudes and public policy 
implications. Journal of Consumer Marketing. 14: 6, 433-447.  
 
Christensen, C.  1997. The innovator’s dilemma. When new technologies cause 
great frims to fail.  Harvard Business School Press, Boston, MA.  
145 
 
Christensen, J., Rama, R. & vonTunzelmann, N., 1996. Study on innovation in the 
European food products and beverages industry. Report for the European 
Commission Sprint Programme, Bruxells. 
 
Christensen, C., 1997. The innovator' s dilemma.  Harvard Business School Press, 
Boston.  
 
Clark, K., Ford, D. & Sarén, M. 1989. Company technology strategy. R&D 
Management 19:3, 215-229. 
 
Clark, J. & Guy, K. 1998. Innovation and Competitiveness: A review, Technology 
Analaysis and Strategic Management,  10:3, 363-395. 
 
Clark, P. & Staunton, N., 1989. Innovation in technology and organization. 
Routledge, London. 
 
Coghlan, A. 2000. Bugs make life better for children with AIDS. New Scientist, 
July 8, 2000, 17.  
 
Consensus Document. 1999. Scientific Concepts of Functional Foods in Europe: 
Consensus Document. Brittish Journal of Nutrition, 81, 1-27.  
 
Cooper, R. 1979. The dimensions of industrial new product success and failure. 
Journal of marketing, 43,  93-103. 
 
Cooper, R. 1990. Stage-gate systems: A new tool for managing new products. 
Business Horizons, May-June, 44-56. 
 
Cooper, R. & Kleinschmidt, E. 1987. What makes a new product a winner:  Success 
factors at the project level.  R&D Management, 17:3, 175-189. 
 
Crawford, M. 1980. Defining the charter for product innovation. Sloan 
Management Review. 21, 3-12. 
 
Crawford, M. 1983. New products management. Richard  D. Irwing Inc., 
Homewood, Il. 
 
Crawford, M. 1991. The dual drive concept of product innovation, Business 
Horizons, 34:3, 32-38. 
 
Czariniawska, B. 1999. Writing management: Organizational theory as a literary 
genre. Oxford Press, Oxford, UK.  
  
146 
Denzin, N & Lincon, Y. 1994. Handbook of Qualitative Research, Sage 
Publications Ltd., Beverly Hills, CA. 
 
Dougherty D. & Corse, S. 1997. What does it take to take advantage of product 
innovation?  Research on technological Innovation, Management and Policy,  
6, 155-190.  
 
Doyle, P. 1998. Marketing Management and Strategy (2
nd ed) Prentice Hall Europe, 
London.  
 
Edgson, V. & Marber, I. 2000. Functional food- matens helande kraft. Natur och 
Kultur/ LTs förlag, Stockholm. 
 
Eklöf, M. 2001. Allt fler patienter söker alternativ och komplementär medicin – en 
utmaning för framtidens hälso- och sjukvård. Läkartidningen, 98:46, 5206. 
 
Ekvall, G., Arvonen, J. & Nyström, H. 1987. Organisation och innovation. 
Studentlitteratur, Lund.  
 
Eliasson, M. & Bergqvist, D. 2001. Forskningsresultat bör vara allmänt 
tillgängliga. Fallbeskrivning visar hinder vid kontakt med 
läkemedelsindustrin. Läkartidningen, 98; 37, 3913. 
 
Ettlie, J. 1980. Adequacy of stage models for decisions on adoption of innovation. 
Pyshchological Report,  46, 991-995. 
 
Ettlie, J. 1983. Organizational policy and innovation among suppliers to the food 
processing sector. Academy of Management Journal,  26:1, 27-44. 
 
Ettlie, J & Reza, E. 1992. Organizational integration and process innovation, 
Academy of Management Journal,  35, 795-827. 
 
Farris, G. 1988. Technical leadership: much discussed but little understood. 
Research Technology Management 1988:March-April, 12-16. 
 
Ferguson, R. 1998. What’s in a location? Science parks and the support of new 
technology-based firms. 1998. Agraria 137, Acta Universitatis Agriculturae 
Sueciae.  
 
Ferust, O. 1991. Kost och hälsa i marknadsföringen  (Engl.summary, Nutrition in 
Marketing). A doctoral dissertation at Dep. of Business Administration, 
Stockholm University, Stockholm (91-7146-928-1). 
 
Ford, D. 1988. Develop your technology strategy. Long Range Planning. 21: 5, 85-
95.  
147 
 
The Foundation for Innovation in Medicine. 1991. The neutraceutical initiative: A 
proposal for economy and regulatory reform. The Foundation for Innovation 
in Medicine, New York.  
 
Gaddefors, J. 1996. Reflexion och handling – entreprenörskap I ett kreativt 
perspektiv. Acta Universitatis Agriculturae sueciae; Agraria 12. 
 
Goldman, J. 1985. Innovation in large firms. Research on Technological 
Innovation, Management and Policy.  2, 1-10.  
 
Gopalakrishnan, S. &  Damanpour, F. 1997. A review of innovation research in 
economics, sociology, and technology management. Omega, International 
Jounal of Management Sciences, 25:1, 15-28. 
 
Gordon, G., DiTomaso, N. & Farris, G. 1991. Managing diversity in R&D groups, 
Research Technology Management, January, 18-23. 
 
Granstrand, O. & Sjölander, S. 1990. Managing innovation in multi-technology 
corporations. Research Policy 19: 1, 35-60. 
 
Grewin, B. 2001. Hälso- och sjukvårdens resursbehov år 2001-2003. Sveriges 
läkarförbund (Box 5610, 114 86 Stockholm, www.slf.se). 
 
Griffin, A. 1996. Negotiating a successful technology implementation: A 
motivation perspective. Journal of Engineering and Technology 
Management,  13, 29-53. 
 
Griffin,  A. & Hauser, J. 1996. Integrating R&D and marketing: A review and 
analysis of the literature. Journal of Product Innovation Management. 13, 
191-215. 
 
Gustavsson, P. 2001. Dyrare och sämre för barn när Draco avregistrerar 
astmaläkemedel. Läkartidningen. 98: 30-31, 3357. 
 
Hamel, G. 1998. Opinion: Strategy innovation and the quest for value. Sloan 
Management Review, winter, 7-14. 
 
Hamel, G. & Heene, A. (eds) 1994. Competence based competition. John Wiley & 
Sons, Chichester, UK.  
 
Hamel, G & Prahalad, C. 1989. Strategic intent. Harvard Business Review, May-
June, 63-76. 
  
148 
Hamilton, W. 1997. Managing technology as a strategic asset. International 
Journal  of Technology Management,  14:2, 163-176. 
 
Hanman, B. 1993. Designing foods. Manipulating foods to promote health. Inform. 
4 : 4, 344-360.  
 
Havnedahl, A.-L., 2001. Tarmflora stärker försvar mot allergi. Dagens Nyheter, 27 
september, 43.  
 
Heasman, M. & Melletin, J., 1998. The Business of Healthy Eating. Global trends 
and strategies in functional foods and neutraceuticals. Financial Times 
Retail and Donsumer, London, UK. 
 
Hellénius, M-L., 2001. Diabetes typ 2 går att förebygga med kost och motion. 
Medikament. 8, 50-51. 
 
Henderson, R. & Clark, K. 1990. Architectural Innovation: The reconfiguration of 
esisting product technologies and the failure of established firms. 
Administrative Science Quarterly, 35, 9-30. 
 
Henry, J. (ed), 1991. Creative management. Sage Publications Ltd., London. 
 
Hilliam, M. & Young, J., 2000. Functional food markets, innovation and prospects. 
A global analysis. Leatherhead Food RA Publishing, Surrey, UK.  
 
Howell, J. & Higgins, C. 1990. Champions of change: Identifying, understanding 
and supporting champions of technological innovations. Organizational 
Dynamics, summer, 40-55. 
 
Huberman, M. & Miles, M. 1994. Data management and analysis methods (428-
444) in Dentzin, N. & Lincoln, Y. (eds). Handbook of Qualitative Research. 
Sage publications Ltd., London. 
 
Håkansson, H. &  Snehota, I. 1995. Developing Relationships in Business 
Networks. International Thomson Business Press, London. 
 
Ingvarsson, A., 2000. Hoppas på nya matsedlar. Teknik och vetenskap. 16: 5, 18-21. 
 
Jacobsson, L. Kolesterolsänkande tuggumi på väg. Dagens medicin.  April 3, 14, 
21. 
 
Janesick, V. 1994. The dance of qualitative research design. Metaphor, 
methodology ane meaning (209-219) in Dentzin, N. & Lincoln, Y. (eds). 
Handbook of Qualitative Research. Sage publications Ltd., London. 
  
149 
Jensenius, J., Andersen I., Hau, J., Crone M., & Koch, C., 1981. Eggs: conveniently 
packaged antibodies. Methods for purification of yolk IgY. J. Immunol. 
Methods  46:63-68. 
 
Johannison, B. (ed.) 1992. Entreprenörskap på svenska. Almqvist & Wiksell, 
Malmö.  
 
Johne A. &  Snelson, P. 1988. Success factors in product innovation: A selective 
review of the literature. Journal of Product Innovation Management. 5, 114-
128. 
 
Jordbruksverket, 1997. Etiska aspekter på jordbruk. Report 14. (ISSN 1102-3007). 
 
Kalliomäke, M., Salminen, S., Arvilommi, H., Kero, P. & Isolauri, E. 2001. 
Probiotics in primary prevention of atropic disease: a randomised placebo-
controlled trial. Lancet. 357: (9262) 1076-1079. 
 
King, N. 1992. Modeling the innovation process: an empirical comparison of 
approaches. Journal of Occupational Psychology, 65, 89-100. 
 
Kimberly, J. 1981. Managerial Innovation in Nystrom, P. & Statbuck, W. (Eds.), 
Handbook of Organizational Design, 1,  84-104,  Oxford University Press, 
Oxford.  
 
Kirzner, I. 1973. Competition & Entrepreneurship, The University of Chicago 
Press, Chicago. 
 
Kleinschmidt, E. & Cooper, R. 1991. The impact of product inovativeness on 
performance. Journal of Product Innovation Management, 8: 240-251. 
 
Kline, S. 1985. Innovation is not a linear process. Research Management, 28:4, 36-
45.  
 
Knox, S. &  Denison, T. 1990. R&D centered innovation: extending the supply side 
paradigm. R&D Management,  20:1,25-34. 
 
Kohler-Reissman, C. 1993. Narrative analysis. Sage publications. Newbury Park 
Ca. 
 
Kollberg, H. 2000. Nutritional support for patients with chronic illnesses- 
Information Technology (IT) and Telemedicines. Scandinavian Journal of 
Nutrition/ Näringsforskning, 44:2, 67-68. 
  
150 
Kollberg, H., Johannesson, M., Schuster, A., Carlander, D. and Larsson, A., 2000 
IgY to prevent infections with Pseudomonas aeruginosa. Results from phase 
I study and how to go on with phase II-III studies. XIIIth International Cystic 
Fibrosis congress 4-8 June 2000, poster, abstract. 
 
Kotler, P. 1976. Marketing management; analysis, planning and control. 3rd ed., 
Pretnice Hall, New Jersey. 
 
Kvale, S. 1997. Den kvalitativa forskningsintervjun. Studentlitteratur, Lund.  
 
Lagnevik, M & Kola, J. 1997. Are Porter’s diamonds forever? in Competitiveness 
in the food industry., Traill, B & Grunert, K (eds), Blackie Academic & 
Professional Ltd., London. 
 
Larsson, A. 2001. Äggantikroppar. Fjäderfä, 2001:1, 26-27. 
 
Larsson, A.,1988. Determination of circulating immune complexes.  Acta 
Universitatis Upsaliensis. 
 
Larsson, A.,  Bålöw, R.-M., Lindahl, T., & Forsberg, P.-O., 1993. Chicken 
antibodies: taking advantage of evolution – A review. Poultry Science, 72; 
1807-1812. 
 
Laser-Reuterswärd, A & Svederberg, S. 1999. Förstår konsumenterna 
förpackningstexterna om nutrition och hälsa? Vad visar litteraturen? 
Scandinavian Journal of Nutrition / Näringsforskning. 43:4, 163-169. 
 
Lee, M. & Na, D. 1994. Determinants of technical success in product development 
when innovative radical ness is considered. Journal of Innovation 
Management, 11:62-68. 
 
Leife, Å. 2001.”Me-too-industrin”. Livsmedelsteknik, 42,5,8. 
 
Leife, Å. 2001. Öderstigert – redaktörens reflexioner. Livsmedelsteknik, 5, 6. 
 
Liljedahl, S. 1994. Strategi för förändring - teknologi och marknadsutveckling av 
oljelin i Örebroområdet. A dissertation at Department of Economics, 
Swedish University of Agricultural Sciences. Dissertation 11. 
 
Lindell, M. 1988. Utveckling av nya produkter. En organisatorisk studie. 
Dissertation, Handelshögskolan in Helsingfors, Helsingfors (ISBN 915-555-
288-5).  
 
Linnala, T. 1998, Svenskt-finskt bråk om djurfoder, Dagens Industri, 98.11.13. 
  
151 
Loveridge, R. & Pitt, M. 1990. The strategic management of technological 
innovation. John Wiley & Sons, Chichester.  
 
Lundgren, A. 1991. Technological innovation and industrial evolution – The 
emergence of industrial networks. Dissertation, Stockholm School of 
Economics, Stockholm (ISBN 91- 7258-332-0). 
 
Lundqvist, M. 1996. Organizing product development – formalizing the informal in 
interdependent knowledge work. Department of Operations Management 
and Work Organization, Chalmers University of Technology, Göteborg 
(ISBN 91- 7197-325-7). 
 
Lynn, G., Monroe, J. & Paulson, A. 1996. Marketing and Discontinuous 
Innovation: The probe and learn process. Califonia Management Review, 
38:3, 8-37. 
 
Läkemedelsindustriföreningen, 2001. Fakta 2001, Pharmaceutical market and 
healthcare Läkemedelsmarknaden och hälso- och sjukvården. (Box 17608, 
118 92 Stockholm, Fax: + 46-8 462 02 92). 
 
Mark-Herbert, C. 1993. Functional foods- En litteratursammanställning om 
livsmedel med medicinsk effekt (Functional foods- A literature review of food 
with medical effects, Eng. summary). Report 67, Swedish University of 
Agricultural Sciences, Uppsala.  
 
Mark-Herbert, C. & Nyström, H. 1993. Functional food i Sverige - Svenska 
livsmedelsföretags syn på produktutveckling och marknadsföring (Functional 
food in Sweden- Attitudes to R&D and marketing in Swedish food 
companies, Engl summary). Report 61, Department of Economics, Swedish 
University of Agricultural Sciences, Uppsala. 
 
Mark-Herbert, C & Nysröm, H. 2000 A. Technological and market innovation – A 
case study of the development of a Functional Food – Pro Viva. Report 133. 
Swedish University of Agricultural Sciences, Uppsala.  
 
Mark-Herbert, C & Nysröm, H. 2000 B. Tekonologi och marknadsutveckling – en 
enkätstudie bland svenska livsmedelsföretag. Report 139. Swedish University 
of Agricultural Sciences, Uppsala.   
 
Markides, C. 1998. Strategic innovation in established companies. Sloan 
Management Review, Spring,  31-42.  
 
McCosh, A., Smart, A. Barrar, P. & Lloyd, S. 1998. Proven methods for innovation 
management: An executive wish list. Creativity and Innovation Management. 
7:4, 175-192.  
152 
 
McCloskey, D. 1986.The rhetoric of economics. Wheatsheaf Books Ltd., Brighton, 
UK.  
 
Mc Closkey, D. 2000. Economical writing. (2
nd ed.) Waveland Press Inc. Prospects 
Hights, Ill.  
 
Meliam, C. 2001 Coordination on an Open Source Development Center, Working 
paper series, Stockholm University School of Business, spring, 2001.  
 
Merriam, S. 1994. Fallstudien som forskningsmetod, Studentlitteratur, Lund. 
 
Miles, M. &  Huberman, A. 1994. Quantitative Data Analysis. Sage Publications, 
Beverly Hills, Califonia. 
 
Miller, D. 1992. The Icarus paradox: How exceptional companies bring about their 
own downfall. Business Horizons, January-February, 24-35. 
 
Mintzberg, H. 1976. Patterns in strategy formation, Management Science 24,;9, 
934-948.  
 
Mintzberg, H. 1978 Patterns in strategy formation. Management Science.1978:9. 
 
Mintzberg, H. 1993. The rise and fall of strategic planning. The free press, New 
York.   
 
Mintzberg, H & Mc Hugh, A. 1985. Strategy formation in an adhocracy. 
Administrative Science Quarterly, 30:2.  
 
Mishler, E. 1986. Research interviewing – context and narrative. Harvard 
University Press, Cambridge. 
 
Moberg, L., 2000.  Nyordsboken. Svenska språknämnden & Nordstedts förlag AB, 
Stockholm. 
 
Nadler, D. &  Tushman, M. 1988. A model for diagnosing organizational 
behaviour. in Tushman, M. & Moore, W. (eds) 1988, 2
nd ed. Readings in the 
management of innovation. (148-163), Ballinger Publishing Company, 
Cambridge, MA.  
 
New Nutrition Business, 2000. The newsletter for functional foods, nutraceuticals 
and healthy eating (ISSN 1464-3308). 
 
Nutrition Today (supplement), 1996, 31:6, pp. 1- 52. 
  
153 
Nyström, H. 1970. Retail pricing. An integrated economic and psychological 
approach. Doctoral dissertation, EFI, Stockholm School of Economics. 
 
Nyström, H. 1972. Modeller för marknadsföring. Prisma, Lund. 
 
Nyström, H. 1990. Technological and market innovation. Strategies for product 
and company development. John Whiley & Sons, Chichester.  
 
Nyström, H. 1997. The dynamic marketing- entrepreneurship interface - a creative 
management approach. Paper presented at the Academy of Marketing 
AMA/UIC/ Special Interest groups on the marketing and entrepreneurship 
interface, University College, Dublin, January, 9-10. 
 
Nyström H. & Edwardsson, B. 1980. Technological and market strategies for 
product development. A study of 20 Swedish food processing companies. 
Report 164. Department of Economics, Swedish University of Agricultural 
Sciences, Uppsala.  
 
Nyström, H. & Liljedahl, S. 1994. From low-tech to high-tech. Development 
strategies for finding new markets and technologies. Working paper seires 
1994:4, Department of Economics, Swedish University of Agricultural 
Sciences, Uppsala.  
 
O’Connell, V &  Sharpe, R. 1998. J&J is told it can’t sell Benecol as dietary aid. 
Wall Street Journal, October 30, A6. 
 
Olsson, M. 2001. Skärpta regler för functional foods. ATL, 45, 9 november, 17.  
 
Parliment, T. Ho, S.-H.& Schieberle, P. (eds) 2000. Caffiinated beverages. 
Health benefits, physiological effects and chemistry. American Chemical 
Society (754), Washington, DC. 
 
PA Consulting, 1990. Functional foods – A new global added value market? PA 
Consulting Group, Royston, Hertforshire, UK.  
 
Pavitt, K. 1986. Technology, innovation and strategic management. (171-190) In 
McGee & Thomas, H.  Strategic management – a European perspective. 
Whiley, New York. 
 
Peryon, B., 2001. Industriperspektiv på övervikt och ohälsa. Fettma- ett av de 
största hoten mot folkhälsan". Medikament. 2001:1, 42-46. 
 
Rafter, J. 2001. Probiotika som kosttillägg kan ha cancerpreventiv effekt. 
Läkartidningen, 98: 50, 5732.  
  
154 
Ragin, C. 1992. Cases of “ What is a case?  “ in Ragin, C. & Becker, H. (eds) What 
is a case? 1-17. Camebridge University Press. 
 
Rasmussen, A. 1968. Pristeori eller parameterteori. Studier omkring 
virksomhedens afsaetning. Handelshögskolen i Köpenhamn, 
Erheverrvosökonomisk förlag S/I, Köpenhamn.  
 
Robertson, A. 1974. Innovation mangement. Management Decisions Monograph, 
12: 6, 330-372. 
 
Rothwell, R. 1992, Successful industrial innovation: critical factors for the 1990:s. 
R&D Management, 22:3, 221-239. 
 
Rothwell, R. 1994, Towards a fifth-generation innovation process. International 
Marketing Review, 11:1, 7-31. 
 
Rudérus, H. 1992. Functional foods – möjligheter och hot för svensk 
livsmedelsindursti och livsmedelsforskning. Nutek, Rapport R:1992:68 
(Närings- och Teknikutvecklingsverket). 
 
Ruiz-Palacios et al. 1996. Feeding of probiotics for the prevention of community-
acquired diarrhea in young Mexican children.  Ped. Res.  39:184. 
 
Rune, G. 2001. Matnyttig forskning i fokus. Sydsvenskan, February 6, B5. 
 
Ruttan, V & Y Hayami. 1984. Toward a theory of induced institutional innovation. 
Journal of Development Studies, 20:4 203- 223. 
 
Saldeen, T. 2001. Effekt av fiskolja på plötslig hjärtdöd. Medikament, 8, 62-67. 
 
Salminen, K. 1996. Editorial: The First Functional Probiotic Food. Nutrition Today 
(supplement), 31:6, p.1. 
 
Sandberg, A-S., 2001. Functional Foods – Är maten genvägen till hälsa? Chalmers 
Tekniska Högskola, Göteborg (ISSN 1400-0385). 
 
Sandberg, F. 2001. Naturläkemedel – ut växtriket framställda mediciner. 
Läkartidningen, 98:46, 5212. 
 
Saren, M. 1984. A classification and review of process models of innovation. R&D 
Management, 14, 11-24. 
 
Saunders, M. Lewis, P. & Thornhill, A. 1997. Research methods for business 
students. Pitman Publishing, London.  
  
155 
Savage, G, Nix, T., Carlton, W & Blair, J. 1991. Strategies for assessing and 
managing organizational stakeholders. Academy of Management Executive. 
5:2, 61-75. 
 
Schewe, G. 1994. Succesful innovation management. An integrative perspective. 
Journal of Engineering and Technology Management, 11:1, 25-53. 
 
Schinker, N. 1998, Unique barley is one facet of ConAgra’s latest concepts, The 
Midlands Business Journal,  October 23-28, 1, 19. 
 
Schon, D. 1971. Beyond the stable state.  Norton Ltd., New York.  
 
Schumpeter, J. 1934. The theory of economic development. Harvard University 
Press, Cambridge, Mass.  
 
Selznick, P. 1957. Leadership in administration. A sociological interpretation. 
University of Califonia Press, Berkley, Ca.  
 
Sharpe, R. 1998. Johnson & Johnson could face delay in bringing Benecol products 
to the market. Wall Street Journal, November 2. 
 
Shepherd, R., 1989.Factors influencing food preferences and choice. In Handbook 
of the psychophysiology of human eating  (Shepherd, R. ed.).  
3-24, Chichester , Whiley. 
 
Sherwood, L. &  Gorbach, L. 1996. The Discovery of Lactobacillus GG, Nutrition 
Today (supplement), 31:6 (December), 2-4. 
 
Shibamoto, T., Terano, J & Osawa, T. (eds) 1997 A. Functional Foods for 
Disease Prevention 1. Fruits, vegetables and teas. American Chemical 
Society (701), Washington, DC. 
 
Shibamoto, T., Terano, J & Osawa, T. (eds) 1997 B. Functional Foods for 
Disease Prevention 2 . Medical plants and other foods. American Chemical 
Society (702), Washington, DC. 
 
Skat- Rørdam, P. 1999. Changing strategic direction. Practical insights into 
opportunity driven business development. Handelshøgskolens Førlag, 
Copenhagen.  
 
SOU, 1997:25. Svensk mat på EU-fat. Betänkande av utredningen av en ny 
konkurrenssituation för livsmedelsindustrin. Fritzes kundtjänst, Stockholm.  
 
Stake, R. 1994. Case studies (236-247) in Dentzin, N. & Lincoln, Y. (eds). 
Handbook of Qualitative Research. Sage publications Ltd., London.  
156 
 
Statistiska Centralbyrån, 2001. Forskning och utveckling inom företagssektorn 
1999. Statistiska meddelanden, UF 14 SM 0001. 
 
Statistiska Centralbyrån & Livsmedelsekonomiska samarbetsnämnden, 1997. 
Tables on Food 1997. När mat kommer på tal. Tabeller om livsmedel. SCB-
Tryck, Örebro. 
 
Strauss, A. & Corbin, J. 1990. Basics of qualitative research. Grounded theory 
procedures and techniques. Sage Publications Inc. Newbury Park, CA. 
 
Stebel, P. 1994. Choosing the right change path. Califonia Management Review, 
Winter, 29-51. 
 
Svederberg, E. 1997.  Tänkande bakom val och användning av livsmedel. Faktorer 
som medverkar till eller utgör hinder för förändring av matvanor i 
hälsofrämjande riktning. (Lunds Studies in Education 1) Lund University 
Press, Lund. 
 
Swahn, J.-Ö., 2000. Fil fläsk och falukorv. Svenska mattraditioner genom tiderna. 
Historiska media, Lund. 
 
Sylwan, P. 2000. Jorden och generna. Skogs- och Jordbrukets Forskningsråd, 
SJFR, särtryck ur Strategi för svensk jordbruksforskning, del 2, 
Bakgrundsanalyser och utvärderingar. 
 
Taylor, J. 1998. New twist on eat it - it' s good for you.  Omaha World-Hearald, 
(sunrise Ed.). October 23, 1-2. 
 
Teece, D. 1986. profiting from technological innovation: Implications for 
integration, collaboration, licensing and public policy. Research policy, 15, 
285-305. 
Tingåker-Johansson, E., 2001 A. Filmjölk bra vid strålbehandling. Verum 
Journalen (Tema: immunologi) 4, 8. 
 
Tingåker-Johansson, E. 2001 B. Fortsatt försöka att förebygga allergi hos barn, 
Verum Journalen (Tema: immunologi) 4, 3-5. 
 
Traill, B. 1997. Structural changes in the European food industry: Consequences for 
competitiveness. in Competitiveness in the food industry., Traill, B & 
Grunert, K (eds), Blackie Academic & Professional Ltd., London.  
 
Traill, B. & Grunert, K. 1997. Product and process innovation in the food industry. 
Chapman & Hall, London. 
  
157 
Tuomilehto, J. Lindström, J. & Eriksson. J. 2001. Prevention of type 2 diabetes 
mellitus by changes in lifestyle among subjects with impaired glucose 
tolerance. N Engl. J Med., 3: 44, 1343-1350. 
 
Tushman, M. & Anderson, P. 1986. Technological discontinuities and 
organizational environment.  Administrative Science Quarterly, 31, 439-465. 
 
Tushman, M. & Moore, W. (eds) 1988. Readings in the management of innovation. 
(2
nd ed.) Ballinger Publishing Company, Cambridge, MA.  
 
Tushman, M. & Nadler, D. 1986. Organizing for innovation. California 
Management Review, 28:3, 74-92. 
 
Twiss, B. 1992. Managing technological innovation. 4
th ed, Financial Times Pitman 
Publishing, London.  
 
Urban , G. & Haruser J. 1980. Design and marketing of new products. Prentice Hall 
inc. Englewood Cliff, NJ.  
 
Utterback, J. 1971. The process of technological innovation within the firm. 
Academy of Management Journal, 10, 75-88. 
 
Utterback, J. 1995. Innovation and the Future of Sweden. Sällskapet Riksdagsmän 
och Forskare, A seminar in Riksdagshuset, October 25, Stockholm, Sweden.  
 
Utterback, J. & Abernathy, W. 1975. A dynamic model of the process and product 
innovation, Omega,  3,  649-656. 
 
Vanderhoof, J. & Young, R. 1998. Use of Probiotics in Childhood Gastrointestinal 
Disorders, Journal of Pediatric Gastenterology and Nutrition, September.  
27: 323-332. 
 
Van de Ven, A. 1986. Central problems in the management of innovation. 
Management Science,  32:5, 590-607. 
 
Van de Ven, A. Polley, D., Garud, R. & Venkataraman, S. 1999. The innovation 
journey. Oxford University Press, Oxford UK. 
 
Van Maanen, J. 1988. Tales of the field. On writing ethnography. The University of 
Chicago Press Ltd., London.  
 
Weinstein, N.D. 1987. Unrealistic optimism about susceptibility to health 
problems: conclusions from a community-wide sample. Journal of 
Behavioral Medicine. 10, 481-500. 
  
158 
Weisenfeld-Scenk, U., Fisscher, O., Pearson, A. & Brockhoff, K. 1998. Managing 
technology as a virtual ‘enterprise’. (315-325) in Technology strategy and 
strategic alliances. Selected papers from the 1998 R&D Management 
Conference. Foundación Cotec para la Innovación Technológica, Madrid.  
 
Veryzer, R. 1998. Discontinuous innovation and the new product development 
process. Journal of Product Innovation Management. 15:4, 304-322. 
 
Von Hippel, E. 1983. Increasing Innovator' s returns from inno vation. Research on 
Technological Innovation  Management and Policy, 1, 35-53. 
 
Von Hippel, E. 1986. Lead users: A source of novel product concepts. Management 
Science. 32:7, 791-805.  
 
Von Hippel, E. 1988. The Sources of Innovation. Oxford University Press, Oxford, 
NY. 
 
Wayner, P., 2000. Free for all: How Linux and the free software movement 
undercut the high tech titans. Harper Business, New York.  
 
Weick, K. 1995 Sensemaking in organizations. Thousand Oaks, Sage.  
 
Wheelwright, S. & Clark, K. 1992. Revolutionizing product development; Quantum 
leaps in speed, efficiency and quality. New York. Free Press.  
 
Wickman, M. 2001. Nyinsjuknande I allergi bland barn kan möjligen minskas med 
hjälp av probiotika. Läkartidningen, 98: 32-32, 3436. 
 
Wigblad, R. 1997. Karta över vetenskapliga samband. Orientering i den 
samhällsvetenskapliga metoddjungeln. Studentlitteratur, Lund. 
 
Wikström, L.2001. Hälsosam mat som affärsidé. Svenska Livsmedel. 2, 21-23.  
 
Wolf, R. 1994. Organizational Innovation: Review, critique and suggested research 
directions. Journal of Management Studies, May, 405-431.  
 
Yin, R. 1984. Case study - Research design and methods. Sage Publications Ltd., 
Beverly Hills, CA. 
 
Yon, B. 1992. Innovation et capital risqué: les cas de biotechnologies. Les editions 
d’organisation, Paris.  
 
Zaltman, G. Duncan, R. &  Holbek, J. 1973. Innovations and Organizations. Wiley, 
New York. 
  
159 
Örn, P. 2001. Beredskapen höjd för snabb diagnostisering av anthrax. 
Läkartidningen. 98:43, 4676 
 
Örnevall, A. 2000. Nära genombrott för Functional foods, Restaurang & Storkök 3, 
66. 
  
160 
 Personal communication 
 
 
Case/ 
market 
Person  Position and 
organization 
Time and 
place 
Kind of 
contact 
ProViva  Kenneth 
Andersson 
Responsible for R&D, 
Skånemejerier Ek. för. 
98.05.11 
Malmö 
personal 
interview 
ProViva  Mats Lönne  Product manager, 
ProViva product group, 
Skåenmejerier Ek för. 
00.02.14 
Stockholm 
01.03.05 
conference 
 
mail 
ProViva  Claes 
Lönner 
CEO,  
 ProbiFeed AB 
98.05.11 
Lund 
personal 
interview 
ProViva  Sam Rao  Vice president of Science 
and Technology, 
ConAgra Inc. 
98.11.12 
Omaha, 
USA 
personal 
interview 
ProViva  Steven 
Stirling 
Vice President Marketing 
and sales, CAG 
Functional foods 
98.11.11 
Omaha, 
USA 
personal 
interview 
ProViva  Kaj 
Vareman 
CEO, 
Probi AB 
(until 2000) 
97.11.26 
Stockholm 
98.02.03 
Lund 
IVA-
seminar 
personal 
interview 
ProViva  Monica 
Walter 
CEO, Probi AB 
(from 2000 ) 
01.05.10 
01.06.19 
mail 
telphone 
interview 
Magiform  Ingmar 
Börjesson 
Responsible for R&D at 
AB Cerealia 
99.06.11 
Stockholm 
personal 
interview 
Magiform  Johanna 
Ehrhardt 
Responsible for 
marketing, BioDoc AB 
00.02.22 
Stockholm 
personal 
interview 
Magiform  Carola 
Lidholm 
Responsible for R&D, 
BioDoc AB 
99.12.17 
Stockholm 
personal 
interview 
Magiform  Lars 
Sjöstrand 
CEO, 
BioDoc AB 
99.08.24 
99.12.17 
Stockholm 
personal 
interviews 
IgY-egg  Bernardt 
Claesson 
ÖL, Klin. Mikrobiologi,  
Kärnsjukhuset 
01.01.09 
01.12.06 
Skövde 
written 
feedback, 
mail 
IgY-egg  Hans 
Kollberg 
Prof. Pediatrics, 
UAS, Uppsala 
00.08.31 
Uppsala 
personal 
interview 
IgY-egg  Anders 
Larsson 
Dr., Head of dep. 
Dep. of Medical 
Sciences, UAS, Uppsala 
00.05.19 
Stockholm 
00.07.04 
Uppsala 
conference 
 
personal 
interview  
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IgY-egg  Per-Erik 
Wejåker 
Agr. and farmer, 
Sörgården, Vittinge 
00.08.10 
Uppsala 
personal 
interview 
IgY-egg  Helena 
Wall 
PhD-student in avian 
studies, SLU, Uppsala 
01.03.27 
 
mail 
 
BRA-
mjölk 
Anita 
Lindström 
Corporate 
Communication, 
BioGaia Biologics AB 
98.09.01 
98.11.25 
conference 
mail 
BRA-
mjölk 
Bo 
Möllstam 
Technical Coordinator, 
BioGaia Biologics AB 
98.11.30.  
Stockholm 
personal 
interview 
BRA-
mjölk 
Peter 
Rothschild 
Managing Director, 
BioGaia Biologics AB 
98.09.01 
98.10.12 
Stockholm 
conference 
personal 
interview 
Market  Göran 
Alsterlind 
Consultant , market 
analysis in the medical 
field  
98.09.02 
Stockholm 
 
conference, 
informal 
talk 
Market  Åke Bruse  Medical expert, 
National Food 
Administration 
00.05.19 
Stockholm 
conference 
+ informal 
talk 
Market  Fred 
Hassan 
Pharmacia Upjohn AB 
CEO 
(Plenary speech at NFF 
conference) 
01.08.17 
Uppsala 
(UU) 
NFF 
conference 
Market  Karin 
Malmcrona
-Friberg 
Managing Director, 
Swedish Center of 
exellence and innovation 
in Functional foods 
99.09.07 
Uppsala 
00.05.18 
Stockholm 
personal 
interview 
conference 
Market  Bertil 
Nobelie 
President , National Food 
Administration 
99.08.26 
Uppsala 
personal 
interview 
Market  Jan 
Rosenström 
Managing Director, 
Livsmedelsindustrierna 
99.07.03 
Stockholm 
telephone 
interview 
Market  Håkan 
Rudérus 
Professor,  
Uppsala University 
93.01.08 
Uppsala 
personal 
interview 
Market 
 
Peter 
Wennström 
Marketing Consultants, 
Lund 
00.04.20 
Stockholm 
99.05.18 
Göteborg 
Personal 
conversation 
Conference 
Market  Per-Olof 
Sjödén 
Professor, 
Uppsala University 
93.05.05 
Uppsala 
personal 
interview 
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Brochures and case specific references  
 
ProViva 
 
ConAgra Inc., 1998, Annual report. An Appetite for Excellence. 
 
Culturelle information materials from CAG Functional Foods (1998). 
 
Living Well With Probiotics, 1998 (an information pamphlet about probiotics, for 
the media, which was sent out by CAG Functional Foods in 1998). 
 
Prevention, Americas # 1 Choice for Healthy Living, 1998, October (a health 
magazine). 
 
Probi AB, 1998, 1999, 2000. Annual report.  
 
Probi AB, 1996, 1997,1998, 1999. An international news letter. 1&2 (1996), 1-3 
(1997) & 1 (1998).   
 
Probi AB, 2001. Half year report.  
 
Probi, börsintroduktionsbroschyr för Skånemejeriers ägare och anställda. To 
order:  046 - 16 87 50 or fax: 046- 16 89 28. (Introduction to the stock market 
brochure). 
 
Skånemejerier Ek. För., 1996, 1997, 1998, 1999, 2000. Annual report.  
 
Skånemejerier, 2001. Svensk forskning bjuder svenska folket på 5 kronor i rabatt. 
ICA-handlarnas tidning, Buffé. 7, 22. 
 
 
 
Magiform 
 
BioDoc (på svenska och engelska, en presentation) 
 
Björck, S., Bosaeus, I.,  Ek, E., Jennische, E., Lönnroth, I., Johansson E. & Lange, 
S. -- Food-induced stimulation of the antisecretory factor improves symptoms 
in human inflammatory bowel disease. -----(KONFIDENTIELLT material, 
som skall publiceras...accept i the Gut, december 1999) 
 
C en idé tidskrift om cerealier, 1999:1.   
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Europeiska gemenskapens officiella tiding, 1999. Kommissionens direktiv 
1999/21/EG (25 mars 1999), L91/29-36. 
 
Lange, S., Jennische, E., Johansson, E. & Lönnroth, I. 1999. The antisecretory 
factor - synthesis and intracellular localisation in porcine tissues. Cell Tissue 
Research 296: 607-617. 
 
New Nutrition Business. 1999: 4:4 (p. 1,6, 40). 
 
Prov från tarmen mer att lita på än provokationer med mat. Tema astma och allergi. 
Dagens Medicin, 1999, 27/4, 28. 
 
 
IgY-egg 
 
A project proposal for a IgY research center. 2000. A project for research and 
development of avian antibodies (IgY). A cross-disciplinary research 
institute in Heby municipality (work in progress).  
 
Carlander, D., Kollberg, H, Wejåker, P. E. and Larsson, A., 1999. Prevention of 
chronic pseudomonas aeruginosa colonisation by gargling with specific 
antibodies. In : Egg Nutrition and Biotechnology (Ed JS Sim). CAB 
International, Wallingford, Oxon, UK. ISBN 0851993303, Book, p371-374. 
 
Carlander, D., Kollberg, H., Wejåker, P.E. and Larsson, A., 2000 A. Peroral 
immunotherapy with specific yolk antibodies for the prevention and 
treatment of enteric infections. Immunologic Research, 21, 1-6. 
 
Carlander, D., Sundström, J., Berglund, Å., Larsson, A., Wretlind, B. and Kollberg, 
H., 2000 B. Immunoglobulin Y (IgY) – A new tool for the prophylaxis 
against Pseudomonas aeruginosa in cystic fibrosis patients. XIIIth 
International Cystic Fibrosis congress 4-8 June 2000, oral presentation, 
abstract. 
 
Carlander, D., Wilhelmsson, M. and Larsson, A.,, 2001. Limited day to day 
variation of IgY levels in eggs from individual laying hens. Food and 
Agricultural Immunology, (accepted but not printed) 
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Lactobacillus Reuteri 
 
BioGaia, 1998. BioGAia Biologics AB. Applied biological systemsfor improving 
health and enhancing protection systems from disease. (An information 
broschure). 
 
BioGaia Biologics AB (publ), 1998 (stock market information). 
 
BioGaia Biologics AB, Annual report for 1997, 1998, 1999.  
 
BioGaia presentation brochure, 1997 (in English). 
 
BioGaia, Functional Foods- en miljardmarknad (a poster). 
 
BioGaia Biologics, Culturing Your ideas. Contract manufacturing of 
biopharmaceuticals (an information broschure).  
 
BioGaia, Lactobacillus Reuteri  - ett effektivt probiotikum. Lägesrapport 1996.           
(a financial statement from 1996). 
 
 
Internet  
 
BioDoc AB, 99.08.24,  www.biodoc.se 
 
BioGaia Biologics AB, 98.10.11; 2001.03.01, www.biogaia.se 
 
ProbiAB, 98.05.11, www. probi.se 
 
Leatherhead, UK, 2001.03.01, www.FunctionalFoodsToday   
     2001.11.29, www. foodlineweb.co.uk 
 
Swedish Centre of Excellence and Innovation in Functional Foods, Sweden, 
2001.03.01, www. functionalfoods.nu  
2001.01.08, www.functionalfoods.nu/file/dyn/0000m/619i/dyn, 2001 
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 Appendix 1 
 
Perspectives of the innovation process in different management schools 
 
Studies conducted by researchers from different disciplines and schools reflect 
several choices in perspective. The business model, main focus and whether or not 
the innovation process is at all recognized will determine what perspective might be 
a fruitful one. Shown below is a timetable for how ideas and concepts have 
developed in management studies during the second half of the twentieth century 
Table A. 
 
Table A. Development of management studies (based on Nyström, 1997, 3-4) 
 
School of 
thought 
Time  Business 
model 
Main focus  Examples of 
authors63 
Economic  - 1960  One entire unit, 
rationality, 
efficiency & 
predictability  
Short run efficiency  Kotler, 
Porter,  
Simon,  
Taylor 
Organizationa
l 
1960:s  Different 
functional units 
Adaptation to a 
given environment 
Lawrence,  
Losch, Porter 
Strategic  1970:s  Different 
strategies needed 
at different times 
Search for the right 
environment 
Ansoff, Crawford, 
Day 
Mintzberg 
Resource-
based 
1980:s  Firm specific 
capabilities and 
assets,  emphasis 
on efficiency 
Ultimate use of 
resources in the 
environment 
Penrose, Rummel,  
Teece,  
Wennerfeldt 
Creative  1990:s 
 
Intellectual 
capital, 
technological 
acquisition and 
management 
Creating 
opportunities and 
the environment 
Nyström, 
Tushman, 
Utterback, 
von Hippel 
 
 
 
The perspective for this study would sort under the creative management school. 
The innovation process is seen as creating opportunities – development of new 
products, processes, markets and businesses. These opportunities are discussed (in 
Chapter six and seven) in terms of innovation management where an external 
environment that sets the outer limits and driving forces for the innovation process 
(presented in Chapter four and five).   
 
                                                       
63 These authors are not listed in the reference list.  
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Appendix 2 
 
An interview guide  
 
Prior to each interview contacts were made with the interviewee. Procedures for 
reviewing the material were decided prior to the meeting. During the interview 
questions are asked based on the themes below in a relaxed conversation. During 
some interviews the first question lead the way for a long “story” that entails most 
of these themes. My follow-up questions, during all interviews, aimed at making 
sure I understood the interviewee’s story.  
 
 
(date, place, conditions) 
 
Interview person 
Name, position, personal history   
 
(What is your role at...?) 
 
Description of the company and its environment 
 
( Would You tell me a little about the development of...? 
critical incidents...  how did You... ?, when did You...?,  why did You...?) 
 
Themes covering: 
A. General characteristics 
B. Company organization 
C. Markets served by the company 
D. Market strategy for the company 
E. R & D strategy for the company 
F. R & D organization 
    A description of products and processes 
G. Product characteristics 
H. Process characteristics 
 
 
(My own reflections regarding the interview)  
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Appendix 3 
 
Products  and websites for functional foods products  
( www.FunctionalFoodsToday , 2001.03.01, Leatherhead, UK)  
    
4 Plus (www.emmi.ch),   ACTIMEL  (www.actimelusa.com; www.actimel.tm.fr), 
AKTIFIT (www.emmi.ch),  
AVIVA www.wander.ch/cgi/de/products/functionalfood/index.asp,  
BARRES MEMOIRE/CARRES MEMOIRE (www.gerble.com), 
BECEL PRO.ACTIV (www.becel.com.br),  BENECOL (www.benecol.com), 
BIENESTA (www.hero.es), BRAIN GUM (www.braingum.com),  
CANDIA (www.candia.fr), CHEERIOS (www.cheerios.com) 
COLUMBUS EGGS (www.columbuseggs.com),  
DANONE BIO (www.danone.it/bio.html), EVOLUS (www.valio.fi),  
FLORA PRO-ACTIV (www.flora.net.au), GAIO/CULTURA (www.mdfoods.dk), 
GEFILUS CHEESE/GEFILUS PRODUCTS (www.valio.fi), 
INDOMILK OMEGA 3 MILK POWDER ( www.indomilk.com), 
JOUR APRES JOUR/LACTEL ET OMEGA 3/LACTEL CALCIUM (www.lactel.fr), 
JUVER CALCIO (www.juver.es), KAIKO CALCIUM (www.iparlat.com) 
LC1(www.lc1.com/homepage.html), LEYMA CALCIO (www.leyma.es), 
LINOBENE (www.hk-ruokatalo.fi),  MAMAN 
 (www.parmalat.net/www/product/ita/prodotti/parmalat/latte_speciale_uht_split.htm) 
MILRAM (www.nordmilch.de),  
NESPRAY (www.nestle.com.my/products/nespray_milk_powder.htm), 
NUTRIBREAD (www.williamjacksonbakery.co.uk/news.html), 
OCLEA (www.wander.ch/cgi/de/products/functionalfood/index.asp),  
OMEGA 3 MILK 
(www.parmalat.net/www/product/ita/prodotti/parmalat/latte_speciale_uht_split.htm) 
PLUS(www.parmalat.net/www/product/ita/prodotti/parmalat/latte_speciale_uht_split.htm) 
PROBIOTIC PLUS OLIGOFRUCTOUS/PROBIOTIC MIT CEREALIEN 
 (www.bauer-milch.de/de/i_produckte.html), 
PROCULT (www.muellermilch.de), PROVIVA (www.proviva.com), 
PULEVA CALCIO/OMEGA 3 (www.puleva.es/_marcos/puleva.htm) 
QUAKER OATS (www.quakeroatmeal.com; www.oatmealforwomen.com),  
TAKE CONTROL (www.takecontrol.com),  
THIS WHITE STUFF/HYFIBE (www.tiptop.com.au)  
TROPICANA CALCIUM (www.tropicana.com),   
UNCLE TOBYS HI-GRAIN (www.uncletobys.com.au)  
VERUM HALSOFIL (www.norrmejerier.se),  
VIVIL FUN FUN + ENERGY/ANTJES ENERGY (www.vivil.de), 
WASA VITAL FIBER+/WASA VITAL SPIRIT+ (www.wasabrod.se),  
YAKULT (www.yakult.co.jp) and  YOSA (www.bioferme.fi) 
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Appendix 4 
 
World Wide Web sites to functional food organizations  
( www.FunctionalFoodsToday , 2001.03.01, Leatherhead, UK)  
 
AACC Functional Foods Online (http://www.scisoc.org/aacc/funcfood), 
Agriculture & Agri-food Canada Food Bureau 
 (www.agr.ca/food/markets/nutraceu/enutrace.html), 
American Nutraceutical Association (www.americanutra.com), 
British Columbia Functional Food & Nutraceutical Network (www.bcfn2.com), 
Cranberry Institute (www.cranberryinstitute.org), 
Emerging Cran-Health News (www.oceanspray.com/cran_health_news.htm), 
Food Navigator (www.foodnavigator.com), 
Food Processing' s Wellness Foods (http://www.wellnessfoodnet.com ), 
Forbes Medi-Tech (www.forbesmedi-tech.com/ffnab.asp), 
Functional Foods Alberta - Centre of Excellence (www.fface.com), 
Functional Foods from Finland (virtual.finland.fi/finfo/english/funcfood.html), 
Functional Foods Today  (www.functional foodstoday. com), 
Herb World News Online (www.herbs.org/current/topnews.html), 
Infant Vision ( www.infantvision.com),  
International Food Information Council (www.ific.infohealth.org/index6.htm), 
Japanscan (www.japanscan.com),  
Loders Croklaan Lipid Nutrition (www.lipidnutrition.com),  
Natural Products Industry Center (www.npicenter.com),  
Nutraceutical Alliance (www.nutraceuticalalliance.com),  
Nutrition Business Journal (www.nutritionbusiness.com,  
NUTRA Solutions (www.nutrasolutions.com),  
Saskatchewan Nutraceutical Network (www.nutranet.org) and 
 Swedish Centre of Excellence and Innovation in Functional Foods 
 (www.functionalfoods.nu) 
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